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Diverse Approaches to Developing Combination Therapies for NF1-Mutant Cancers 
Abstract 
The NF1 tumor suppressor is lost or mutated in a variety of sporadic cancers, as well as in the 
hereditary cancer predisposition syndrome neurofibromatosis type 1 (NF1).   NF1 patients have 
an 8-13% risk of developing a malignant peripheral nerve sheath tumor (MPNST), which are 
lethal when they cannot be surgically resected. There are currently no effective therapies for 
NF1-mutant cancers. This dissertation focuses on the development of combination therapies 
using two distinct approaches: inhibiting specific oncogenic signaling pathways activated by 
NF1 mutation (or loss), and exploiting cellular stresses in cancer cells. 
 NF1 encodes a RAS GTPase activating protein. Therefore, when NF1 is lost, RAS 
pathway signaling is hyper-activated. However, the signaling node or nodes most critical for 
tumor growth were not known.  Here, we report that p110α and mTORC1 are essential for 
NF1-deficient proliferation, while AKT and mTORC2 are dispensable.   Moreover, we 
demonstrate that sustained inhibition of both the mTORC1 and MEK/ERK pathways is required 
for MPNST regression.  To identify molecular biomarkers of combined target inhibition we 
performed transcriptional profiling. GLUT1, which encodes a glucose transporter, is 
significantly repressed when both mTORC1 and MEK are inhibited. 18F-FDG uptake is also 
suppressed, indicating that FDG-PET imaging could be a useful biomarker.   A clinical trial 
based on these findings is being developed. 
 We have previously found that the combination of ER-stress inducing agents and 
rapamycin causes MPNST regression.  Here, we show that the combination of the histone 
deacetylase inhibitor vorinostat with rapamycin exploits this same vulnerability and promotes 
iv 
tumor regression.  This effect is dependent on activation of the unfolded protein response and 
production of reactive oxygen species. The thioredoxin interacting protein TXNIP is 
upregulated by combined treatment and appears to be a driver of cell death in this context.  
These studies suggest that the combination of two FDA-approved drugs, rapamycin and 
vorinostat, could be rapidly translated to clinical trials.  
 In summary, we have identified two promising combination therapies for NF1-mutant 
cancers.  These studies highlight the therapeutic utility of exploiting both signaling and stress 
vulnerabilities in cancer.  These findings have promising clinical applications, and provide a 
framework for future therapeutic and mechanistic exploration.   
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Chapter 1: Introduction  
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The NF1 tumor suppressor is mutated in a familial cancer syndrome as well as a large 
number of sporadic cancers. Currently there are no effective therapies for any NF1-mutant 
tumors. Therefore, treatment for NF1-deficient tumors represents a huge unmet clinical need 
and the focus of this work is to identify novel therapeutic approaches for these tumors. This 
chapter will provide background on normal NF1 function and regulation of the RAS pathway, 
and the role of NF1 in disease pathogenesis. Additionally, this chapter will provide information 
on downstream RAS effector pathways, proteotoxic stress, and oxidative stress, which are 
three important topics related to the work in this dissertation.  
 
NEUROFIBROMATOSIS TYPE 1  
Germline loss of NF1 causes the inherited cancer predisposition syndrome 
neurofibromatosis type 1 (NF1). NF1 is an autosomal dominant disorder that affects about 1 in 
every 3500 births, making it one of the most common monogenic disorders. Approximately 
50% of these cases involve de novo mutations in NF1, while the other half are familial (Huson 
et al., 1989). NF1 has a penetrance of nearly 100% although the symptoms occur on a 
spectrum with some patients only mildly affected while others experience significant morbidity 
and mortality.  
Clinical Features of NF1 
Patients with NF1 can develop a variety of symptoms (Table 1–1). One of the hallmarks 
of NF1 is the development of café-au-lait spots. Café-au-lait spots are flat areas of hyper-
pigmentation, typically light brown in color, which gives them their name. While they can be 
associated with a number of inherited disorders including McCune-Albright syndrome, Legius 
syndrome, and tuberous sclerosis, over 99% of NF1 patients have café-au-lait spots (Ferner et 
al., 2007). Thus, the number of café-au-lait spots is an important diagnostic feature of NF1.  
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These spots can be present at birth and typically occur within the first five years of life, so they 
are frequently the first clinical manifestation of NF1. In addition to café-au-lait spots, NF1 
patients typically display Lisch Nodules, impaired cognitive development, optic gliomas, and, 
most commonly, peripheral neurofibromas.  
Neurofibromas are benign peripheral nerve tumors and are the defining feature of NF1. 
They can occur on nerves anywhere in the peripheral nervous system and can be disfiguring, 
although they are typically not life-threatening. Neurofibromas can be further subdivided into 
    
Clinical Manifestation Frequency (%) Age of Onset 
Café-au-lait patches >99 Birth to 12 years 
Skin-fold freckling 85 3 years to adolescence 
Lisch nodules 90-95 > 3 years 
Cutaneous neurofibromas >99 >7 years, usually late adolescence 
Plexiform neurofibromas 30-50 Birth to 18 years 
Disfiguring facial plexiform 
neurofibromas 3-5 Birth to 5 years 
Malignant peripheral nerve sheath 
tumor 
2-5 (8-13% 
lifetime risk) 5-75 years 
Scoliosis 10 Birth to 18 years 
Scoliosis requiring surgery 5 Birth to 18 years 
Pseudoarthrosis of tibia 2 Birth to 3 years 
Renal artery stenosis  2 Lifelong 
Pheochromocytoma 2 >10 years 
Severe cognitive impairment (IQ <70) 4-8 Birth 
Learning problems 30-60 Birth  
Epilepsy 6-7 Lifelong 
Optic pathway glioma 15 Birth to 30 years 
Cerebral glioma 2-3 Lifelong 
Sphenoid wing dysplasia <1 Congenital 
Table 1–1. Major Clinical Features of NF1. Shown is the frequency (%), and age of onset 
for the major clinical manifestations of NF1. Adapted from Ferner et al., 2007. 
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two classes: (1) dermal neurofibromas and (2) plexiform neurofibromas. Dermal neurofibromas 
occur in more than 99% of NF1 patients and can range in size from 0.1cm to >3 cm in 
diameter. NF1 patients frequently have a large number of neurofibromas, which can arise all 
over the body. Plexiform neurofibromas are less common, but are one of the most debilitating 
features of NF1 and can result in significant morbidity. Plexiform neurofibromas are larger and 
more extensive than dermal neurofibromas. They invade nearby tissue and organs causing 
significant disfigurement, pain, and loss of nerve or body function (Korf, 1999). While these 
tumors are benign, unlike dermal neurofibromas, plexiform neurofibromas can undergo 
malignant transformation into malignant peripheral nerve sheath tumors (MPNST), which are 
discussed in detail below (Ferner et al., 2007). 
NF1-Associated Tumors 
 In addition to the neurofibromas discussed above, NF1 patients develop a number of 
other tumor types at a higher rate than the general population. Optic pathway gliomas are one 
of the most common lesions associated with NF1, occurring in 15% of NF1 patients (Ferner et 
al., 2007). These gliomas are typically low grade and many are asymptomatic, however in more 
than a third of cases patients will experience visual impairment or blindness (Balcer et al., 
2001). NF1 patients are also at elevated risk for developing gastrointestinal stromal tumors 
(GIST) and pheochromocytomas (Erem et al., 2007; Maertens et al., 2006). Several 
myeloproliferative disorders also occur at an increased rate in NF1 patients, most notably 
juvenile myelomonocytic leukemia (JMML) (Lauchle et al., 2006). NF1 patients have an 8–13% 
lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST), which is a 
significantly elevated risk relative to that of the general population where the lifetime risk is 
approximately 0.001% (Evans et al., 2002). Indeed, MPNSTs represent 10% of all sarcomas, 
and more than 50% of MPNSTs occur in NF1 patients (Doorn et al., 1995). Furthermore, the 
average age at diagnosis in the NF1 population is only 26 years, compared with 62 years in the 
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general population (Evans et al., 2002). MPNSTs, which are the focus of this dissertation and 
are described in detail below, are the leading cause of death in NF1-patients and represent a 
huge unmet clinical need for this population.  
 
MALIGNANT PERIPHERAL NERVE SHEATH TUMORS  
MPNSTs are soft tissue sarcomas that develop along peripheral nerves. The cell of 
origin of MPNSTs appears to be a Schwann cell precursor cell type (Chen et al., 2014; Gupta 
and Maniker, 2007). Histologically, MPNSTs are poorly differentiated and exhibit a wide range 
of potential features, but most typically they contain whorling spindle-like cells (Gupta and 
Maniker, 2007). MPNSTs can arise from major or minor nerve branches or from the nerve 
sheath, and can be associated with many nerves although the most common nerve of origin is 
the sciatic nerve (Ducatman et al., 1986). MPNSTs are poorly encapsulated and locally 
invasive, often extending along the axis of the nerve and into neighboring soft tissue (Kumar et 
al., 2009). They can arise anywhere on the body: 46% arise on the trunk, 34% arise on 
extremities, and 19% arise in the head/neck region (Ducatman et al., 1986). MPNSTs are 
extremely aggressive tumors, and frequently metastasize. As discussed below, MPNSTs do 
not significantly respond to conventional chemotherapy, and MPNSTs remain the leading 
cause of death among NF1-patients (Evans et al., 2002; Porter et al., 2009; Zehou et al., 2013).  
Diagnosis and Clinical Management of MPNSTs 
 In NF1 patients, MPNSTs can arise from pre-existing non-malignant plexiform 
neurofibromas, or they can arise spontaneously (Ducatman et al., 1986). Early detection of an 
MPNST is critical for patient outcome, as the size of the MPNST at diagnosis is one of the 
biggest predictors of prognosis (Gupta and Maniker, 2007). However, the diagnosis of an 
MPNST is complicated by the presence of non-malignant peripheral nerve tumors in NF1 
patients. Plexiform neurofibromas must be monitored carefully for potential malignant 
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transformation. MPNSTs are more metabolically active than non-malignant pre-cursor tumors, 
so 18F-fluorodeoxyglucose (18F-FDG) uptake measured by positron emission tomography (PET) 
imaging is an important clinical tool for distinguishing between benign and malignant tumors. 
Elevated SUVmax, a quantitative readout of FDG-uptake, is significantly correlated with MPNSTs 
and has an 89% sensitivity and a 95% specificity (Benz et al., 2010). The characteristic high 
glucose uptake of MPNSTs is important for findings in Chapter 2 of this thesis.  
 Unfortunately at the time of presentation most MPNSTs are already quite large (>5cm in 
size) and in up to 50% of cases have already metastasized (Farid et al., 2014). As treatment 
options are limited, patients with MPNSTs have a poor 5-year survival ranging between 15-
50% (Farid et al., 2014). Complete surgical resection with clear margins remains the treatment 
of choice for MPNSTs, although MPNSTs are not always resectable (Widemann, 2009). Even in 
cases where MPNSTs can be resected, there is local recurrence in 32–65% of cases after an 
average of 5 to 32.2 months (Baehring et al., 2003; Doorn et al., 1995; Ducatman et al., 1986; 
Gupta and Maniker, 2007). Unfortunately when complete resection is not achieved, which 
occurs in about 70% of cases, MPNSTs are uniformly lethal (Evans et al., 2002; Zehou et al., 
2013). Conventional chemotherapy can prolong progression free survival but does not appear 
to improve overall survival (Porter et al., 2009). Treatment options remain limited for metastatic, 
unresectable, or recurrent MPNSTs, although several investigational agents, many from our 
laboratory, are in clinical trials and will be discussed in detail later in this chapter.  
MPNST Pathogenesis 
Inactivation of both NF1 alleles seems to be an early and requisite step in 
tumorigenesis. Benign neurofibromas display loss of heterozygosity (LOH) of NF1, and 
progression to an MPNST requires further alterations, most notably those involved in cell cycle 
control. Loss of p53 is frequent in MPNSTs, through both mutation and deletion, and this is not 
observed in benign neurofibromas (Birindelli et al., 2001; Frahm et al., 2004; Jhanwar et al., 
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1994; Koga et al., 2002; Legius et al., 1994; Leroy et al., 2001; Liapis et al., 1999; Menon et al., 
1990; Rasmussen et al., 2000). Mutations in CDK2NA, the gene encoding both p16INK4A and 
p19ARF, are also reported at high levels, with mutations in 75% and 60% of MPNSTs, 
respectively (Berner et al., 1999; Kourea et al., 1999). Loss of other cell cycle genes including 
RB1, MDM2, CDK4, CDKN2B, and CCND2 are also reported in MPNSTs, demonstrating that 
loss of cell cycle regulation is an important step in malignant transformation (Berner et al., 
1999). The tumor suppressor PTEN may also contribute to tumorigenesis as protein levels are 
low in many human MPNSTs (Gregorian et al., 2009).  
Mouse Models of MPNSTs 
 Genetically engineered mouse models of MPNSTs have provided further insight into 
cooperating mutations and provide pre-clinical models for therapeutic testing. Unlike humans, 
mice that are heterozygous for Nf1 (Nf1+/-) do not develop MPNSTs (Brannan et al., 1994; 
Jacks et al., 1994). Homozygous deletion of Nf1 is embryonic lethal, and chimeric Nf1-/-Nf1+/+ 
mice develop plexiform neurofibromas, but not MPNSTs (Cichowski et al., 1999). Similarly, 
mouse models with floxed Nf1 and Cre driven by Plp, Dhh, and Krox20 develop plexiform 
neurofibromas but not MPNSTs (Mayes et al., 2011; Wu et al., 2008; Zhu et al., 2002) This is 
likely due to the fact that mutation in a secondary pathway is required for MPNST 
development, as benign lesions in humans are NF1 null as well. Mice that are heterozygous for 
both Nf1 and p53 develop MPNSTs with an average latency of 5 months, but only when these 
deletions are in cis, as Nf1 and p53 are closely linked in the mouse. These mice (NPcis mice) 
consistently lose both of the wild type Nf1 and p53 alleles in the tumors they develop, therefore 
they genetically and histologically recapitulate human MPNSTs (Cichowski et al., 1999). The 
tumors develop with a relatively short latency (5 months) and the tumors are very aggressive 
(on average they reach maximal size within 10-15 days). Therefore the NPcis model is a useful 
pre-clinical tool, and pre-clinical testing of therapies using this model is a major focus of this 
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dissertation. Another mouse model of MPNSTs has since been developed, which 
demonstrates that other “second-hit” mutations can also contribute to MPNST pathogenesis. 
About 26% of mice that are heterozygous for Nf1 and deficient for both Ink4a and Arf (Nf1+/-
Ink4a/Arf-/-) develop MPNSTs with a latency similar to the NPcis model (Joseph et al., 2008).  
 
THE NF1 TUMOR SUPPRESSOR 
 The 350 kb gene encoding human NF1 is located on chromosome 17 (chromosomal 
region 17q11.2). NF1 encodes a relatively large protein of 2839 amino acids known as 
neurofibromin (Figure 1–1). The RAS GAP related domain (GRD) is a 332 amino acid stretch 
near the middle of the protein (Bernards, 2003). This domain directly interacts with RAS and 
promotes RAS hydrolysis of GTP to GDP, which is discussed in detail below (Martin et al., 
1990). Neighboring the GRD, there is a SEC14-like lipid-binding domain (SEC14), followed by a 
plekstrin homology domain (PH), which is thought to be involved in membrane localization, but 
the majority of the protein contains regions of unknown function. Expression of the GRD in 
many contexts is sufficient to restore tumor suppressive function, suggesting that many of the 
effects of NF1-loss may be mediated by RAS, as discussed below (Hiatt et al., 2001; 
Johannessen et al., 2008). Moreover, missense point mutations in the GRD are found in NF1 
1 500 1000 1500 2000 2500 2839aa
GRD PHSEC14
Figure 1–1. Schematic of NF1 Protein Domains. NF1 is a 2839 amino acid protein with a 
GAP-related domain (GRD), a SEC14-like lipid-binding domain (SEC14), and a plekstrin 
homology domain (PH). Adapted from Bernards et al., 2003.  
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patients and are sufficient to cause disease (Klose et al., 1998). Nevertheless, it is possible that 
NF1 has other functions that have not been discovered yet.  
NF1 was originally described as a tumor suppressor in the context of neurofibromatosis 
type 1, however it is now clear that NF1 also functions as a tumor suppressor in sporadic 
cancer. NF1 mutations have now been reported in a wide variety of human cancers (Figure 1–
2, TCGA). While these mutations may not all be inactivating mutations, further studies in 
glioblastoma, non-small cell lung cancer (NSCLC), and melanoma demonstrate that NF1 does 
function as a tumor suppressor (Boudry-Labis et al., 2013; Ding et al., 2008; Hölzel et al., 2010; 
Maertens et al., 2013; McGillicuddy et al., 2009; Parsons et al., 2008). Importantly, NF1 
expression can also be regulated by non-genetic mechanisms including proteosomal 
degradation, which is frequently observed in glioblastoma (McGillicuddy et al., 2009). Therefore 
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Figure 1–2. NF1 Mutations across Cancer Types. Graph shows the frequency of NF1 
mutations in various cancers. Data sets with lower than a 3% mutation rate are not shown. 
Data are from the TCGA and cBioPortal (Cerami et al. 2012, Gao et al. 2013).  
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the number of mutations shown in Figure 1-2 may under-represent the frequency of NF1 
inactivation in sporadic cancer.  
Nearly 1500 point mutations in NF1 capable of causing NF1 have been identified, as 
well as single or multiple exon deletions, micro deletions, micro insertions, and large insertions 
(Abramowicz and Gos, 2014). Mutations in NF1 are relatively evenly spread throughout the 
protein from exon 3 to intron 47, with no known mutational hotspots (Jeong et al., 2006; Ko et 
al., 2013). Interestingly, sporadic mutations in NF1 are also distributed throughout the gene 
without any clear hotspot mutations (Figure 1-3).  
 
 
NEUROFIBROMIN AND THE RAS PATHWAY 
 NF1 is a negative regulator of the RAS pathway. The RAS pathway is a critical regulator 
of normal cell growth and homeostasis, linking extracellular growth signals to intracellular 
effector pathways. The RAS superfamily contains approximately 150 low molecular weight 
GTPases. There are over thirty RAS genes, however only three of these, HRAS, KRAS, and 
NRAS have an established role in cancer. 
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Figure 1–3. Spectrum of NF1 Mutations in Human Cancer. Shown are the sites of 
mutations identified in human cancer. Red circles indicate truncating mutations, green 
circles indicate missense mutations, black circles indicate in-frame mutations, and purple 
circles indicate sites that are affected by different mutation types at the same frequency. 
The y-axis indicates the number of mutations identified at a given residue. The green box 
indicates the general location of the GRD. The red box indicates the general location of the 
SEC14 domain. Figure is adapted from the cBio Portal and data is from the TCGA database 
(Cerami et al. 2012, and Gao et al. 2013).  
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The RAS proteins have critical roles in normal growth and proliferation. Therefore their 
activity must be tightly regulated. RAS itself is a small GTPase, which switches between a 
GDP-bound inactive state, and a GTP bound active state, with the GDP/GTP state essentially 
functioning as an on/off switch. Two classes of proteins control RAS activity: the RAS guanine 
exchange factors (RAS GEFs), and the RAS GTPase activating proteins (RAS GAPs). The RAS 
GEFs promote the exchange of GDP for GTP, allowing RAS to become activated (Figure 1–4). 
Conversely, the RAS GAPs catalyze the GTPase activity of RAS allowing hydrolysis of GTP to 
GDP and effectively turning off RAS activity.  
  
 
RAS Pathway Deregulation in Human Cancer 
The RAS pathway is one of the most frequently altered pathways in human cancer. 
Mutations in the H-, K-, and NRAS isoforms occur in approximately 20-30% of all human 
cancers, with mutation rates exceeding 90% in certain subtypes of cancer such as pancreatic 
cancer. Most mutations in RAS itself fall into two classes of mutations, point mutations 
RAS
GTP
RAS
GDP
GAP
GEF
GDP
Pi
Effector 
Pathways
GTP
Figure 1–4. Regulation of RAS Activity by RAS GEFs and RAS GAPs RAS switches 
between an inactive GDP-bound state and an active-GTP bound state. The conversion of 
GTP to GDP is catalyzed by RAS GAPs, inactivating RAS. Conversely, RAS GEFs promote 
the exchange of GDP for GTP, activating RAS and allowing RAS to signal to downstream 
effectors.  
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affecting codons 12 or 13, and point mutations in codon 61. Both classes are considered 
activating mutations, although the mechanism is distinct. Mutations in codons 12 and 13 do 
not affect the active site of RAS, but instead impairs RAS binding to GAPs, and GAP binding 
can no longer promote GTPase activity. As intrinsic RAS GTPase activity is limited, this 
effectively leads to constitutive activation of RAS with no regulation by the RAS GAPs. Codon 
61 is located in the active site of RAS and mutations in this codon impair the catalytic site and 
block GTPase activity. While mutations in RAS itself are common, upstream regulators of RAS 
and downstream effectors of RAS are also frequently mutated in human cancer.  
 In addition to mutations in RAS itself, it has been proposed that RAS GEFs and RAS 
GAPs could function as oncogenes and tumor suppressors respectively. Inherited mutations in 
SOS1, a RAS GEF, cause a congenital disorder called Noonan syndrome. Noonan syndrome 
patients are at an elevated risk for some type of cancer including JMML. However, to date no 
mutations in RAS GEFs have been identified in sporadic cancers, suggesting that the 
oncogenic potential of these proteins is limited. In contrast, there is a growing body of 
evidence to suggest that a number of RAS GAPs can and do function as tumor suppressors in 
human cancer. 
 As discussed above, NF1 is an established tumor suppressor, both for its role in the 
inherited cancer predisposition syndrome neurofibromatosis type 1, and in sporadic cancer. In 
addition to NF1, our lab has shown that DAB2IP and RASAL2 function as tumor and 
metastasis suppressors in prostate cancer and breast cancer, respectively (McLaughlin et al., 
2013; Min et al., 2010).  
 
RAS EFFECTOR PATHWAYS 
Because NF1 is a negative regulator of RAS, the pathogenesis of NF1-deficient tumors 
is driven, at least in part, through aberrant activation of the RAS pathway. RAS mediates its 
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effects through activation of a variety of downstream pathways that affect cell growth, 
proliferation, and survival among other critical processes (Figure 1–5). RAS has been 
demonstrated to regulate many effector pathways, but the extracellular signal-regulated kinase 
(ERK) and phosphotidylionsitol 3-kinase (PI3K) pathways appear most critical for the 
pathogenesis of human cancer. 
 
PI3K/AKT/mTOR Signaling 
 PI3K consists of a p110 catalytic subunit and a p85 regulator subunit. There are three 
Class IA catalytic isoforms of PI3K: p110α, p110β and p110δ which are encoded by distinct 
genes: PIK3CA, PIK3CB, and PIK3CD, respectively. p110α and p110β are ubiquitously 
expressed, while p110δ shows a more limited expression pattern, mostly limited to white blood 
RAS
PI3K RAF
RAL-GDS PLCε
MEK
ERK
Cell Cycle Progression
Transcription
AKT
mTOR
Survival
Transcription
Cytoskeletal Signals
Translation
Calcium SignalingCell Cycle Progression
Transcription
Figure 1–5. RAS Effector Pathways Regulate Cellular Growth and Proliferation.  
Schematic showing the main downstream effector pathways activated by RAS, RAL-GDS, 
PI3K, RAF and PLCε, which jointly regulate cell cycle progression, transcription, survival, 
and calcium signaling, among other processes.  Adapted from Downward et al., 2003.  
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cells and neurons (Bi et al., 1999; 2002; Chantry et al., 1997; Eickholt et al., 2007; Geering et 
al., 2007; Hu et al., 1993; Vanhaesebroeck et al., 1997). PIK3CA is mutated in approximately 
15% of human cancers with higher incidence in specific cancer subtypes (Karakas et al., 
2006). Overexpression studies and gene deletion experiments have demonstrated that hotspot 
mutations in PIK3CA are in fact oncogenic as they induce transformation of primary fibroblasts, 
allow anchorage independent growth, and promote tumor formation in animal models (Bader et 
al., 2006; Ikenoue et al., 2005; Isakoff et al., 2005; Kang et al., 2005; Samuels et al., 2005; Zhao 
and Vogt, 2008). Somatic mutations in PIK3CB and PIK3CD are notably absent from human 
cancer (Thorpe et al., 2015). However, overexpression of wild type p110β and p110δ is 
sufficient to induce cellular transformation (Kang et al., 2006), in contrast to wild type p110α, 
which is not a sufficient oncogenic signal in primary fibroblasts suggesting that mutations may 
not be necessary for p110β and p110δ to act as oncogenes, which is supported by their 
frequent over expression in human cancer (Thorpe et al., 2015).  
 The enzymatic activity of all three isoforms is identical, however they appear to have 
non-redundant roles in human cancer. As described, PIK3CA mutations are relatively common. 
However, it was recently shown that p110β appears to be the primary isoform responsible for 
oncogenic activity in the context of PTEN deficiency (Jia et al., 2008). Furthermore, p110δ 
activity appears to be the primary isoform functioning in hematopoietic cancers, as p110δ-
specific inhibitors show profound anti-cancer activity in B-cell malignancy cell lines (Herman et 
al., 2010; Hoellenriegel et al., 2011; Ikeda et al., 2010; Lannutti et al., 2011; Meadows et al., 
2012). Isoform-specific inhibitors against all three isoforms are being developed and are likely 
to have unique applications in human cancer.  
 RAS drives the PI3K signaling pathway through direct interaction with the p110 catalytic 
subunit (Pacold et al., 2000; Rodriguez-Viciana et al., 1994). This interaction leads to 
conformational changes and the translocation of PI3K to the cellular membrane where it can 
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phosphorylate phosphtidylinostiol-4,5-biphosphate (PIP2) resulting in the formation of 
phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 can be converted back into PIP2 by the 
phosphatase PTEN. In addition to activating mutations in PIK3CA and over-expression of 
p110β and p110δ, loss of PTEN is also common in human cancer, including MPNSTs as 
discussed above.  
When activated, PIP3 interacts with a large number of downstream proteins, but most 
notably leads to activation of AKT by PDK1 through binding to AKT at the plasma membrane 
allowing PDK1 to phosphorylate AKT on threonine 308 (T308). This phosphorylation event is 
sufficient for AKT phosphorylation of many target proteins, but full activation of AKT requires a 
second phosphorylation event on serine 473 (S473) by mTORC2 (Loewith et al., 2002; 
Sarbassov et al., 2005). This second phosphorylation event allows AKT to activate its full 
spectrum of target proteins.  
One of the key substrates of activated AKT is tuberous sclerosis protein 2, or tuberin 
(TSC2) (Manning et al., 2002). There are at least five known AKT phosphorylation sites on 
TSC2, and phosphorylation of all five is necessary for full mTORC1 activation (Inoki et al., 2002; 
Manning et al., 2002; Potter et al., 2002). TSC2, together with tuberous sclerosis protein 1, or 
hamartin (TSC1) forms a complex that negatively regulates mTORC1 signaling (Tee et al., 
2002). Phosphorylation of TSC2 by AKT releases the suppression of the TSC complex on 
mTORC1, thus leading to activated mTORC1 signaling. Phosphorylation of TSC2 releases it 
from the lysosomal membrane where mTORC1 and RHEB are located (Menon et al., 2014). 
When TSC2, a RHEB-GAP, is present, RHEB is maintained in an inactive state and cannot 
activate mTORC1, but once TSC2 is released from the membrane more RHEB is in the active 
GTP-bound state, which in turn activates mTORC1. NF1 loss leads to hyperactivation of 
mTORC1, which is critical for NF1-deficient cell growth, underscoring the importance of this 
pathway (Johannessen et al., 2008; 2005). 
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mTOR Complex 1 and mTOR Complex 2 
mTOR exists in two distinct complexes: mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) (Figure 1–6). While mTOR is the catalytic subunit of both complexes,  
 
each complex contains distinct obligate subunits and has distinct functions (Loewith et al., 
2002). mTORC1 consists of RAPTOR and mLST8/GβL. PRAS40 and DEPTOR can also interact 
with mTORC1, but appear to be recruited to the complex to suppress mTORC1 activity and 
thus are not essential for catalytic function (Peterson et al., 2009; Thedieck et al., 2007). The 
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Figure 1–6. mTORC1 and mTORC2 are Functionally Distinct Complexes. Shown is a 
diagram of mTORC1 and mTORC2 functions. mTORC2 phosphorylates AKT on S473, 
allosterically activating AKT. mTORC1 phosphorylates S6Kinase (S6K) and 4E-BP1, 
activating S6K and inhibiting 4E-BP1 function. Activating phosphorylation events are shown 
in black and inhibitory phosphorylation events are shown in white. For simplicity, a single 
phosphorylation event is shown, although in many cases there are multiple phosphorylation 
sites. Also for simplicity, only RAPTOR and RICTOR component proteins of mTORC1 and 
mTORC2 are shown.  
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exact role of RAPTOR and mLST8 is still unclear, but RAPTOR is required for proper mTORC1 
function. mTORC1 activity is directly regulated by RHEB and TSC2 as discussed above. In 
addition to regulation by growth factors through RAS and PI3K, mTORC1 activity is also 
regulated by nutrient and energy levels. 
mTORC1 is a master regulator of cellular growth and metabolism. mTORC1 positively 
regulates protein translation, lipid synthesis, and mitochondrial metabolism, and negatively 
regulates autophagy (Düvel et al., 2010; Fingar and Blenis, 2004; Hay and Sonenberg, 2004; 
Laplante and Sabatini, 2009; Morita et al., 2015). mTORC1 regulates these processes by 
phosphorylating a number of targets, including ULK1, 4-EBP1, and p70S6kinase (Hara et al., 
1997; Kim et al., 2011; Park et al., 2002; Price et al., 1992). mTORC1 activation also leads to 
the phosphorylation of eIF4G, although this may be indirect (Raught et al., 2000). The 
phosphorylation of 4-EBP1 releases eIF4E from 4-EBP1 suppression allowing cap-dependent 
protein translation to occur (Ma and Blenis, 2009). On the other hand, the phosphorylation of 
p70S6kinase is an activating event that allows p70S6kinase to phosphorylate its targets 
including ribosomal protein S6 (Fingar et al., 2004). 
mTORC2 is comprised of RICTOR, SIN1, and mLST8/GβL. DEPTOR, PROTOR, and 
PRR5L have also been found to associate with mTORC2 (Pearce et al., 2007; Peterson et al., 
2009; Thedieck et al., 2007; Woo et al., 2007). mTORC2 phosphorylates AGC kinases such as 
AKT, PKC, and SGK and allosterically activates them. This phosphorylation event is in addition 
to a catalytically activating phosphorylation event by PDK1 on AGC kinases, and is required for 
these kinases to interact with their full spectrum of substrates (Oh and Jacinto, 2011). 
mTORC2 seems to regulate a number of critical cellular processes including protein synthesis, 
cellular survival, and actin organization, although the mechanism of how mTORC2 regulates 
some of these processes remains elusive (Jacinto et al., 2004; Oh and Jacinto, 2011; Oh et al., 
2010; Sarbassov et al., 2004).   
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The ERK Pathway 
The first identified RAS effector protein is the serine/threonine kinase RAF (Moodie et 
al., 1993; Vojtek et al., 1993; Warne et al., 1993; Zhang et al., 1993). There are three closely 
related RAF isoforms: ARAF, BRAF, and CRAF. When RAS is in its active GTP-bound state, it 
can directly bind RAF and leads to translocation of RAF to the plasma membrane, which 
contributes to activation of RAF. RAF activation induces a kinase phosphorylation cascade, 
beginning with the phosphorylation of its direct targets, the mitogen activated kinase kinases 1 
and 2 (MEK1 and MEK 2), which in turn phosphorylate and activate extracellular signal-
regulated kinases 1 and 2 (ERK1 and ERK2), which are also referred to as the mitogen 
activated kinases 1 and 2 (Kolch, 2005). ERK has a wide variety of substrates that are both 
nuclear and cytoplasmic. ERK can directly phosphorylate a number of transcription factors 
including ETS-1, c-MYC, and c-JUN. Through this direct transcription factor phosphorylation, 
as well as indirect regulation such as the phosphorylation of RSK, which then activates the 
transcription factor CREB, ERK activation drives a transcriptional program that promotes cell-
cycle progression. ERK is also hyper-activated in NF1-mutant tumors, as discussed in detail 
below. 
 
TARGETING RAS AND RAS EFFECTOR PATHWAYS IN CANCER 
Given its role in human cancer, there has been much interest in RAS inhibition. Ablation 
studies have demonstrated that many cancers have a dependency on RAS signaling, validating 
RAS as a therapeutic target (Chin et al., 1999; Fisher et al., 2001; Singh et al., 2009; Ying et al., 
2012). RAS has a picomolar affinity for GTP, and cellular concentrations of GTP are very high, 
so developing inhibitors that can outcompete for GTP binding has not been possible (John et 
al., 1990). Recently two inhibitors of KRAS with the G12C mutation have been identified: an 
allosteric inhibitor that alters RAS affinity for GTP and a covalent irreversibly binding GDP 
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analogue (Lim et al., 2014; Ostrem et al., 2013). These inhibitors rely on the unique ability of 
cysteine to interact with molecules that contain disulfide, and thus are only effective on the 
mutations that cause an amino acid change to cysteine, but not wild type RAS or mutations 
that lead to other amino acid changes. To date, there are no inhibitors that can directly target 
wild type RAS.  
An alternative approach has focused on post-translational modification of RAS. RAS 
must be localized at the cellular membrane in order to have oncogenic activity (Willumsen et 
al., 1984). RAS prenylation is required for translocation of RAS to the membrane and activation 
of many effector pathways. Farnesyl transferase inhibitors have been developed, but 
unfortunately they have not proved to be clinically useful, likely because while HRAS appears 
to be inhibited, both KRAS and NRAS can be geranylgeranylated when farnesyl transferases 
are inhibited and this still yields proper cellular localization of these RAS isoforms.  
The farnesyl transferase inhibitor Tipifarnib was tested in a clinical trial in children and 
young adults with NF1 and plexiform neurofibromas, but, as with most FTIs that have been 
tested clinically, this did not prolong time to progression likely because they are not inhibiting 
all RAS isoforms (Widemann et al., 2014). Because effectively targeting RAS itself has not yet 
proved possible, a large number of agents targeting RAS effector pathways have been 
developed, many of which are in clinical trials.  
Inhibitors are either approved or in clinical development for all members of the 
PI3K/AKT/mTOR pathway (Table 1–2). The p110δ-specific inhibitor idelalisib is the only 
clinically approved PI3K inhibitor, but both pan-PI3K inhibitors as well as isoform-specific 
inhibitors against p110α, p110β, and p110δ are currently in clinical trials for a variety of 
oncology indications. A number of AKT inhibitors have also been developed and are in early 
stage clinical trials. Allosteric inhibitors against mTORC1 including rapamycin (sirolimus) and 
the rapalogs (everolimus, temsirolimus, ridaforlimus) are FDA-approved for a variety of  
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Agent Target(s) Clinical Status 
mTOR INHIBITORS   
Sirolimus (rapamycin) mTORC1 (allosteric) FDA-approved 
Everolimus mTORC1 (allosteric) FDA-approved 
Temsirolimus mTORC1 (allosteric) FDA-approved 
Ridaforolimus mTORC1 (allosteric) FDA-approved 
MLN0128/INK128 mTORC1/2 Phase I 
OSI-027 mTORC1/2  Phase II 
CC-223 mTORC1/2  Phase II 
DS-3078a mTORC1/2 Phase I 
AZD 2014 mTORC1/2 Phase II 
PI3K INHIBITORS   
Buparlisib (BKM120) Pan-PI3K (class 1) Phase III 
Copanlisib (BAY80-6946) Pan-PI3K (class 1) Phase III 
Pictilisib (GDC-0941) Pan-PI3K (class 1) Phase II 
SAR245408 Pan-PI3K (class 1) Phase II 
ZSTK474 Pan-PI3K (class 1) Phase I 
BYL719 PI3K p110α Phase I/II 
MLN1117/INK1117 PI3K p110α Phase I 
AZD 8835 PI3K p110α Phase I 
Taselisib PI3K p110α Phase I 
BAY1082439 PI3K p110α/β Phase I 
GSK2636771 PI3K p110β Phase I/II 
SAR260301 PI3K p110β Phase I/II 
Idelalisib (CAL-101)  PI3K p110δ FDA-approved 
INCB040093 PI3K p110δ Phase I 
AMG 319 PI3K p110δ Phase I 
TGR 1202 PI3K p110δ Phase I 
IPI-145 PI3K p110δ/γ Phase III 
RP6530 PI3K p110δ/γ Phase I 
DUAL INHIBITORS   
SAR245409 PI3K/mTORC1/2 Phase I/II 
GDC-0980 PI3K/mTORC1/2 Phase II 
VS-5584 PI3K/mTORC1/2 Phase I 
PKI-587/ PF-05212384 PI3K/mTORC1/2 Phase I/II 
DCBCI0901 PI3K/mTORC1/2 Phase I 
DS-7423 PI3K (p110α)/mTORC1/2 Phase I 
AKT INHIBITORS   
MK-2206 Pan-AKT Phase II 
Afuresertib (GSK2110183) Pan-AKT Phase II 
Ipatasertib (GDC-0068) Pan-AKT Phase II 
ARQ 092 Pan-AKT Phase I 
BAY1125976 AKT1/2 Phase I 
RX-0201 AKT1 Phase I/II 
AZD-5363 Pan-AKT Phase II 
GSK 2141795 Pan-AKT Phase II 
LY-2780301 AKT/p70S6K Phase I/II !
Table 1–2. Inhibitors for the PI3K/AKT/mTOR Pathway in Clinical Development. Shown 
are inhibitors against PI3K, AKT, and mTOR and their current stage in clinical trials. 
Compiled from the NCI Drug Encyclopedia and clinicaltrials.gov. 
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indications. Rapamycin and other rapalogs function by creating a complex with the mTOR 
binding protein FKBP12, which then binds to mTORC1 near the catalytic site of mTOR, 
exclusively inhibiting mTORC1 kinase activity.  mTOR kinase inhibitors, which are active 
against mTORC1 and mTORC2 are in clinical development. Finally, dual-specificity inhibitors 
that target the kinase activity of both PI3K and mTOR are also being investigated clinically, 
although none have been approved to date. 
The PI3K/AKT/mTOR axis is known to be hyper-activated when NF1 is lost 
(Johannessen et al., 2005). Furthermore, mTORC1 has been demonstrated to be critical for 
proliferation of NF1-deficient MPNSTs, and mTORC1 inhibition has a cytostatic effect on 
MPNSTs in a genetically engineered mouse model (Johannessen et al., 2008). Currently mTOR 
inhibitors are being evaluated in clinical trials for plexiform neurofibromas (NCT00652990, 
NCT01365468). While the results of these trials are not yet published, they have been  
presented publically and indicate that mTOR inhibitors seem to be producing a cytostatic 
response, as was seen in the mouse model. An additional trial combining everolimus and the 
angiogenesis inhibitor bevacizumab is entering Phase II as a result of observations in our lab 
that tumors treated with mTOR inhibitors long-term become highly de-vascularized. 
(NCT01661283). 
These data suggest that the components of this pathway are potentially good 
therapeutic targets, however it remains unclear which signaling nodes represent the most 
critical therapeutic targets. Given the large number and variety of agents being investigated 
clinically, a better understanding of the pathway components and their relative contribution to 
the pathogenesis of NF1-mutant cancer is critical for selecting the best therapeutic 
combinations. This problem is the focus in Chapter 1 of this thesis.  
The ERK pathway is similarly hyper-activated when NF1 is lost. As with the PI3K/AKT/mTOR 
pathway, a number of clinical agents targeting these signaling nodes have been or are being 
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clinically developed (Table 1–3). The RAF inhibitors sorafenib, dabrafenib, and vemurafenib 
have been FDA-approved, and more recently the MEK inhibitor trametinib was approved for 
use in combination with dabrafenib in melanoma. More recently, ERK inhibitors have been 
identified and they are actively being explored in clinical trials now, although none are FDA-
approved yet.  
 
Pre-clinical evidence strongly supports a role for both the mTOR pathway and the ERK 
pathway in NF1-deficient tumorigenesis. NF1-mutant tumor cell lines and primary tissue 
display RAF/MEK/ERK hyper-activation (Donovan et al., 2002; Ingram et al., 2000; Jessen et 
al., 2013; Lau et al., 2000). Furthermore, NF1 –null cells show increased proliferation in an ERK-
dependent manner, and expression of the NF1 GAP-related-domain (GRD) can rescue this 
effect, indicating that ERK activation contributes to the pathogenesis of NF1-deficient cancers 
(Donovan et al., 2002; Hiatt et al., 2001; Ingram et al., 2000). Inhibition of the MAPK pathway 
Agent Target(s) Clinical Status 
RAF INHIBITORS   
Sorafenib CRAF/BRAF FDA-approved 
Dabrafenib BRAF/BRAFv600E/CRAF FDA-approved 
Vemurafenib BRAFv600E FDA-approved 
Encorafenib BRAFV600 Phase III 
RAF265 BRAF/VEGFR2 Phase II 
CEP-32496 BRAF/ BRAFv600E/CRAF Phase I/II 
MEK INHIBITORS   
Trametinib MEK 1/2 FDA-approved 
Cobimetinib MEK 1/2 Phase III 
Binimetinib (MEK 162) MEK 1/2 Phase I/II 
PD-0325901 MEK 1/2 Phase II 
Selumetinib (AZD6244) MEK 1/2 Phase I/II 
ERK INHIBITORS   
BVD-523 ERK 1/2 Phase I/II 
GDC-0994 ERK 1/2 Phase I 
CC-90003 ERK 1/2 Phase I 
Table 1–3. Inhibitors for the ERK Pathway in Clinical Development. Shown are 
inhibitors against RAF, MEK, and ERK and their current stage in clinical trials. Compiled 
from the NCI Drug Encyclopedia and clinicaltrials.gov. 
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using the MEK inhibitor PD-0325901 has been shown to have a profound cytotoxic effect in a 
mouse model of neurofibromas, demonstrating that this pathway is also critical to NF1-
deficient pathogenesis (Jessen et al., 2013). A phase II clinical trial using PD-0325901 in NF1-
adolescents with plexiform neurofibromas is currently enrolling, and preliminary results, which 
have been presented publically, are promising (NCT02096471, clinicaltrials.gov). 
While there is ample evidence that both the PI3K/AKT/mTOR pathway and the ERK 
pathway are hyperactivated when NF1 is lost, it is unlikely that inhibition of either of these 
pathways will be sufficient to induce tumor regression as monotherapies. Inhibitors directed 
against both pathways are currently in clinical trials as monotherapies, but MPNST mouse 
models have shown cytostatic responses at best to mTOR inhibitors and MEK inhibitors 
(Jessen et al., 2013; Johannessen et al., 2008). To date, no single agent has shown clinical 
efficacy in this aggressive tumor type. Therefore, it is likely that a combination therapy will be 
necessary to achieve tumor regression, as is addressed in both Chapter 2 and Chapter 3 of 
this thesis.  
 
 
 
THE STRESS PHENOTYPE OF CANCER 
Mutations in oncogenes and tumor suppressors are the causal events in cancer leading 
to the well-described hallmarks of cancer: self sufficiency in growth signals, insensitivity to 
anti-growth signals, evading apoptosis, limitless replicative potential, increased angiogenesis, 
and tissue invasion and metastasis (Hanahan and Weinberg, 2000). Targeting the specific 
alterations that give cancer these properties, as discussed above, is the focus of Chapter 2 of 
this thesis. However, it has recently been appreciated that many other pathways in the cell may 
be activated in a response to the tumorigenic state to allow cancer cell survival and that these 
processes may also represent potential therapeutic targets. This increased dependence of a 
24 
cancer cell on the activity of a normal gene is called non-oncogene addiction. Thus, in addition 
to the canonical hallmarks induced by oncogenes and tumor suppressors, several new 
hallmarks related to the stress phenotype of cancer have been proposed: DNA damage and 
replicative stress, proteotoxic stress, mitotic stress, metabolic stress, and oxidative stress (Luo 
et al., 2009). While these alterations are not causative of tumorigenesis they are characteristics 
present in most, if not all, tumors and are essential to maintaining the tumorigenic state. 
Chapter 3 of this thesis will focus on exploiting the oxidative and proteotoxic stress of cancer 
cells to develop therapies, so these specific types of stress are discussed in detail below.  
 
PROTEOTOXIC STRESS 
Most tumors are highly aneuploid and have a large number of gene copy number 
changes (Holland and Cleveland, 2009). These alterations can promote tumor growth by 
altering the balance between positive and negative regulators of proliferation and survival. 
However, these imbalances can also change the transcriptional stoichiometry of cellular 
complexes leading to an increased number of misfolded proteins and protein aggregates that 
the cellular machinery that regulates protein folding and degradation must attenuate. Studies 
of aneuploid mouse embryonic fibroblast cells observe high levels of chaperone protein 
expression, suggesting that aneuploidy puts a strain on the protein folding capabilities of the 
cell (Oromendia and Amon, 2014; Sheltzer et al., 2012; Williams et al., 2008). Further, a large 
number of aneuploid cell lines have been characterized and regardless of specific genetic 
alterations, they share a common set of expression alterations termed the environmental stress 
response, which is indicative of proteotoxic stress (Sheltzer et al., 2012). 
 Aneuploidy leads to slower growth in most contexts, despite the fact that 90% of solid 
tumors are aneuploid (Williams et al., 2008). MPNSTs in particular are known to have a 
complex karyotype with numerous chromosomal alterations and frequent aneuploidy (Bridge et 
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al., 2004). Thus cancer cells must adapt to maintain an increased proliferative rate despite the 
presence of aneuploidy (Torres et al., 2010). Cancer cells may be more reliant on the protein 
chaperone machinery responsible for attenuating proteotoxic stress, and similarly hyper-
sensitive to any further induction of proteotoxic stress.  
The Unfolded Protein Response 
 The unfolded protein response (UPR) is a cellular stress response primarily responsible 
for attenuating endoplasmic reticulum stress (ER stress). This process is inherently connected 
to proteotoxic stress as the ER is the site of cellular protein folding. When misfolded or 
unfolded proteins accumulate in the lumen of the ER, this leads to induction of the UPR, which 
is initially a protective response but will trigger apoptosis in the case of irresolvable ER stress. 
As will be discussed later in this thesis, we have found that induction of ER stress and 
modulation of the UPR can induce tumor regression. Therefore, a detailed description of the 
UPR is included, which will be important for Chapter 3. 
 BIP (or GRP78) is an ER luminal protein, which is the initial trigger for the UPR. BIP is a 
protein chaperone, which can assist in the folding of unfolded proteins. When no unfolded 
proteins are present, BIP is bound to the three main effectors of the UPR: Inositol requiring 
protein 1 (IRE1), Protein kinase RNA-like endoplasmic reticulum kinase (PERK), and activating 
transcription factor 6 (ATF6), and prevents their activation. However, as the number of unfolded 
proteins in the ER lumen rises, BIP is recruited away from the UPR initiators to refold these 
proteins. This releases these proteins to trigger activation of downstream UPR effector proteins 
(Figure 1–7). There is some evidence that unfolded proteins can also directly activate IRE1α 
and PERK. The three canonical sensors of ER stress, IRE1α, PERK, and ATF6, and their direct 
effectors are discussed in detail below, however in reality there is a large amount of cross-talk 
and integration of these pathways. 
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IRE1α 
IRE1α is a serine/threonine protein kinase as well as an endonuclease. IRE1α is a 
luminal transmembrane protein that contains an ER luminal portion that can sense the 
presence of unfolded proteins, and a cytoplasmic kinase domain-containing portion that can 
signal to effector pathways to alter protein transcription and translation in response to ER  
P
PP
P
IRE1α
PERK
ATF6
P eIF2α
XBP1(u) 
mRNA 
XBP1(s) 
mRNA 
XBP1(s)
Target Genes
ATF6
Target Genes
CHOP
ATF4Translation 
Inhibition
Chaperone 
Proteins
ERAD
ATF3
Translocation 
to Golgi
BIP
BIP
BIP
BIP BIP
BIP
ER Lumen
Figure 1–7. The Unfolded Protein Response (UPR). The three main transducers of the 
UPR—IRE1α, PERK, and ATF6 are all activated in response to the presence of unfolded 
proteins in the ER lumen. In an unstressed ER, the protein chaperone BIP binds to these 
transducers and keeps them inactive. When unfolded proteins are present, they recruit BIP 
away, and release IRE1α, PERK, and ATF6. There is also evidence that unfolded proteins 
can directly activate at least IRE1α and PERK. IRE1α auto-phosphorylates and then splices 
XBP1 mRNA to produce XBP1(s), which can activate a number of genes involved in the 
stress response. PERK phosphorylates eIF2α, which blocks global translation. When BIP 
releases ATF6, ATF6 translocates to the Golgi where it is cleaved, which allows ATF6 to 
then activate a number of UPR genes in the nucleus.  
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stress (Sidrauski and Walter, 1997). When unfolded proteins are present, IRE1α oligomerizes 
and auto-phosphorylates. IRE1α is unusual amongst transmembrane kinases, as this 
autophosphorylation does not lead to a phosphorylation cascade—the only known substrate of 
IRE1α is itself. Instead, activation and autophosphorylation of IRE1α allows IRE1α to perform 
its other function: endonucleolytic cleavage of X-box binding protein-1 (XBP1). IRE1α cuts 
XBP1 in two locations, removing an intron, and the remaining pieces are ligated creating a 
spliced mRNA. This spliced version of XBP1 encodes a transcriptional activator of a number of 
UPR effectors (Sidrauski and Walter, 1997). IRE1α may also have endonuclease activity against 
other mRNAs, but this activity seems to lead to their degradation (Hollien and Weissman, 2006; 
Hollien et al., 2009). 
PERK 
Similar to IRE1α, PERK is a transmembrane protein with a luminal stress-sensing 
domain, and a cytoplasmic kinase-containing domain. PERK also oligomerizes under stressful 
conditions, and autophosphorylates. However, in contrast to IRE1α, PERK can phosphorylate 
eIF2α. This phosphorylation event is an inhibitory phosphorylation signal, and reduces eIF2α 
activity, which leads to a suppression in translation, to prevent a further increase in the number 
of proteins requiring folding in the ER lumen (Harding et al., 1999; Shi et al., 1998). In addition 
to suppression of translation, it seems that PERK activation can also regulate the transcription 
of some UPR-associated genes, including CHOP, ATF3, and ATF4 (Teske et al., 2011). In cells 
where PERK has been knocked out, the transcription of a number of UPR effector genes is 
impaired (Harding et al., 2000; 2003; Teske et al., 2011), and a similar effect was observed in 
cells containing an eIF2α Ser51Ala mutation, suggesting that most of the transcriptional effects 
of PERK activation are mediated through eIF2α phosphorylation (Scheuner et al., 2001). 
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ATF6  
The third main arm of the unfolded protein response is through ATF6, a transmembrane 
transcription factor. ATF6 is normally retained in the ER lumen through interaction with BIP, 
however as BIP is recruited away by unfolded proteins, ATF6 is released from the ER and 
moves to the Golgi (Chen et al., 2002). ATF6 is processed in the Golgi by the serine protease 
site-1 protease (S1P) and the metalloprotease site-2 (S2P) to release a soluble transcription 
factor, which regulates a number of UPR-associated genes. In the nucleus, ATF6 recognizes 
ER stress response elements, UPR elements, and cAMP response elements in gene promoters 
leading to transcription of a program of genes to mediate cellular survival and the production of 
proteins involved in ER associated-degradation to promote the clearance and degradation of 
accumulated misfolded proteins (Kokame et al., 2001; Yoshida et al., 1998; 2001).  
UPR-Mediated Cell Death 
While most aspects of the unfolded protein response are directed at protecting the cell 
from further damage by halting translation to relieve stress and promoting degradation of 
misfolded proteins and aggregates, the unfolded protein response can also trigger apoptosis in 
the face of irremediable ER stress. Several UPR-regulated factors have been implicated in the 
induction of ER-stress induced apoptosis. IRE1α can activate Apoptotic Signaling Kinase 1 
(ASK1), which causes activation of a phosphorylation cascade that can promote apoptosis 
(Kim et al., 2008). CHOP activation has also been implicated in ER-stress mediated apoptosis, 
as CHOP seems to promote transcription of apoptotic genes such as BIM. However, CHOP is 
clearly not the only path to ER-stress induced apoptosis as CHOP-/- cells are only partially 
resistant to ER-stress induced death and PERK-/- cells are not resistant to apoptosis despite 
low levels of CHOP (Oyadomari and Mori, 2004). A third mechanism by which ER-stress can 
induce apoptosis is through calcium release from the ER lumen, which is mediated by BAX and 
BCL-2 (Sano and Reed, 2013).  
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The exact signals that cause the UPR to switch from an adaptive response to a terminal 
response remain unclear. However, recently, increased expression of thioredoxin interacting 
protein (TXNIP) has been implicated in the switch to an apoptotic fate, at least in the setting of 
pancreatic β-cells (Anthony and Wek, 2012; Lerner et al., 2012; Oslowski et al., 2012). In these 
studies, TXNIP expression was increased in conditions of ER stress through PERK and IRE1α, 
and suppression of TXNIP promoted cell survival in these conditions. This role for TXNIP is 
particularly interesting, as TXNIP is also an important factor in the oxidative stress response as 
discussed below. TXNIP induction by the UPR thus connects both proteotoxic and oxidative 
signals with an apoptotic cellular fate.  
 
OXIDATIVE STRESS 
 Oxidative stress refers to the imbalance of naturally occurring reactive oxygen species 
(ROS) and the endogenous systems that detoxify the ROS and repair any resulting damage. In 
cancer cells this balance is typically disturbed for a variety of reasons. Cancer cells exhibit an 
accelerated metabolism as well as a high proliferative rate, both of which contribute to the 
elevated production of ROS. In order to attenuate this increased oxidative stress, cancer cells 
often upregulate cellular ROS scavenging systems, producing a paradoxical situation in which 
cancer cells have higher levels of ROS than normal cells, despite a much higher antioxidant 
capacity. Importantly, there is an interdependent relationship between oxidative stress and 
proteotoxic stress: oxidative stress results in misfolded proteins and induces proteotoxic 
stress, and proteotoxic stress results in mitochondrial damage and oxidative stress. This link 
between proteotoxic and oxidative stress is discussed in detail later, and is critical for Chapter 
3 of this thesis. 
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Reactive Oxygen Species 
 The term ROS refers to any oxygen-containing chemical species that has reactive 
properties. This includes a number of different free radicals and non-radical molecules. 
Mitochondria are the major source of cellular ROS. Approximately 3–5% of the oxygen 
consumed by mitochondria is converted to ROS (Finkel, 2012). Different levels of ROS produce 
different physiological effects, so the regulation of redox balance is critical for cellular 
homeostasis. At low levels, ROS function as important signaling molecules within the cell, 
regulating proliferation and differentiation (Janssen-Heininger et al., 2008). At moderate levels, 
ROS will induce cellular stress responses to promote cellular survival, but at high levels ROS 
can damage DNA, RNA, proteins, and lipids (Veskoukis et al., 2012). Excessive ROS will 
ultimately lead to cell death (Gorrini et al., 2013).  
Antioxidant Systems  
There are two thiol-dependent anti-oxidant systems that promote the detoxification of ROS: 
the glutathione (GSH) system and the thioredoxin (TRX) system. Generally, these systems can 
scavenge ROS either directly or indirectly through enzymatic reactions, reducing the level of 
ROS present in the cell. These two systems are described in detail below.  
Glutathione System 
Reduced glutathione (GSH) is the main cellular defense against ROS. Glutathione 
contains a reducing thiol group (-SH), which becomes oxidized when it reacts with oxidized 
molecules. Oxidized glutathione quickly reacts with another reduced glutathione producing 
glutathione disulfide (GSSG). Glutathione disulfide can be converted back into reduced 
glutathione in an NADPH-dependent manner by glutathione reductase (GR). In normal cells, 
90% of the GSH is reduced, and only 10% is oxidized, providing a large buffering capacity for 
the cell. One combination therapy our lab has developed, which is discussed in detail later, 
functions in part by decreasing the level of reduced GSH present in the cell.  
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Thioredoxin System 
The thioredoxin (TRX) system is very similar to the GSH system. TRX contains two 
reducing thiol groups, which can reduce target molecules resulting in oxidized thioredoxin. 
Thioreductase (TrxR) then reduces thioredoxin in an NADPH-dependent fashion (Lu and 
Holmgren, 2014). There are two thioredoxin proteins, thioredoxin 1 (TRX1) which is 
predominantly cytoplasmic and nuclear, and thioredoxin 2 (TRX2), which is mitochondrial. The 
TRX system can directly induce apoptosis via activation of apoptosis regulating signal 1 
(ASK1). Reduced TRX directly binds ASK1, and inhibits ASK1 activity. When TRX is oxidized, 
this causes the dissociation of TRX and ASK1, releasing ASK1 to initiate apoptosis. The 
thioredoxin interacting protein (TXNIP) regulates this interaction. TXNIP is an inhibitor of 
reduced TRX; TXNIP blocks the reducing capabilities of TRX via a direct binding. When TXNIP 
is bound to TRX, this similarly causes a dissociation of ASK1, and allows apoptosis initiation 
(Lu and Holmgren, 2012).  
Crosstalk between the ER and the Mitochondria during Stress 
While proteotoxic and oxidative stress can arise for distinct reasons, the cellular 
response pathways are interconnected, linking the ER and the mitochondria in a complex and 
interdependent manner. Activation of the unfolded protein response results in a release of 
calcium from the ER, which depolarizes the mitochondrial membrane and leads to increased 
ROS production, which in turn can further impair protein folding (Malhotra and Kaufman, 2007). 
Conversely, oxidative stress can induce protein misfolding, which will engage the UPR, and 
again, lead to further mitochondrial damage and ER stress (Eletto et al., 2014). At moderate 
levels of stress the cell can engage compensatory mechanisms such as the UPR and the GSH 
and TRX systems that will attenuate the ER stress and ROS, and the cell will survive. However, 
if the stress is insurmountable, or the adaptive pathways are impaired, this will result in a 
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vicious cycle of damage between the ER and the mitochondria, ultimately resulting in cell death 
(Kim et al., 2008). 
 
TARGETING THE STRESS PHENOTYPE IN MPNSTS 
The elevated proteotoxic and oxidative stress observed in cancer cells could make 
them more sensitive to inducers of stress or modulators of stress responses (Figure 1–8).  
MPNSTs in a genetically engineered mouse model display high levels of ER stress, and 
MPNST cell lines are sensitive to a number of ER-stress inducing agents in vitro, including 
thapsigargin, tunicamycin, and HSP90 inhibitors. However, these agents do not induce tumor 
shrinkage as a monotherapy in vivo (De Raedt et al., 2011). When ER stress inducing agents  
are combined with the mTOR inhibitor rapamycin, which is cytostatic as a monotherapy, they 
convert the cytostatic response to a cytotoxic response (De Raedt et al., 2011; Johannessen et 
al., 2008). Interestingly, this effect was shown to be dependent on ROS, as ER stress inducing 
agents increased ROS levels, and the ROS scavenger ascorbic acid could block this effect (De 
Raedt et al., 2011). ER stress inducing agents alone induce ER stress and ROS, but the cell is 
able to attenuate this stress by activating stress response pathways. However, we found that 
mTOR inhibitors reduce activity of the pentose phosphate pathway—one of the key sources of 
NADPH in the cell (De Raedt et al., 2011; Düvel et al., 2010). The glutathione system is 
dependent on NADPH to maintain reduced GSH; when mTOR inhibitors are added to ER 
stress inhibitors the cell can no longer attenuate the oxidative stress resulting from the ER 
stress, and a vicious cycle of ER and mitochondrial damage is triggered (Figure 1–9) (De Raedt 
et al., 2011).  
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The combination of ER stress inducing agents and mTOR inhibitors is the first 
combination discovered that reduces tumor size in this aggressive mouse model of MPNSTs. 
Of the ER stress inducing compounds included in that study, only HSP90 inhibitors are being 
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Figure 1–8. Diagram of Cancer Susceptibility to Modulators of Proteotoxic and 
Oxidative Stress. A, Cancer cell display increased ROS relative to normal cells. Agents 
that increase ROS or impair ROS scavenging systems will push the ROS level beyond the 
threshold for survival in cancer cells, while normal cells can accommodate the increased 
ROS. B, Similar to A, cancer cells have elevated ER stress so ER stress inducers or agents 
that impair the UPR will further increase the ER stress levels in cancer cells beyond the 
threshold of acceptable stress, while normal cells can attenuate the increased stress and 
survive. 
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clinically developed. A Phase I/II trial of restapimycin (IPI-504) and everolimus (an mTOR 
inhibitor) was recently completed in patients with KRAS-mutant non-small cell lung cancer, 
however study results are not yet public (NCT01427946). A Phase I/II of second-generation 
HSP90 inhibitor ganetespib (STA-9090) and sirolimus in MPNST patients is currently enrolling 
(NCT02008877). To date however, there are no FDA-approved HSP90 inhibitors, and it remains 
possible that a tolerable therapeutic window for this particular combination will not be 
identified. However, given the proposed mechanism of synergy, a large number of ER stress 
modulators or ROS modulators could potentially induce the same process in combination with 
mTOR inhibitors. Chapter 2 of this thesis explores an alternative approach to exploiting tumor 
stress in MPNSTs by combining the histone deacetylase inhibitors with mTOR inhibitors.  
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Figure 1–9. Model for Synergy between ER Stress Inducers and mTOR Inhibitors. 
Schematic of the proposed mechanism of synergy between ER Stress Inhibitors and mTOR 
inhibitors. ER Stress inducers activate the UPR and cause a release of calcium from the ER, 
triggering ROS production in the mitochondria. mTOR inhibitors reduce the cell’s ROS 
scavenging abilities through a reduction in levels of reduced glutathione, and a vicious cycle 
is activated.  
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HISTONE DEACETYLASE INHIBITORS 
 The histone deacetylase (HDAC) inhibitor vorinostat is FDA-approved for use in 
cutaneous t-cell lymphoma (CTCL), and is known to induce ER stress and ROS (Kahali et al., 
2010; Petruccelli et al., 2011). Vorinostat is a pan-HDAC inhibitor with activity against all Zn2+-
dependent HDACs. Histone deacetylases received their name because they enzymatically 
remove acetyl groups from lysines on histones, counteracting the activity of histone acetyl-
transferases. However, this is a bit of a misnomer as HDACs also have important roles 
deacetylating proteins and indeed some HDACs, such as HDAC6, are entirely cytoplasmic and 
have no known role in the nucleus. Thus inhibition of HDACs affects function of acetylated 
proteins, which become hyper-acetylated in the context of HDAC inhibition, as well as global 
gene transcription through modulation of histone acetylation.  
 Vorinostat induces the unfolded protein response, and this activation has been shown 
to contribute to its antitumor effect in some settings (Kahali et al., 2010; 2011). The mechanism 
for this effect on the unfolded protein response remains unclear. A primary proposed 
mechanism has focused on HDAC6 inhibition. HDAC6 is a cytoplasmic HDAC that has been 
shown to deacetylate HSP90 (Kekatpure et al., 2009). When HSP90 is acetylated, it cannot act 
as a chaperone for target proteins (Scroggins et al., 2007), effectively inhibiting HSP90 activity. 
Thus HDAC inhibition could represent an alternative way of inducing ER stress through HSP90 
inhibition. Alternatively, it has been proposed that BIP is also acetylated, and that this 
acetylation event prevents BIP from binding the UPR transducers in the ER lumen, releasing 
them to activate the UPR (Choudhary et al., 2009; Kahali et al., 2012). The class I HDACs (1-3), 
as well as HDAC6, are implicated in the deacetylation of BIP (Kahali et al., 2012; Rao et al., 
2010). Vorinostat has also been shown to increase ROS (Ungerstedt et al., 2012). This effect is 
thought to be through modulation of the TRX system. Vorinostat induces an upregulation of 
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TXNIP, a negative regulator of TRX, thus limiting one of the key ROS scavenging pathways 
(Butler et al., 2002; Ungerstedt et al., 2005).  
 
OVERVIEW OF THESIS 
  Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of death 
among patients with NF1 and current treatment options are limited. Loss of the tumor 
suppressor NF1 is a critical component of MPNST pathogenesis, and is also a common event 
in a wide variety of sporadic cancers. Thus, therapies for NF1-deficient cancers represent an 
important clinical need. During my dissertation research, I aimed to better understand the 
signaling and stress vulnerabilities of this tumor type. I identify two novel combination therapies 
that I hope can be translated to meaningful clinical benefit for patients.  
In Chapter 2, I dissect key signaling nodes downstream of NF1 loss to identify a 
combination therapy and describe a therapeutic biomarker of effective target inhibition. In a 
panel of NF1-deficient cell lines we show that p110α and mTORC1 are the key signaling nodes 
downstream of NF1 loss. Conversely, we find that p110β, p110δ, mTORC2, and AKT are not 
necessary for proliferation or sustained mTORC1 signaling. Using a genetically engineered 
mouse model of MPNSTs we show that combined inhibition of mTORC1 and MEK promotes 
tumor regression, but only when target inhibition is sustained. Transcriptional profiling of the 
tumors unexpectedly identified the glucose transporter GLUT1 as a biomarker of dual target 
inhibition. We show that early changes in FDG-PET uptake correlate with eventual tumor 
regression, suggesting that this could serve as a non-invasive proxy measurement for target 
inhibition.  
In Chapter 3, I describe a combination of two FDA-approved agents that exploits 
proteotoxic and oxidative stress vulnerabilities in MPNSTs. We find that the pan-HDAC 
inhibitor vorinostat induces ER stress in MPNSTs, and that MPNST cell lines are sensitive to 
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HDAC inhibition in vitro. I demonstrate that addition of an mTOR inhibitor sensitizes cells to 
vorinostat in vitro, and that the combination of vorinostat and rapamycin leads to MPNST 
regression in vivo. I further show that HDAC6 inhibition alone is not sufficient. I identify 
modulation of the unfolded protein response, oxidative stress, and the thioredoxin system as 
one mechanism likely contributing to the therapeutic efficacy of this combination. 
In Appendix A, I report the effective combination of a second-generation HSP90 
inhibitor STA-1474 and rapamycin in MPNSTs. In Appendix B, I reprint a publication from the 
laboratory that describes the effective combination of ER stress inducers and mTOR inhibitors 
in MPNSTs. This work, to which I contributed, provides the basis for the studies described in 
Chapter 3. Appendix C contains supplemental materials for Chapter 2.  
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Therapeutic Biomarkers in NF1-Mutant Cancers 
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INTRODUCTION 
The NF1 tumor suppressor is mutated or suppressed in a variety of sporadic cancers 
including glioblastoma, neuroblastoma, melanoma and non-small cell lung cancer (Ding et al., 
2008; Maertens et al., 2013; McGillicuddy et al., 2009; Parsons et al., 2008; The et al., 1993). 
NF1 mutations also underlie the familial cancer syndrome, neurofibromatosis type 1 (NF1) 
(Cawthon et al., 1990; Martin et al., 1990). NF1 patients exhibit a variety of tumorigenic and 
non-tumorigenic manifestations but the most common cause of death is malignant peripheral 
nerve sheath tumors (MPNSTs). These highly aggressive tumors are lethal in approximately 
70% of patients, and conventional chemotherapy and radiation do not reduce mortality in 
individuals with inoperable tumors (Evans et al., 2002; Porter et al., 2009; Zehou et al., 2013). 
Therefore, developing effective targeted therapies for these individuals represents an important 
and unmet clinical need. Moreover, an effective therapy for this tumor type may be more 
broadly applicable to other sporadic NF1-mutant cancers.  
The NF1 tumor suppressor gene encodes a RAS GAP, which inactivates RAS by 
catalyzing the hydrolysis of RAS-GTP (Cawthon et al., 1990; Martin et al., 1990). As such, when 
NF1 is mutated or suppressed, RAS and downstream effectors become hyperactivated 
(DeClue et al., 1992). Both the PI3K/mTOR and MEK/ERK pathways have been shown to be 
important in various NF1-mutant tumors and therefore components of these pathways 
represent potential therapeutic targets (Endo et al., 2013; Johannessen et al., 2008; Parkin et 
al., 2010; See et al., 2012). However, given the plethora of available drugs that target these 
pathways we set out to genetically and chemically deconstruct the most important signaling 
nodes in NF1-mutant MPNSTs. Together with preclinical studies in a genetically engineered 
mouse tumor model, we found that mTORC1 is the key PI3K pathway component in these 
NF1-mutant malignancies, AKT and TORC2 are dispensable, and only sustained mTORC1 and 
MEK inhibition promotes tumor regression.  
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Several combined PI3K/MEK pathway trials are in development or are being considered 
for other cancers (Britten, 2013). However, the clinical challenge will be to identify a drug 
combination and dose that effectively suppresses both pathways, while minimizing toxicity. It 
is currently unclear how dosing can be adjusted while confirming that both targets are 
sufficiently inhibited in real time, especially given that the duration of inhibition appears to be 
an important determinant of efficacy. Thus, establishing a tractable biomarker for effective, 
combined target inhibition would greatly facilitate this effort. By performing transcriptional 
profiling and imaging studies we unexpectedly identified GLUT1, which mediates 18F-
fluorodeoxyglucose (18F-FDG) uptake, as a key gene that is suppressed prior to tumor 
regression but only when both pathways are effectively inhibited. Moreover, we show that 18F-
FDG uptake is a reliable readout of combined target inhibition. This insight can be directly 
applied to the design of clinical trials in NF1 mutant cancers and may also have broader utility 
in other RAS-driven tumors.  
 
RESULTS  
p110α and mTORC1 are the Key Effectors in NF1-Mutant Nervous System Malignancies 
We previously showed that loss or inactivation of NF1 triggers the aberrant activation of 
PI3K/mTORC1 signaling in human and mouse MPNSTs (Johannessen et al., 2005). However, it 
is currently unclear which specific components within this pathway represent the best 
therapeutic targets. Such insight would reveal which drugs should be preferentially evaluated 
or excluded in clinical trials. Therefore, we sought to genetically and chemically deconstruct 
this pathway in NF1-mutant MPNSTs. There are three Class 1A catalytic PI3K isoforms: p110α, 
p110β, and p110δ. While p110α is frequently mutated in human cancer, p110β has been 
shown to play an essential role in PTEN mutant cancers and p110δ is critical in chronic 
lymphocytic leukemia (Herman et al., 2010; Jia et al., 2008; Samuels et al., 2004). To identify 
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which catalytic isoform(s) are essential in NF1-mutant nervous system malignancies, we first 
assessed the biological effects of isoform-specific ablation in human MPNST cells derived from 
NF1 patients. While all three isoforms were present in MPNSTs, genetic ablation of p110α, but 
not p110β or p110δ, dramatically impaired the proliferation of both tumor lines (Figure 2–1A). 
Similarly, NF1-mutant gliblastoma (GBM) cells were exclusively sensitive to siRNA-mediated 
depletion of p110α, but not p110β or p110δ, suggesting that p110α may play a more general 
role in NF1-deficient cancers (Figure 2–1A). To complement these findings, we utilized PI3K 
isoform-specific inhibitors: the p110α- specific inhibitor A66-(S), the p110β-specific inhibitor 
AZD-6284, and the p110δ-specific inhibitor CAL-101, as well as GDC-0941, a pan-PI3K 
inhibitor (Folkes et al., 2008; Jamieson et al., 2011; Lannutti et al., 2011; Nylander et al., 2012). 
The reported specificities of each drug are outlined in Appendix C (Table C–1). In human 
MPNST cell lines, the p110α-specific inhibitor A66-(s) and GDC-0941 potently inhibited the 
phosphorylation of AKT and S6; however, the p110β- or p110δ-specific inhibitors, AZD-6284 
and CAL-101 respectively, did not suppress the phosphorylation of either protein (Figure 2–
1B). Accordingly, A66-(S) was the only isoform-specific inhibitor that suppressed proliferation 
in these cells (Figure 2–1C; p=0.039 in 90-8TLs and p=0.0006 in S462s). Together, these 
observations suggest that p110α is the primary catalytic subunit responsible for pro-
proliferative PI3K signaling in NF1-mutant nervous system malignancies.  
mTOR functions in two distinct complexes: the rapamycin-sensitive complex mTORC1, 
which phosphorylates 4E-BP1 and S6 kinase, and the relatively rapamycin-insensitive complex 
mTORC2, which phosphorylates AKT at serine 473 (Loewith et al., 2002; Sarbassov et al., 
2005). NF1-deficient MPNSTs have been shown to be sensitive to rapamycin, indicating that 
mTORC1 plays a role in this tumor type; however, the contribution of mTORC2 activity, if any, 
to MPNST growth is unknown (Johannessen et al., 2005; 2008). We genetically targeted  
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Figure 2–1. p110α and mTORC1 are Critical for the Proliferation of NF1-Deficient Tumor 
Cells. A, S462, 90-8TL, and LN-229 cells were transfected with pooled siRNAs 
targeting PIK3CA, PIK3CB,PIK3CD, or non-targeting siRNA. Bar graphs, relative change in cell 
number from day 0 to 96 hours as compared with control cells transfected with the non-targeting 
siRNA. Data points, triplicate averages ± SD. Immunoblots depict p110α, p110β, and p110δ 
protein levels 72 hours after transfection with the indicated siRNA. Actin serves as a loading 
control. *, P < 0.002. B, Immunoblots showing pAKT and pS6 levels in S462 cells following 
treatment with indicated inhibitors (4 hours; 500 nmol/L). AKT, S6, and actin serve as controls. C, 
Bar graphs of S462 and 90-8TL cells treated inhibitors as specified. Numbers represent the 
relative change in cell number from day 0 to 96 hours as compared with vehicle-treated control 
cells. Data points, triplicate averages ± SD. *, P < 0.04. D, S462 and 90-8TL cells were 
transfected with pooled siRNAs targeting MTOR, RAPTOR, RICTOR, or non-targeting siRNA. Bar 
graphs, relative change in cell number from day 0 to 96 hours as compared with control cells 
transfected with the non-targeting siRNA. Data points, triplicate averages ± SD. Immunoblots 
show mTOR, Raptor, Rictor, pAKT, and pS6 levels 72 hours after transfection with the indicated 
siRNA. AKT, S6, and actin levels serve as controls. *, P < 0.02. E, S462 cells were treated with the 
rapamcyin (Rap) at 100 nmol/L, Torin1 at 250 nmol/L, or MK-2206 (concentration indicated). Bar 
graph, relative change in cell number from day 0 to 96 hours as compared with vehicle-treated 
control cells. Data points, triplicate averages ± SD. Immunoblots show pAKTT308, pAKTS473, 
pTSC2T1462, pS6, and 4E-BP1 levels in the presence of the specified inhibitors. AKT, TSC2, S6, 
and actin serve as controls. *, P < 0.0001. F, S462 cells treated with either rapamycin at 100 
nmol/L, MK-2206 at 5 μmol/L, or both drugs together. Bar graphs, relative change in cell number 
from day 0 to 96 hours as compared with vehicle-treated control cells. Data points, triplicate 
averages ± SD. p, phosphorylated. 
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essential component proteins of each complex in order to evaluate the relative contribution of 
these two complexes. RAPTOR, is an essential component of mTORC1, but is not present in 
mTORC2, while RICTOR, a primary component protein of mTORC2, is not a member of the 
mTORC1 complex (Huang and Manning, 2009; Sarbassov et al., 2004) As expected, siRNA-
mediated-loss of RAPTOR or mTOR suppressed S6 phosphorylation and led to impaired 
proliferation of MPNST cell lines (Figure 2–1D). However, loss of RICTOR had no effect on 
MPNST proliferation, despite the effective suppression of phosphorylation of the mTORC2 
target AKT (Figure 2–1D).  
To further evaluate a role for AKT, or lack thereof, tumors cells were treated with the 
allosteric AKT inhibitor MK-2206 (Hirai et al., 2010). MK-2206 suppressed the phosphorylation 
of AKT at S473 and T308, and effectively inhibited AKT kinase activity as confirmed by the loss 
of TSC2 phosphorylation on T1462 (Figure 1–1E and Appendix C Figure C–1). However, unlike 
rapamycin, MK-2206 had no effect on the proliferation of NF1-mutant MPNST cells (Figure 2–
1E). The mTOR kinase inhibitor Torin1 inhibits both the mTORC1 and mTORC2 complexes. 
Notably, Torin1 has been reported to more effectively inhibit mTORC1, as compared to 
rapamycin, and in particular more potently suppresses 4E-BP1 phosphorylation, as observed 
in these studies (Figure 2–1E and Apppendix C Figure C–1). Accordingly, Torin1 potently 
suppressed the proliferation of NF1 mutant cells and did so better than rapamycin (p< 0.02). As 
noted, both MK-2206 and Torin1 equivalently and potently suppressed AKT phosphorylation 
and activity, although only Torin1 suppressed MPNST cell proliferation. Moreover, MK-2206 
did not enhance the anti-proliferative effects of rapamycin (Figure 2–1F). Taken together, these 
results suggest that mTORC1 is a critical effector in NF1-mutant cancers and that mTORC2 
and AKT are dispensable in these tumor cells.  
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Selection of an Effective PI3K/mTOR Pathway Inhibitor  
These in vitro studies suggested that pan-PI3K inhibitors, p110a-specific inhibitors or 
mTORC1 inhibitors should suppress the growth of NF1-mutant MPNSTs. Therefore, we first 
evaluated the in vivo effects of GDC-0941 and rapamycin in a genetically engineered mouse 
MPNST model. Like human MPNSTs, tumors from these animals harbor compound mutations 
in Nf1 and p53, and develop with an average latency of five months. These MPNSTs are highly 
aggressive, and mice survive for an average of 10.7 days after tumors are detected, thus 
recapitulating the aggressive nature of human tumors (Cichowski et al., 1999). As previously 
shown, rapamycin suppressed the growth of Nf1/p53 mutant MPNSTs (p<0.0001) 
(Johannessen et al., 2008); however, GDC-0941 did so significantly less well (p=0.0021) (Figure 
2–2A). Notably, the maximum tolerated dose of GDC-0941 (150mg/kg) inhibited the 
phosphorylation of AKT, S6 and 4E-BP1 in tumors within 1 hour, however these pathways 
were reactivated within 4 hours after treatment (Figure 2–2B). In contrast, rapamycin 
suppressed S6 and 4E-BP1 phosphorylation for at least 18 hours, consistent with the observed 
enhanced efficacy and the demonstrated importance of mTORC1 is these tumors. It should be 
noted that AKT is not activated by relief of feedback mechanisms in this model, as we have 
previously shown (Figure 2–2B) (De Raedt et al., 2011; Johannessen et al., 2008). Several other 
PI3K/mTOR pathway inhibitors including BEZ-235, Torin2, and INK-128 were evaluated in 
these animals (data not shown); however we were unable to identify an inhibitor that exhibited 
better pharmacodynamics or growth inhibition than rapamycin at tolerable doses in these 
animals. Therefore, rapamycin was selected for further studies.  
Combined, Sustained Inhibition of mTORC1 and MEK Promotes MPNST Regression in vivo 
Although mTORC1 is a critical signaling node in NF1 mutant tumors, mTORC1 inhibition 
exerted only cytostatic effects on MPNSTs in vitro and in vivo (Figure 2–1D, E, 2–2A) 
(Johannessen et al., 2008). Therefore, we evaluated the effects of rapamycin combined with a  
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Figure 2–2. Therapeutic Effects of PI3K and MEK Pathway Inhibitors in vivo. A, Waterfall 
plot depicting change in tumor volume in NPcis mice after 10 days of treatment with vehicle 
(black), GDC-0941 (blue), or rapamycin (green). The left y-axis indicates the log2 of the fold 
change in volume after 10 days. The right y-axis indicates the percent change in tumor 
volume relative to day 0. B, pAKT/pS6/4E-BP1 immunoblots of tissue from animals exposed 
to GDC-0941 or rapamycin for the indicated amount of time. AKT, S6, and vinculin serve as 
controls. C, Waterfall plot depicting change in tumor volume after 10 days of treatment with 
PD-0325901 (yellow) or rapamycin and PD-0325901 (Rap–PD) in combination (purple). Vehicle 
and rapamycin (gray) are reprinted from A for reference. The left y-axis indicates the log2 of 
the fold change in volume after 10 days. The right y-axis indicates the percent change in 
tumor volume relative to day 0. D, Immunoblots showing pERK levels in tissue after treatment 
with PD-0325901 once daily (top) or twice daily (bottom). Hours, number of hours from initial 
treatment. Representative samples from three biologic replicates are shown. Vinculin and ERK 
serve as controls. E, Waterfall plot depicting change in tumor volume after 10 days of 
treatment with PD-0325901 twice daily or PD-0325901 twice daily in combination with 
rapamycin. The left y-axis indicates the log2 of the fold change in tumor volume relative to day 
0 and the right y-axis indicates the percent change in tumor volume. 
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MEK inhibitor, which targets a second critical RAS effector pathway. Tumor-bearing mice were 
treated with vehicle, the MEK inhibitor PD-0325901, rapamycin, or the combination of 
rapamycin and PD-0325901. As a monotherapy, PD-0325901 slightly attenuated the growth of 
MPNSTs, but did so less than rapamycin (Figure 2–2C). However, combined PD-0325901 and 
rapamycin treatment induced tumor regression in these mice (Figure 2–2C). Interestingly, these 
observations differ from effects observed in benign NF1-deficient peripheral nervous system 
tumors and myeloid malignancies, where MEK appears to function as the dominant RAS-
effector pathway and MEK inhibitors exert cytotoxic effects alone, suggesting that different 
tumor types harboring the same initial driving genetic lesion may rely on different downstream 
signals (Chang et al., 2013; Jessen et al., 2013). Nevertheless, upon examining the 
pharmacodynamics of PD-0325901 at this dose, we found that ERK phosphorylation was 
inhibited for only 4–6 hours, whereas sustained inhibition could be achieved by dosing with 
PD-0325901 twice daily (Figure 2–2D). As such, we hypothesized that a revised dosing 
schedule might exert more potent therapeutic effects. Twice-daily PD-0325901 treatment did 
not promote tumor regression as a monotherapy, however when combined with rapamycin, 
twice daily PD-0325901 treatment improved the therapeutic response (Figure 2–2E). All mice 
treated with this combination responded, and more than half of the tumors regressed 50% or 
more, with several shrinking 75% or more. Together, these observations indicate that the 
duration of both MEK and mTORC1 inhibition is a critical determinant of the therapeutic 
response. 
Identifying GLUT1 as a Component of the Therapeutic Signature that is Suppressed Prior to 
Tumor Regression 
Pharmocodynamic markers in tumors are often not examined during clinical trials, and 
when they are, the kinetics of suppression are difficult to evaluate. Therefore, if a treatment 
does not show efficacy, especially in cases of dose de-escalation, it is often unclear whether 
51 
the target or targets were sufficiently inhibited. Therefore, we sought to identify a molecular 
change that might serve as a functional biomarker of effective, combined inhibition of mTORC1 
and MEK pathways. The transcriptional profiles of tumors from animals treated with vehicle,  
rapamycin, PD-0325901 (twice daily), or the combination of rapamycin and PD-0325901 were 
evaluated. Importantly, tissues were collected after 14 hours of treatment: a time point that 
would capture transcriptional changes caused by sustained target inhibition but occurring prior 
to tumor regression. Using a gene expression class comparison, we identified a gene set that 
was exclusively regulated by combined rapamycin and PD-0325901 treatment (Figure 2–3A). 
Interestingly Slc2a1, which encodes a glucose transporter and is commonly referred to as 
Glut1, was identified as one of the uniquely suppressed genes in rapamycin/PD-0325901 
treated tumors (Figure 2–3A) Effective mTORC1 and MEK target inhibition in tumor tissue was 
verified (Figure 2–3B). Q-PCR analysis confirmed that Glut1 levels were reduced 64% after only 
14 hours of treatment compared to vehicle treated tumors and that neither rapamycin nor PD-
0325901 exerted suppressive effects alone (Figure 2–3C). A dramatic decrease in GLUT1 
protein levels was further confirmed by evaluating its expression in tumor biopsies taken before 
and 3 days after treatment (Figure 2–3D). These findings differ from observations in VHL and 
LKB1 mutant tumors, where GLUT1 mRNA and consequently protein expression is primarily 
regulated by mTOR and HIF1a, and its expression can be suppressed by mTORC1 inhibitors 
alone (Shackelford et al., 2009; Thomas et al., 2006). However in these Nf1-mutant MPNSTs, 
suppression of both mTORC1 and the MEK/ERK pathways are required. This finding resolves a 
longstanding observation that rapamycin is not sufficient to suppress the expression of GLUT1, 
or other HIF-1a target genes in vitro or in vivo in this tumor type (Johannessen et al., 2008). 
Together, these results demonstrate that GLUT1 is suppressed in MPNSTs only after 
combined mTORC1 and MEK inhibition, which could be exploited for developing an imaging 
biomarker of combined target inhibition. 
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significance level of P = 0.001. The arrow denotes Slc2a1(encoding GLUT1), highlighted in 
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4E-BP1 levels in individual tumors as described in A. ERK and GAPDH serve as a 
control. C, Quantitative PCR showingSlc2a1 transcript levels in individual tumors 
described in A. D, Immunoblot showing GLUT1 levels in a pretreatment biopsy sample, 
and in the same tumor after treatment with PD-0325901 (twice daily) and rapamycin. p120 
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Only combined, effective suppression of mTORC1 and MEK inhibit 18F-FDG uptake  
GLUT1 is a membrane bound glucose transporter that is frequently over-expressed in 
tumors, in part, because altered tumor metabolism requires increased glucose uptake  
(Amann et al., 2009; Grover-McKay et al., 1998; Sakashita et al., 2001; Younes et al., 1997b). 
This metabolic activity can be measured by positron emission tomography (PET) scans 
designed to quantify 18F-FDG uptake (Som et al., 1980). GLUT1 has been shown to regulate 
18F-FDG uptake in a variety of tumor types (Avril, 2004; Smith, 2001). MPNSTs are generally 
FDG-PET positive, and enhanced 18F-FDG uptake is used to diagnose a conversion to 
malignancy, as MPNSTS often arise from benign precursor lesions (Benz et al., 2010). Because 
human MPNSTs exhibit a strong FDG-PET signal, and because GLUT1 was specifically 
suppressed in tumors treated with combined rapamycin and PD-0325901, we hypothesized 
that the substantial reduction in GLUT1 mRNA and protein might inhibit 18F-FDG uptake in 
these tumors. To evaluate this possibility, FDG-PET imaging was performed on tumor bearing 
mice. As expected, MPNSTs were FDG-PET positive at baseline, mirroring the behavior of 
human MPNSTs (Figure 2–4A). Mice were then treated with vehicle, PD-0325901, rapamycin or 
PD-0325901/rapamycin and PET analysis was performed a second time, 40 hours after the 
baseline scan. This time point was selected because it represents a time before detectable 
regression occurs, in order to avoid any confounding change in the FDG-PET signal due to a 
reduction in tumor size. It should be noted that the initial (64%) decrease in Glut1 mRNA levels 
can be detected 14 hours after treatment, however given the dramatic decrease in GLUT1 
protein after 72 hours this repression is sustained and perhaps enhanced, Animals treated with 
vehicle, PD-0325901, or rapamycin, did not have a significant change in 18F-FDG uptake after 
treatment (Figure 2–4A,B); however, animals treated with both PD-0325901 and rapamycin 
exhibited a significant decrease in SUVmax values (p<0.004) (Figure 2–4A,B). Importantly, while 
hexokinase and other GLUT genes can regulate glucose uptake in some settings  
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Figure 2–4. 18F-FDG Uptake is a Noninvasive Biomarker of Combined MEK–mTORC1 
Inhibition. A, Representative images of FDG–PET scans of animals treated with vehicle, 
PD-0325901, rapamycin, or both (Rap–PD). PD-0325901 was dosed twice daily. Baseline 
scans are shown at left (pre-), and the right image shows the same view of the same 
animal 40 hours after treatment with the indicated compound (post-). Arrow, MPNST. 
Scale bar, relative 18F-FDG uptake, with low uptake in blue and highest uptake in white. B, 
The 18F-FDG uptake by tumors was quantified using SUVmax, and the log2 of the fold 
change of this number was calculated to indicate the change in 18F-FDG uptake 40 hours 
after treatment relative to baseline for each animal. The change in combination-treated 
animals (Rap–PD) is compared with monotherapy and vehicle-treated animals (controls). 
The y-axis indicates the log2 of the fold change in SUVmax relative to baseline. C, 
Representative images of FDG–PET scans of animals treated with 100% PD-0324901–
rapamycin, 50%PD-0325901–rapamycin, or 25% PD-0325901–rapamycin. The left image 
(pre-) shows the baseline scan for each animal and the right (post-) shows the scan 40 
hours after treatment with the indicated dose. Again, the tumors are indicated with arrows. 
Scale bar, relative FDG uptake, with low uptake in blue and highest uptake in white. D, 
Left, a waterfall plot depicting the log2 fold change of SUVmax, a quantification of tumor 
FDG–PET activity, of selected tumors at 40 hours after treatment with PD-0325901 (25%, 
50%, or 100% of the dose) and rapamycin. Right, a waterfall plot depicting the log2 of fold 
change in tumor volume of the same mice after 10 days. Individual tumors are graphed in 
the same order on each plot. E, Regression analysis of nine combination-treated mice 
(100%, n = 3; 50%, n = 3; 25%, n = 3). The x-axis represents the log2 of fold change in 
tumor volume at 10 days, and they-axis represents the log2 of fold change in SUVmax levels 
after 40 hours of treatment. Both numbers are relative to day 0 measurements. Line, best-
fit linear correlation, and the Pearson coefficient (r) was calculated. 
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(Aloj et al., 1999; Ito et al., 1998; Smith, 2001; Younes et al., 1997a), rapamycin/PD-0325901 
treatment did not affect the expression of any of these genes suggesting that GLUT1 may be 
the rate-limiting step for FDG-PET uptake in MPNSTs (Appendix C, Table C–2). 
These observations suggested that FDG-PET imaging could be used as a biomarker of 
effective combined mTORC1/MEK inhibition in NF1-mutant tumors. Such a biomarker would 
be invaluable in the course of evaluating similar therapies in the clinic and in the course of dose 
de-escalation/escalation studies. This biomarker would be particularly useful if the early 
change in FDG-PET imaging were predictive of a later change in tumor size. To experimentally 
evaluate this possibility, we performed a dose de-escalation study in mice. Mice were treated  
with rapamycin in combination with 100%, 50%, or 25% of the PD-0325901 dose. As 
expected, this produced a range of responses in FDG-PET uptake at 40 hours and tumor 
regression after 10 days (Figure 2–4C,D). Importantly, the suppression of FDG-PET activity at 
40 hours, as measured by change in SUVmax, correlated with the ultimate decrease in tumor 
size after 10 days (Pearson R=0.711, p=0.03) (Figure 2–4D,E). These results suggest that early 
changes in the FDG-PET signal are indicative of the degree of target inhibition and correlate 
with eventual tumor regression in MPNSTs treated with combined mTORC1/MEK inhibitors.  
 
DISCUSSION 
Numerous PI3K pathway inhibitors have been developed and are being evaluated in 
clinical trials (Britten, 2013). However in many cancers it is not clear which specific 
component(s) within this pathway are most critical or to what degree they must be inhibited. 
Such information would undoubtedly facilitate the selection of the most appropriate drugs for 
clinical studies. In this study we used a genetic and chemical approach to systematically 
deconstruct the PI3K signaling pathway in NF1-mutant nervous system malignancies. 
Importantly, we found that mTORC1, which is regulated by p110a in these tumors, is the 
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minimal, essential PI3K pathway component and that surprisingly AKT and mTORC2 are 
dispensable. However, while agents that inhibit mTORC1 promote cytostasis in human tumor 
cells and genetically engineered models, tumor regression requires concomitant suppression 
of the MEK/ERK pathway.  
Notably, there are currently no effective therapies for MPNSTs. As such, these studies 
reveal a promising therapeutic approach as well as a mechanistic framework for selecting the 
most appropriate agents for clinical trials. For example, because p110β does not appear to 
contribute to the therapeutic response in these tumors perhaps p110a-specific, β-sparing PI3K 
inhibitors could be used with less toxicity (Liu et al., 2009). Alternatively, because mTORC1 
appears to be the key PI3K effector in these tumors perhaps rapalogs, which exhibit excellent 
pharmacokinetic properties, may be suitable for combination therapies. The observation that 
AKT is not activated in these tumors by feedback inhibition and that AKT inhibitors do not 
enhance the effects of rapamycin, further alleviates the concern that AKT suppression may be 
required in this setting. Nevertheless, these studies suggest that successful agents must 
promote sustained inhibition of both ERK and mTORC1. Importantly, suppression of these 
same targets results in tumor regression in a mouse model of NF1-mutant melanoma, 
underscoring the importance of these pathways in NF1-deficient cancers (Maertens et al., 
2013). Nevertheless, establishing the sufficient degree/length of inhibition of both targets that 
will be required to mediate an efficacious response in patients represents a formidable 
challenge.  
While mouse models are useful for identifying critical therapeutic targets in genetically 
defined cancers, the ultimate success of a therapy in humans depends on many factors. 
Certainly, species-specific differences in tumor complexity may limit efficacy or restrict 
therapeutic responses to a subset of patients. However, perhaps an even more important 
consideration relates to dosing. One of the primary obstacles in developing combination 
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therapies, especially when targeting two major signaling pathways, is achieving efficacy while 
preventing toxicity. As such, even if the correct therapeutic targets have been identified, it may 
not be possible to sufficiently suppress these targets in humans. MEK inhibitors have been 
shown to exhibit toxicity in humans at high doses (LoRusso et al., 2010; Renouf et al., 2012). 
Therefore in this study we used a dose of PD-0325901 that is comparable to the tolerable dose 
in humans. Similarly, the dose of rapamycin was selected based on a previous preclinical study 
that led to successful human clinical trial in a number of tuberous sclerosis complex related 
pathologies, although reported trough plasma levels were somewhat higher than what has 
been observed in humans (~50ng/ml versus 3–20 ng/ml in humans) (Ando et al., 2013; Franz et 
al., 2013; Krueger et al., 2013; Meikle et al., 2008). However our preliminary observations 
suggest that lower doses and/or intermittent dosing of mTOR inhibitors/rapalogs are also 
effective when combined with MEK inhibitors. Given the differences in toxicity observed 
between mice and humans, only clinical trials will reveal whether an effective, non-toxic dose 
can be achieved. As such, another important goal of this study was to develop a biomarker 
that could be used to guide dosing in the clinic.  
Current clinical trial strategies involve dosing up to the Maximum Tolerated Dose of one 
drug, and adding the second drug to the tolerable dose when possible. However, it is not 
always clear how dose escalation/de-escalation affects the degree or kinetics of target 
inhibition or if dosing at the MTD is necessary. As such, we set out to identify a biomarker(s) 
that would serve as an early downstream readout of effective, combined inhibition of MEK and 
TORC1. While several genes were identified in these tumors, GLUT1 stood out as an important 
and tractable molecular change. Consistent with the documented role of GLUT1 in regulating 
glucose uptake, we found that 18F-FDG uptake, as measured by FDG-PET, was a reliable 
readout of effective, combined target inhibition in vivo. Importantly, changes in GLUT1 
expression and 18F-FDG uptake occurred prior to tumor regression, supporting its role as a 
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molecular marker of TORC1/MEK suppression rather than a consequence of tumor shrinkage. 
Interestingly, neither GLUT1 expression nor glucose uptake were suppressed after treatment 
with either rapamycin or MEK inhibitors alone. This observation differs from findings in a subset 
of other mTOR-driven tumor types, where HIF1α-dependent GLUT1 expression is decreased 
after treatment with rapamycin, as is 18F-FDG uptake (Shackelford et al., 2009; Thomas et al., 
2006). We have previously shown that neither GLUT1 nor HIF1α levels are altered in MPNSTs 
when treated with rapamycin, marking an important distinction between NF1-deficient tumors 
and these other mTOR-driven tumors (Johannessen et al., 2008). Here, we provide an 
explanation for this difference, as simultaneous inhibition of both the mTORC1 and MEK are 
required to suppress GLUT1 and 18F-FDG uptake in MPNSTs. It will be interesting to determine 
whether inhibition of both pathways is required to alter glucose uptake in other tumors, in 
particular other RAS-driven tumors. Certainly, other factors, such as hexokinase activity or 
other members of the GLUT family, may contribute to glucose uptake in some cancers and in 
these instances 18F- FDG uptake might not be an effective biomarker. However our studies 
suggest that FDG-PET imaging represents a promising, non-invasive means of measuring 
combined mTORC1/MEK inhibition in vivo in these NF1-mutant tumors, which can be readily 
incorporated into clinical trials. Such a tool should help identify the most effective drugs, 
facilitate dosing, and its utility may extend beyond NF1-mutant cancers.  
 
METHODS 
Cell Lines and Reagents 
S462s and LN229s were purchased from ATCC. 90-8TLs were generously provided by 
Dr. Eric Legius (KULeuven). The authors performed no further authentication of the cell lines. 
Cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with fetal 
bovine serum (10%) and L-glutamine. Antibodies were obtained from the following sources: 
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Cell Signaling Technologies: pAKT (4060), AKT (9272), pERK (4370), ERK (9102), pS6 (2211), 
S6 (2217), p110α (4255), p110β (3011), Vinculin (4650), 4E-BP1 (9452), mTOR (7C10), Rictor 
(53A2), Raptor (24C12) pTSC2 (3611), TSC2 (3612) GAPDH (2118); Santa Cruz Biotechnology: 
p110δ (sc-7176); Trans Labs: p120 (G12920), Sigma: Actin (A2066), Alpha Diagnostics: Glut1 
(GT11-A). Torin1, A66-(S), AZD-6284, and CAL-101 were kindly provided by Nathanael Gray 
(Dana Farber Cancer Institute/Harvard Medical School). MK-2206 was generously provided by 
D. Wade Clapp (Indiana University). GDC-0941 was provided by Genentech (San Francisco, 
CA). PD-0325901 was a gift from Kevin Shannon (University of California, San Francisco). 
Rapamycin was purchased from LC Labs.  
RNAi  
Non-Targeting and PIK3CA, PIK3CB, PIK3CD, Raptor, Rictor, mTOR siRNA pools were 
purchased from Dharmacon (D-001810-10, L-003018-00, L-003019-00, L-006775-00, L-
004107-00, L-016984-00, L-003008-00, respectively). siRNAs were transfected overnight in 
antibiotic free medium using RNAiMax lipofectamine from Invitrogen.  
Cellular Proliferation Studies 
Approximately 125,000 cells per well were seeded in 6-well plates. For siRNA 
experiments, cells were seeded 12–16 hours after transfection. 24-hours after plating, day 0 
counts were taken using a hemocytometer and trypan blue exclusion. For inhibitor 
experiments, drug treatments were started at this time. Inhibitors were changed once daily, 
except for PI3K isoform experiments where drugs were replenished twice daily. Final cell 
counts were taken 96 hours after day 0 counts.  
Drug Treatments and Dosing Schedule  
Animal procedures were approved by the Center for Animal and Comparative 
Medicine in Harvard Medical School in accordance with the NIH Guild for the Care and Use of 
Laboratory Animals and the Animal Welfare Act. C56/BL6 NPcis mice have been previously 
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described (Cichowski et al., 1999). Mice were treated daily with rapamycin via IP injections at 5 
mg/kg, which were prepared as previously described (Johannessen et al., 2008). PD-0325901 
was administered at 1.5 mg/kg once or twice daily (10 hours apart) by oral gavage. PD-
0325901 was prepared as previously described.(Brown et al., 2007). GDC-0941 was 
administered at 150mg/kg once daily by oral gavage. GDC-0941 was prepared as previously 
described (Wallin et al., 2012). Compounds given in combination were administered 
sequentially.  
Biopsy 
Tumor biopsy was performed on mice prior to drug treatment using the wedge biopsy 
technique and snap-frozen. Drug treatment was started 8 hours after initial biopsy. The post-
treatment biopsy was performed 3 days after treatment began. The mouse was anesthetized 
by isoflurane inhalation and given a local block with lidocaine and marcaine while the tumor 
biopsy was collected. 
Tumor Volume Measurements 
Mice were started on a treatment when tumor size reached 200–1000 mm3. Tumor size 
was measured every 2–3 days by Vernier calipers. Tumor volume was calculated using the 
standard formula L x W2 x 0.52. A mouse pathologist confirmed that all tumors in this study are 
MPNSTs.  
18F-FDG-PET Imaging and Analysis 
PET/CT scans were performed on the Bioscan NanoPET/CT at the Longwood Small 
Animal Imaging Facility. This PET scanner is equipped with a dedicated isoflurane anesthesia 
system, temperature controlled platform, cardiac gating, and respiratory gating. PET scanning 
was performed on anesthetized animals lying motionless on a table, after Retro-orbital IV 
injection of 0.1 to 10 mCi of F18-FDG PET radioisotope, while being imaged with a coincidence 
camera. The mice were imaged after a pre-determined “washout” period (30-60 min). Individual 
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mice were first scanned pre-treatment and then 40 hours after the treatment regimen was 
initiated (see dosing schedule methods). For quantitative analysis, the standardized uptake 
value (SUV) normalized to body weight in the tumor was calculated using SUV= ACvoi 
(kBq/ml)/(FDGdose(MBq)/BW(kg)) where ACvoi is the average activity concentration in the 
tumor volume (or the maximum value); FDGdose is the dose of F18-FDG administered; and 
BW is the body weight. For evaluating tumors the highest SUV in the tumor was taken as the 
SUVmax.  
Microarray 
RNA isolated from MPNST tumor samples from NPcis mice treated for 14 hours with 
vehicle, rapamycin, PD-0325901, or the combination of rapamycin and PD-0325901 For all PD-
0325901 treated samples, PD-0325901 was dosed a second time at 10 hours. RNA was 
isolated with Trizol following the manufactures protocol. RNA clean-up was then performed 
using Qiagen’s RNA easy kit (#74104). The Partners HealthCare Center for Personalized 
Genetic Medicine core facility hybridized the RNA to the Affymetrics Mouse Gene 1.0 STS. To 
determine genes differentially expressed in the combination treatment, a class comparison 
between the combination treated samples and all other samples was performed. Analysis was 
completed using BRB-Array tools developed by Dr. Richard Simon and the BRB-ArrayTools 
Development team. Thresholds were set at p<0.001. Microarray data can be accessed in the 
GEO database (accession number: GSE57141 ).  
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INTRODUCTION 
 Mutations in the NF1 tumor suppressor are frequently found in sporadic cancers and 
cause the familial cancer predisposition syndrome neurofibromatosis type 1 (NF1). NF1 
patients experience a variety of symptoms, most commonly café-au-lait spots, benign 
neurofibromas, and Lisch nodules. However, 8–13% of NF1 patients will develop a malignant 
peripheral nerve sheath tumor (MPNST) in their lifetime (Evans et al., 2002). These tumors are 
highly aggressive, readily metastasize, and are the leading cause of death in NF1 patients 
(Evans et al., 2002; Porter et al., 2009). Complete surgical resection is currently the only 
effective treatment, as conventional radiation and chemotherapy do not prolong overall survival 
(Zehou et al., 2013). Therefore, identifying novel therapeutic approaches for these tumors is of 
critical clinical importance.  
 We have previously focused on identifying therapies that target specific signaling 
pathways that become activated upon NF1 loss (Malone et al., 2014). However, in addition to 
specific mutations in oncogenes and tumor suppressors, which cause the pro-tumorigenic 
hallmarks of cancer (Hanahan and Weinberg, 2000), there are a number of cellular adaptations 
that are not sufficient to induce transformation but are nonetheless required for maintenance of 
the tumorigenic state (Solimini et al., 2007). In particular, cancer cells frequently exhibit high 
levels of proteotoxic and oxidative stress as a result of aneuploidy, high mutational load, and 
altered cellular metabolism (Klaunig et al., 2010; Oromendia and Amon, 2014; Williams et al., 
2008). Cancer cells are reliant on stress response pathways in order to survive with high levels 
of unfolded proteins and reactive oxygen species (ROS), and thus targeting the stress 
phenotype of cancer is an alternative therapeutic approach (Luo et al., 2009). Inhibiting 
adaptive stress responses or inducing further stress could push the level of stress in cancer 
cells beyond the survival threshold while neighboring normal cells, which have low levels of 
basal stress, will survive.  
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Previously, our lab has shown that MPNSTs are very sensitive to the combination of 
mTOR inhibitors and agents that induce endoplasmic reticulum stress, which demonstrates 
that proteotoxic stress can be therapeutically exploited in this context (De Raedt et al., 2011). 
The combined effects of mTOR inhibition and ER stress induction initiated a vicious cycle of 
ER and mitochondrial damage leading to destruction of cellular organelles and eventual cell 
death. Importantly, the production of ROS was critical, and treatment with a ROS scavenger 
blocked the effects of this combination. ROS was produced after ER stress, and mTOR 
inhibition lowered the levels of reduced glutathione (GSH), an important ROS scavenger, so 
that cells could no longer attenuate increased ROS. In particular, that study identified that 
HSP90 inhibition induced ER stress and could synergize with mTOR inhibition. The 
combination of ganetespib, an HSP90 inhibitor, and everolimus, an mTOR inhibitor, recently 
entered clinical trials for MPNSTs (NCT02008877). However, to date there are no approved 
HSP90 inhibitors, and it remains to be determined whether an acceptable toxicity level can be 
achieved by combining these two agents.  
 Therefore, we decided to look for an FDA-approved drug that can also induce ER stress 
and possibly exploit these same vulnerabilities to promote tumor regression in combination 
with an mTOR inhibitor. The pan-HDAC inhibitor vorinostat is approved for use in cutaneous T-
cell lymphoma (CTCL) and has been shown to induce ER stress in some settings (Kahali et al., 
2010). Here, we report that the combination of two FDA-approved agents, vorinostat and 
rapamycin, effectively promotes MPNST regression in a genetically engineered mouse model 
of MPNSTs. We further show that this combination exploits both proteotoxic and oxidative 
stress to promote cell death. 
 
RESULTS 
HDAC Inhibition Induces ER Stress and Promotes MPNST cell death  
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Induction of ER stress leads to activation of the unfolded protein response (UPR). The 
UPR is initially a cytoprotective process designed to reduce translation and increase 
chaperone function to attenuate the accumulation of unfolded proteins in the ER lumen. 
However, if ER stress is prolonged and excessive, the UPR will drive apoptosis (Ron and 
Walter, 2007). The FDA-approved, pan-HDAC inhibitor vorinostat has been reported to induce 
ER-stress and the unfolded protein response (Kahali et al., 2010; 2012). Therefore, we were 
interested in whether vorinostat would induce ER stress in MPNSTs. Treatment with vorinostat 
induced a number of markers of the UPR, including BIP, EIF2α phosphorylation, spliced XBP1, 
ATF4, and CHOP, indicating that the UPR was indeed activated by vorinostat treatment (Figure 
3–1A). ER-stress inducing agents such as thapsigargin, tunicamyicn, and HSP90 inhibitors are 
cytotoxic in vitro in MPNST cells (De Raedt et al., 2011). Consistent with this, vorinostat has a 
cytotoxic effect on MPNST cell lines as a monotherapy (Figure 3–1B, C). Importantly, these 
concentrations are more than 10-fold lower than lethal concentrations reported for non-
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Figure 3–1. HDAC Inhibition Induces ER Stress and Kills MPSNT Cells in vitro. A, 
immunoblot of UPR markers BIP, p-EIF2α, XBP1-(s), ATF4, and CHOP, as well as 
Acetylated histone H3K9 after treatment with 2μM vorinostat for the indicated amount of 
time. Actin serves as a control. B, the percent of viable cells relative to day 0 after 72 hours 
of treatment with vorinostat at the indicated dose. C, the experimentally determined dose of 
vorinostat at which 50% of cells are dead (LD50) for two MPNST cell lines 
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transformed cells, indicating that MPSNT cell lines are hyper-sensitive to HDAC inhibition 
(Bolden et al., 2013).  
Combined mTOR and HDAC Inhibition Promotes Tumor Regression in vivo 
 While ER stress inducers, such as the HSP90 inhibitor IPI-504, kill human and mouse 
MPNST cells in vitro, we have shown that they are not sufficient to induce tumor regression in 
vivo as a monotherapy (De Raedt et al., 2011). However, when ER stress inducers are 
combined with mTOR inhibition, which alone is cytostatic, this induces a profound cytotoxic 
effect by enhancing lethal ER stress through increased ROS, as discussed above. Therefore, 
we were interested in whether the addition of an mTOR inhibitor could improve the therapeutic 
effects of vorinostat in vitro. Interestingly, at sub-LD50 doses of vorinostat, treatment with INK-
128, an mTOR kinase inhibitor, enhanced the cytotoxic effect of vorinostat, indicating that the 
combination of these two agents might be an effective therapy (Figure 3–2A).  
To test the effects of this combination in vivo, we employed a genetically engineered 
mouse model of MPNSTs. In this model, mice are heterozygous for Nf1 and p53, and the 
deletions are in cis (NPcis), such that mice experience simultaneous loss of heterozygosity for 
Nf1 and p53. MPNSTs, which genetically and histologically recapitulate human tumors, 
develop with an average latency of about 5 months and grow aggressively—tumors reach 
maximal acceptable size within 10–15 days. Tumor bearing animals were treated with 
vorinostat or the combination of rapamycin and vorinostat. A dose of 100mg/kg of vorinostat 
was selected as this is a standard pre-clinical dose (Saelen et al., 2012; Xu et al., 2013). 
Vorinostat alone had no effect on tumor growth (p=0.35, Figure 3–2B) in contrast to xenograft 
models of MPNSTs where HDAC inhibition has a cytostatic effect (Lopez et al., 2011). 
However, as with other ER-stress inducing agents, when vorinostat and rapamycin were 
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administered together, tumors regressed dramatically, with an average 62% decrease in tumor 
volume (Figure 3–2A). These studies provided proof of principle that dual HDAC and mTOR 
inhibition is a promising therapeutic strategy for MPNSTs.  
 However, while this dose of vorinostat (100mg/kg) is commonly used pre-clinically in 
mouse models, it does not accurately reflect human dosing. To verify the clinical relevance of 
Control
INK-128
Lo
g2
 o
f F
ol
d 
Gr
ow
th
0
1
2
3
-1
-2
Vorinostat 
0
1
2
3
-1
-2
Lo
g2
 o
f F
ol
d 
Gr
ow
th
90-8TL S462
**
A
Vehicle Vorinostat Vehicle
3
2
1
0
-1Lo
g2
 o
f F
ol
d 
Gr
ow
th
300
100
700
0
-50
-75
Change in Tum
or Volum
e (%
)
Vehicle RapVor Rap/Vor-2
B C
3
2
1
0
-1Lo
g2
 o
f F
ol
d 
Gr
ow
th
-2
300
100
700
0
-50
-75
Change in Tum
or Volum
e (%
)
Vehicle RapamycinVorinostat Rap/Vor
Figure 3–2. Combined mTOR and HDAC Inhibition Kills MPNSTs in vitro and in vivo. A, 
MPNST cell lines were treated with vorinostat (2μM) plus vehicle (black) or INK-128 (100nM 
in 90-8TLs, 200nM in S462s, white) for 72 hours. Bar graphs indicate the log2 of fold 
change in growth relative to day 0. Data points, triplicate averages ± SD. * p<0.05. B, 
waterfall plot depicting the log2 of fold change in MPNST volume after 10 days of treatment 
with 100mg/kg vorinostat daily (pale green), or vorinostat plus 5mg/kg rapamycin daily (dark 
green). Vehicle and rapamycin data is reprinted from Figure 2-2 for reference (grey). Left y-
axis, log2 fold of tumor growth. Right y-axis, percent change in tumor volume. C, waterfall 
plot depicting the log2 of fold change in tumor volume after 10 days of treatment with 
50mg/kg vorinostat (teal) or vorinostat plus 5mg/kg rapamycin (dark blue). Vehicle and 
rapamycin values are reprinted from figure 2-2 for reference (grey). Left y-axis, log2 fold of 
tumor growth. Right y-axis, percent change in tumor volume. 
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this result, we wanted to determine whether a human equivalent dose of vorinostat could also 
induce tumor shrinkage when combined with rapamycin. To this end, we calculated the mouse 
equivalent dose using a formula for dose translation based on body surface area (Reagan-
Shaw et al., 2008). The standard human dose of vorinostat is 400mg daily, which can be 
reduced to 300mg daily in the event of toxicity (Mann et al., 2007). A primary concern with any 
combination therapy is achieving an effective therapeutic dose without inducing toxicity. 
Therefore, we decided to treat mice with 50mg/kg of vorinostat, a very conservative dose that 
is even lower than the dose that would recapitulate the lowest human dose of 300mg. Tumor-
bearing mice were treated with 50mg/kg vorinostat once a day, either alone or in combination 
with rapamycin. As with the higher dose, vorinostat alone had no significant effect on tumor 
growth (p=0.7768), but when combined with rapamycin tumors regressed, with half of the 
tumors shrinking 50% or more. Thus, even at a clinically relevant dose of vorinostat, the 
combination of these two FDA-approved agents has substantial anti-tumor activity.  
Combined HDAC and mTOR Inhibition Promotes ER and Mitochondrial Damage 
One of the distinguishing features of HSP90 inhibitors and rapamycin in this model was 
the ER swelling and mitochondrial swelling observed by transmission electron microscopy (De 
Raedt et al., 2011). Given that HDAC inhibition induces ER stress in MPNST cells, we sought to 
determine whether this novel combination was inducing a similar phenotype. Tumors were 
examined by transmission electron microscopy 16 and 40 hours after treatment with 
rapamycin and vorinostat. However, at these time points, much of the tumor had already 
begun to die, leaving very few live cells to examine. In the cells that were still alive, there was 
visible swelling of the ER and mitochondria (Figure 3–3). This evidence is consistent with the 
induction of irresolvable ER stress and mitochondrial damage resulting in a catastrophic cycle 
of organelle damage and cell death, similar to the effect of HSP90 inhibition.  
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Figure 3–3. Combined HDAC and mTOR Inhibition Causes ER and Mitochondrial 
Swelling in MPNSTs. A, Transmission electron microscopy of MPNST after 16 hours of 
treatment with 100mg/kg vorinostat and 5mg/kg rapamycin showing mitochondrial 
swelling. Boxed area is enlarged at right, showing a number of swollen mitochondria. B, 
Transmission electron microscopy of MPNST after 40 hours of treatment with 100mg/kg 
vorinostat and 5mg/kg rapamycin. Top box is enlarged on top right, showing swollen 
mitochondria. Bottom box is enlarged on bottom right, showing swollen ER, indicated with 
a red arrow. 
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HDAC6 Suppression is not Sufficient to Synergize with Rapamycin 
In order to investigate the mechanism by which vorinostat might be inducing ER stress 
we examined the connection between HDAC inhibition and HSP90. Vorinostat treatment has 
been reported to impair HSP90 function in some settings (Rao et al., 2009). Specifically, 
HDAC6 is the primary deacetylase for HSP90. When HDAC6 is inhibited, HSP90 becomes 
hyper-acetylated, which blocks its chaperone function (Boyault et al., 2007; Kekatpure et al., 
2009; Scroggins et al., 2007). Vorinostat is a pan-HDAC inhibitor with activity against all Zn2+-
dependent HDACs, including HDAC6. HSP90 inhibitors are known to induce ER stress and 
synergize with mTOR inhibition in this tumor model, and we observed a similar cellular 
phenotype by electron microscopy, so we wanted to determine whether vorinostat was 
mediating its effects through HDAC6 inhibition and HSP90 hyper-acetylation. To this end, we 
ablated HDAC6 expression in MPNST cells through siRNA-mediated knockdown, and then 
treated with the mTOR inhibitor INK-128. There was no difference in response to INK-128 
treatment between HDAC6-deficient cells and controls (Figure 3–4A), suggesting that HDAC6 
inhibition is not sufficient to synergize with INK-128. Furthermore, treatment with Nexturastat 
A, a highly specific HDAC6 inhibitor, did not affect MPNST cell growth at concentrations from 
0.1 to 1μM (Figure 3–4B). Moreover, the addition of INK-128 did not have any combined effect, 
in marked contrast to what was observed with vorinostat (Figure 3–4B). Importantly, even at a 
concentration of 0.1μM, tubulin, an established target of HDAC6, was hyper-acetylated 
demonstrating effective HDAC6 inhibition. In contrast, histone acetylation was not substantially 
elevated suggesting that Nexturastat A is indeed HDAC6-specific (Figure 3–4B). 
 HDAC6 has been reported to be the primary deacetylase for HSP90, but there is some 
evidence that other HDACs may be able to deacetylate HSP90 as well (Nishioka et al., 2008).  
73 
 
Tubulin
Histone H3
HSP90
IP: IgGAcK 2% Input
Treatment: Vor
Vor
Vinculin
Veh
Veh
0 0.1 0.5 1
0
0.5
1
2
1.5
2.5
Nexturastat A (μM)
Lo
g2
 F
ol
d 
Gr
ow
th Vehicle
INK-128
S462
0
0.5
1
2
1.5
2.5
Lo
g2
 F
ol
d 
Gr
ow
th
90-8TL
0 0.1 0.5 1
Nexturastat A (μM)
Acetylated
Tubulin
Acetylated 
H3K9
Vinculin
INK-128:
Nexturastat A (μM):
-
-
- - -+ + + +
0.1 0.5 1
B
C
n.s. n.s.
Vehicle
 INK-128
siHDAC6
2.5
2
1
1.5
0.5
0
Lo
g2
 F
ol
d 
Gr
ow
th
Acetylated Tubulin
p-S6
HDAC6
Vinculin
- -+ +
A
siCTRL
INK-128:
CTRLsiRNA: HDAC6n.s.
Figure 3–4. HDAC6 Inhibition is not Sufficient to Synergize with mTOR Inhibition. A, 90-
8TLs were transfected with pooled siRNA targeting HDAC6 or non-silencing siRNA and then 
treated with vorinostat (white) or 100nM INK-128 (black). Data points, triplicate averages ± 
SD of log2 of fold change relative to day 0 after 72 hours of treatment. Immunoblot shows 
HDAC6, acetylated tubulin, and phosphorylated S6 48 hours after transfection with 
indicated siRNA and 24 hours after indicated treatment. Vinculin serves as a control. B, 
MPNSTs were treated with indicated concentration of Nexturastat A, plus vehicle (white) or 
INK-128 (100nM 90-8TLs, 200nM S462s, black). Immunoblot shows acetylated tubulin and 
acetylated H3K9 after treatment with indicated concentration of Nexturastat A plus or minus 
INK-128 as indicated. Vinculin serves as a control. C, Acetylated lysine or IgG was 
precipitated from 90-8Tls after 16 hours of treatment with vehicle (Veh) or 2μM vorinostat 
(Vor). Immunoblot shows HSP90, tubulin, and Histone H3. Vinculin serves as a control.  
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Given the strong connection between HSP90 and ER stress, and our previous studies outlining 
the efficacy of HSP90 inhibitors in combination with mTOR inhibitors, we wanted to determine 
whether HSP90 was acetylated after treatment with vorinostat. To that end, we treated MPNST 
cells with vorinostat and then immunoprecipitated acetylated lysine, and probed for HSP90, 
Histone H3, and Tubulin. As expected, acetylated histone H3 was present in the vorinostat 
treated cells, as well as acetylated tubulin, which is indicative of successful HDAC 1–3 and 
HDAC6 inhibition, respectively (Figure 3–4C). However, there was no increase in HSP90 
acetylation in vorinostat treated cells. Together, this data demonstrates that HDAC6 inhibition 
alone is not sufficient and that HSP90 hyper-acetylation does not appear to be a primary 
contributor to the efficacy of this combination therapy.  
Activation of the Unfolded Protein Response Contributes to Cell Death in Combination treated 
MPNSTs 
 Modulation of HSP90 activity does not seem to be contributing to the efficacy of 
vorinostat in this context, so we wanted to determine whether activation of the unfolded 
protein response is related to the therapeutic effect. The UPR is initially a cell protective 
response, but when ER stress is unresolved, the UPR can become a driver of apoptosis (Sano 
and Reed, 2013). Given this dual role for the UPR, we were interested in whether activation of 
the UPR was protecting against ER stress induced by the combination therapy, or was 
contributing to the cell death observed after treatment. In order to address this, we used 
pooled siRNAs to ablate expression of two of key UPR mediators: PERK, which is encoded by 
the gene EIF2AK3, and IRE1α, which is encoded by ERN1. We found that ablation of IRE1α 
had no effect on the efficacy of the combination therapy in either MPNST cell line, suggesting 
that this arm of the UPR is not significantly protecting against or inducing the observed cell 
death (Figure 3–5A). However, PERK ablation partially protected both MPNST cell lines from 
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Figure 3–5. The UPR Contributes to Combination Induced Cell Death. A, S462s and 90-
8TLs were transfected with pooled siRNAs against EIF2AK3 (PERK, black) or ERN1 (IRE1α, 
grey), or non-silencing (white) and then treated with vehicle or vorinostat (2μM) and INK-128 
(200nM S462, 100nM 90-8TLs) as indicated. Bar graphs are triplicate averages ± SD of the 
log2 of fold change after 72 hours. Below, immunoblot shows PERK and IRE1α protein levels 
72 hours after transfection with indicated siRNA. Tubulin serves as a control. B, 90-8TLs and 
S462s were transfected with pooled siRNAs targeting ATF4 (black) or non-targeting (white) 
and treated with vehicle or vorinostat and INK-128 as indicated. . Bar graphs are triplicate 
averages ± SD of the log2 of fold change after 72 hours. At right, immunoblot shows ATF4 
and Acetylated H3K9 levels in S462s 72 hours after transfection with either non-targeting 
siRNA, or siATF4, and treatment with vehicle or 2μM vorinostat as indicated.  
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combination-induced death (Figure 3–5A), demonstrating that PERK activation in combination 
treated cells is likely promoting cell death.  
 PERK canonically drives apoptosis through activation of the transcription factor ATF4, 
which upregulates CHOP, and together they promote apoptosis (Han et al., 2013; Kim et al., 
2008; Sano and Reed, 2013). To determine whether PERK activation was driving cell death 
through this canonical apoptotic pathway we tested the effect of ATF4 ablation. ATF4 
knockdown reduced basal levels of ATF4 and blocked ATF4 upregulation after vorinostat 
treatment (Figure 3–5B). Unexpectedly, ATF4 knockdown not only failed to rescue the effects 
of the combination, but in fact ATF4 loss increased the sensitivity of both MPNST cell lines to 
combination treatment. The increased sensitivity of ATF4-deficient cells suggests that PERK’s 
contribution to cell death is not through ATF4 in this context.  
HDAC Inhibition Induces Oxidative Stress which is Essential for Synergy with mTOR inhibition 
 In order to better understand the mechanism of synergy between mTOR and HDAC 
inhibition, we performed transcriptional profiling in vehicle, INK-128, vorinostat, or combination 
treated MPNST cells, after 24 hours of treatment to allow time for epigenetic-mediated 
changes in transcription to occur. We performed a gene set class comparison to identify gene 
sets where more genes are differentially expressed than would be expected due to random 
chance in the combination treated cells relative to the other treatments, using gene sets in the 
Molecular Signatures Database. As expected, a number of gene sets involved in the unfolded 
protein response were differentially expressed in the combination treated cells by at least one 
metric of statistical significance (Figure 3–6A). Interestingly, we also found a number of gene 
sets related to oxidative stress were altered in the combination treated cells, suggesting a 
potential mechanistic role for oxidative stress in the therapeutic efficacy of the combination.  
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Figure 3–6. HDAC Inhibitor Induced Oxidative Stress is Critical for Therapeutic 
Efficacy. A, a microarray analysis was performed on 90-8TLs treated with vehicle, 
100nM INK-128, 2μM vorinostat, or both for 24 hours. Table indicates proteotoxic and 
oxidative stress-related gene sets with differential expression in the combination treated 
cells relative to the other treatment groups that reached at least one metric of 
significance. Significance values for KS permutation, LS permutation, and the Efron-
Tibshirani GSA p-value is shown. Values in red reach the cutoff for significance 
(p<0.005). B, Representative histogram of fluorescence intensity for S462s treated with 
vehicle (light grey), 2μM vorinostat (light green), or 1mM H2O2 (dark green), and dyed 
with DCFDA. An un-dyed vehicle-treated control is shown in dark grey. C, As in B, 
S462s were treated with vehicle or 2μM vorinostat and dyed with DCFDA. Bar graph 
indicates average mean fluorescent intensity from three independent experiments. A 
ratio-paired student’s t-test was performed, and the p-value is shown. D, S462s and 90-
8TLs were treated with 3μM vorinostat plus (black) or minus (white) 5mM N-acetyl 
cysteine (NAC). Bar graphs indicate triplicate average ± log2 of fold change after 72 
hours of treatment. E, S462s were treated with vehicle or 2μM vorinostat as indicated, 
plus vehicle (white), 200nM INK-128 (black) or 200nM INK-128 and 5mM NAC 
(INK+NAC, grey). Data points indicate triplicate averages ± SD of log2 fold of tumor 
growth after 72 hours of treatment. * p<0.05. 
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Gene Set 
LS 
Permutation 
Value 
KS 
Permutation 
Value 
Efron-
Tibshirani’s GSA 
test p-value 
Oxidative Stress    
KYNG_RESPONSE_TO_H2O2 0.00039 0.00039 0.07 
CHUANG_OXIDATIVE_STRESS_RESPONSE_UP 0.00066 0.02977 0.0005 
CHUANG_OXIDATIVE_STRESS_RESPONSE_DN 0.00361 0.11379 0.57 
WIEGEL_OXIDATIVE_STRESS_BY_TBH_AND_H2O2  0.00933 0.00047 0.36 
MOOTHA_ROS 0.09478 0.0017 0.525 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN  0.0004 0.01311 0.62 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_UP 0.00062 0.00005 0.085 
Proteotoxic Stress    
REACTOME_UNFOLDED_PROTEIN_RESPONSE 0.00353 0.0029 0.545 
REACTOME_ACTIVATION_OF_CHAPERONES_BY_IRE1_ALPHA 0.01542 0.0042 0.32 
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_ATF6_ALPHA 0.01644 0.00462 0.06 
REACTOME_ACTIVATION_OFCHAPERONES_BY_ATF6_ALPHA  0.02922 0.00488 0.075 
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This finding was particularly striking because there is a well-established interdependent 
relationship between ER stress and oxidative stress. Increased oxidative stress promotes 
protein misfolding, and the accumulation of misfolded proteins causes calcium to be released 
from the ER, which promotes ROS production in the mitochondria (Eletto et al., 2014; Malhotra 
and Kaufman, 2007). We have previously found that oxidative stress is critical for the synergy 
between HSP90 inhibitors and mTOR inhibitors in this tumor type. Inhibition of mTOR lowers 
levels of the NADPH-dependent ROS scavenger reduced glutathione (GSH) in MPNSTs, 
sensitizing them to oxidative stress induced by HSP90 inhibitors (De Raedt et al., 2011). 
Notably, we found that vorinostat treatment increased cellular reactive oxygen species (ROS) 
by an average of 1.5 fold, as measured by DCFDA fluorescence (Figure 3–6B, C). Furthermore, 
cells treated with the broad ROS scavenger N-acetyl cysteine (NAC) were resistant to the 
cytotoxic effects of vorinostat alone, as well as the combination of INK-128 and vorinostat 
(Figure 3–6D, E) suggesting that oxidative stress is a critical component contributing to the 
therapeutic effect of this combination.  
The Thioredoxin Inhibitor TXNIP is Upregulated by Combination Therapy  
To identify specific gene targets that were altered during combination therapy, which 
might be mechanistically contributing to the oxidative and proteotoxic stress, we performed a 
gene expression class comparison on our transcriptional profile between combination treated 
cells and all other treatment groups. One of the most significantly upregulated genes in the 
combination treated cells was thioredoxin interacting protein (TXNIP) (2.47 fold, p=0.0000807, 
Figure 3–7A). TXNIP expression is modestly, but significantly, elevated by both vorinostat and 
INK-128 treatment in MPSNT cells (1.4 fold, p=0.0003273, and 1.7 fold, p=0.0000251, 
respectively) but it is significantly further upregulated in the combined treatment relative to 
either single treatment (2.3 fold relative to vorinostat p=0.0000187, and 1.95 fold relative to 
INK-128 p=0.0000012). Protein levels of TXNIP also increased modestly after treatment with 
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Figure 3–7 TXNIP is Upregulated after Combination Treatment and Contributes to Cell Death. 
A, Heat map showing genes whose expression was altered more than 1.5-fold and reached a 
significance of at least p<0.001 in the combination treated cells relative to single treatment and 
untreated cells. Dark blue indicates highest expression while pale blue indicates lowest expression. 
In red, TXNIP is highlighted. B, Immunoblot showing TXNIP, phosphorylated S6 and histone 3 
lysine 9 (H3K9) acetylation levels after 24 hours of treatment with vehicle, INK-128 (100nM 90-8TLs, 
200nM S462s), vorinostat (2μM) or both. Actin and S6 serve as controls. C, S462s were transfected 
with siRNAs targeting TXNIP (black) or control siRNA (white) and treated with vehicle or INK-128 
(200nM) and vorinostat (2μM). Data points indicate triplicate averages ± SD of log2 fold growth 
after 72 hours. Immunoblot at right shows TXNIP, phosphorylated S6, and acetylated H3K9 72 
hours after transfection with indicated siRNA, and 24 hours after treatment with vehicle or INK-128 
(200nM) and vorinostat (2μM). Actin serves as a control. 
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either INK-128 or vorinostat in both MPNST cell lines, but TXNIP levels were even further 
elevated after combined treatment, confirming that this transcriptional change leads to 
increased protein levels (Figure 3–7B). TXNIP is a negative regulator of the cellular ROS 
scavenger thioredoxin (TRX), and has been previously reported to be upregulated by HDAC 
inhibition (Butler et al., 2002). In addition to increasing ROS, TXNIP binding to TRX can drive 
apoptosis by blocking the interaction between TRX and ASK1 (Lu and Holmgren, 2012; Saitoh 
et al., 1998). Interestingly, TXNIP is also transcriptionally induced by proteotoxic stress in a 
PERK-dependent but ATF4-independent manner, and is in fact key for the switch from a 
protective UPR to a terminal UPR (Anthony and Wek, 2012; Lerner et al., 2012; Oslowski et al., 
2012). Thus TXNIP provides a potential mechanistic link between oxidative and proteotoxic 
stress and cell death.  
 Because TXNIP can be a driver of apoptosis in the context of unresolved ER stress and 
oxidative stress, we wanted to determine whether the increased TXNIP expression observed 
after combination treatment was contributing to the therapeutic effect. To that end, we ablated 
TXNIP expression using pooled siRNAs targeting TXNIP. We were able to decrease basal 
TXNIP expression as well as block the increase in expression induced by the combination of 
vorinostat and INK-128 (Figure 3–7C). We found that siRNA-mediated inhibition of TXNIP 
completely blocked the cytotoxic effect of combined vorinostat and INK-128 treatment, 
suggesting that TXNIP could in fact be a key driver of the therapeutic response. Additional 
studies that are currently underway to better understand this mechanism will be discussed 
later.  
DISCUSSION 
 The combination of HSP90 inhibitors and mTOR inhibitors recently entered clinical trials 
for MPNSTs, based on promising pre-clinical data. However, it remains unclear whether an 
acceptable therapeutic window can be determined for this combination Even if an appropriate 
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dose can be identified, some patients may not be able to tolerate this particular combination. 
Thus, alternative therapeutic options that target the same cancer vulnerabilities could provide 
significant clinical benefit. In the present study, we have identified the successful therapeutic 
combination of rapamycin and vorinostat, which are both FDA-approved agents. This 
combination could be rapidly translated to the clinic where there are currently no effective 
therapies for MPNSTs. Phase I clinical trails are currently underway to determine the dosing of 
this combination in other cancers (NCT01087554, NCT01174199) so the tolerable dose will be 
determined soon, at which point this dosing strategy could be tested for efficacy in patients 
with MPNSTs. We have previously found that effective therapies in this model of NF1-mutant 
cancer can be successfully translated to other NF1-deficient models and KRAS mutant lung 
cancer (De Raedt et al., 2011; Maertens et al., 2013; Malone et al., 2014). Therefore, this 
combination should also be tested in pre-clinical models for other cancer types to determine 
the full scope of efficacy.  
 One of the key considerations for any combination therapy is whether a tolerable but 
effective combined dose can be identified, which is why we selected a relatively low dose of 
vorinostat for these studies. However, vorinostat is a pan-HDAC inhibitor, and thus is likely to 
have more side effects than more selective HDAC inhibitors now in development 
(Balasubramanian et al., 2009). Therefore, it will be important to identify which specific HDACs 
are mediating this effect. Notably, we found that HDAC6 inhibition alone is not sufficient to 
synergize with rapamycin, suggesting that HDAC6 specific inhibitors are unlikely to be effective 
in this setting. Further study is warranted to determine whether a specific HDAC or HDACs are 
mediating this effect, which could inform future clinical drug selection and development. 
 Moreover, our studies demonstrate the mechanism of action of this combination.  
Interestingly, we identified the UPR mediator PERK as necessary for a full therapeutic response 
to the combined therapy, suggesting that UPR activation is driving cell death in this context. 
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This is an important mechanistic difference between HSP90 inhibition and HDAC inhibition, as 
UPR destabilization is a critical mediator of HSP90 efficacy (De Raedt et al., 2011). This further 
underscores the double-edged sword of the UPR, and demonstrates that both the adaptive 
and terminal roles of the UPR can be therapeutically exploited. Unexpectedly, we found that 
PERK is not driving apoptosis through ATF4, and in fact ATF4 is promoting cellular survival in 
this context. In addition to regulation of the pro-apoptotic transcription factor CHOP, ATF4 has 
a large number of transcriptional targets that could be promoting cellular survival. It is 
interesting to note that ATF4 upregulates a number of genes involved in protein synthesis 
including genes encoding proteins that are essential for GSH synthesis (Han et al., 2013; 
Harding et al., 2003). As a result, ATF4 -/- cells have been reported to have decreased levels of 
GSH and are hyper sensitive to oxidative stress (Dickhout et al., 2012). Given the critical role 
for oxidative stress identified here, this could explain why ATF4 loss sensitizes MPNSTs to 
combination treatment. It will be important to determine which specific targets of ATF4 are 
sensitizing MPNSTs to this combination, as this could provide further mechanistic insight and 
might reveal therapeutic opportunities.  
Transcriptional profiling identified the thioredoxin inhibitor TXNIP as one of the most 
significantly upregulated genes in combination treated cells. Interestingly, both mTOR and 
HDAC inhibition have been reported to upregulate TXNIP transcription in other contexts. mTOR 
directly interacts with MondoA-Mxl, a transcription factor complex that regulates TXNIP 
expression (Kaadige et al., 2015). When mTOR is inhibited, MondoA-Mxl is released, driving 
TXNIP expression. HDAC inhibition on the other hand has been shown to increase histone H3 
and histone H4 acetylation of the TXNIP gene, promoting transcription, but activation of the 
UPR may also be driving TXNIP expression (Cha-Molstad et al., 2009; Oslowski et al., 2012). 
Here we found that PERK ablation contributes to cell death, but ATF4 ablation does not. 
However, PERK has been shown to increase TXNIP expression through ATF5 and chREBP 
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(Oslowski et al., 2012). Therefore, we are currently interested in determining whether UPR 
activation is directly affecting TXNIP expression, and whether ATF5 or chREBP are contributing 
to the therapeutic effect of HDAC and mTOR inhibition (Figure 3–8).  
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Figure 3–8. Model of UPR Activation Contributing to TXNIP-Mediated Cell Death. 
IRE1α and PERK are key arms of the unfolded protein response that can drive a terminal 
UPR. IRE1α canonically activates cell death through ASK1, while PERK drives cell death 
through ATF4 and CHOP. Loss of IRE1α (grey) does not affect therapeutic efficacy. Loss 
of PERK or TXNIP (red) has a protective effect, suggesting that they are driving cell death 
after combined treatment. Loss of ATF4 (green) exacerbates cell death, indicating that 
ATF4 has a protective role in this context, possibly due to its regulation of ROS 
attenuating genes. We are now looking at the contribution of CHOP, ATF5, and chREBP 
(black) to the therapeutic response, as well as to TXNIP upregulation. Additionally, we are 
interested in determining whether TXNIP is driving cell death through ASK1 or the NLRP3 
inflammasome.  
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It appears that TXNIP expression is essential for the therapeutic effect of combined 
mTOR and HDAC inhibition in this context. TXNIP binds the reduced form of thioredoxin, a 
major cellular ROS scavenger, and impairs the thiol-reducing activity of TRX (Lu and Holmgren, 
2014). Thus TXNIP expression increases ROS, and could at least partially be driving oxidative 
stress in this context. Importantly, TXNIP is directly connected with apoptotic pathways in the 
context of both ER stress and oxidative stress. TXNIP drives apoptosis through ASK1 in 
conditions of oxidative stress, and can activate the NLRP3 inflammasome to promote cell 
death during either oxidative or proteotoxic stress (Lerner et al., 2012; Oslowski et al., 2012; 
Zhou et al., 2010). We are currently exploring whether activation of either ASK1 or the NLRP3 
inflammasome is promoting cell death in this context (Figure 3–8).  
It remains unclear whether TXNIP upregulation drives oxidative stress, which induces 
proteotoxic stress and the unfolded protein response, or whether activation of the unfolded 
protein response is in part driving TXNIP expression, contributing to oxidative stress because 
these processes are all intimately connected (Figure 3–9). While the exact details of this 
mechanism are still being explored, our data demonstrate that the UPR, ROS, and TXNIP 
expression are all mediating the therapeutic response, suggesting that a vicious cycle of 
oxidative and proteotoxic stress is induced by HDAC and mTOR inhibition and that TXNIP is a 
key point of convergence between these stress pathways. Our studies provide further support 
for the concept that oxidative stress and proteotoxic stress represent vulnerabilities for cancer 
cells that can be therapeutically exploited and we have identified key regulators of this 
process.  
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METHODS 
Cell Lines and Reagents 
S462s were purchased from the ATCC. 90-8TLs were kindly provided by Dr. Eric Legius (KU 
Leuven, Belgium). All cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FBS and L-glutamine. Antibodies were purchased as follows: Cell 
Signaling Technologies: HDAC6, pS6, Vinculin, pEIF2α, XBP1-(s), ATF4, CHOP, Histone H3, 
PERK, IRE1α; Millipore: HSP90; Sigma Aldrich: Tubulin, Actin; Acetylated Tubulin. Nexturastat 
A, Vorinostat, and INK-128 were all purchased from Selleck Chemicals. Rapamycin was 
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Figure 3–9. Combined HDAC and mTOR Inhibition Drives a Vicious Cycle of 
Proteotoxic and Oxidative Stress Converging on TXNIP. HDAC inhibition may directly 
upregulate TXNIP through histone acetylation; in addition HDAC inhibition induces ER stress 
and activates the UPR, which can further drive TXNIP expression. mTOR inhibition also 
upregulates TXNIP transcription, possibly through activation of the transcription factor 
MondoA-Mxl, in addition to lowering levels of reduced GSH and TRX, impairing the cellular 
attenuation of ROS. Increased ER Stress promotes increased ROS, and increased ROS 
causes further ER stress, producing a vicious cycle of stress.  
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purchased from LC Laboratories. For all in vitro studies, inhibitors were dissolved in DMSO. 
DCFDA was purchased from Life Technologies.  
RNAi 
ON-TARGETplus siRNA pools were purchased from Dharmacon. siRNAs were transfected 
overnight in antibiotic free medium using RNAiMax lipofectamine from Invitrogen.  
Cellular Death Studies 
Approximately 250,000 cells per well were seeded into 6-well plates. For siRNA experiments, 
cells were seeded 12-26 hours after transfection. Twenty-four hours after plating, day 0 counts 
were taken using a hemocytometer. For drug treatment experiments, inhibitors were added at 
this time. Final cell counts were taken 72 hours after day 0 counts.  
In Vivo Drug Treatments 
 Animal procedures were approved by the Center for Animal and Comparative Medicine at 
Harvard Medical School in accordance with the NIH Guide for the Care and Use of Laboratory 
Animals and the Animal Welfare Act. C56/BL6 NPcis mice have been previously described 
(Cichowski et al., 1999). Mice were treated daily with 50mg/kg vorinostat, 100 mg/kg 
vorinostat, 5mg/kg rapamycin, or a combination of rapamycin and vorinostat via i.p. injections. 
Compounds given in combination were administered sequentially. Rapamycin was prepared as 
previously described (Johannessen et al., 2008). Vorinostat was dissolved directly into 
cyclodextrin as described (Hockly et al., 2003). 
Tumor Volume Measurements 
Tumors were measured every 2–3 days using a Vernier caliper. Tumor volume was calculated 
using the standard calculation L X W2 X0.52.  
Microarray 
RNA was isolated using a Trizol extraction, and RNA was purified using an RNeasy kit (Qiagen) 
according to manufacturers instructions. RNA was hybridized to the Affymetrix Human 1.0 STS 
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array chip by the Molecular Biology Core Facilities at Dana-Farber Cancer Institute. To 
determine genes and gene sets differentially expressed amongst treatment groups a class 
comparison analysis was performed using BRB-Array tools developed by Dr. Richard Simon 
(National Cancer Institute, NIH, Rockville, MD) and the BRB-ArrayTools Development team. 
Thresholds were set at P <0.001.  
Flow Cytometry 
Cells were stained with 10μM DFCDA for 15 minutes and then analyzed Accuri C6 Analyzer. 
Counts were gated on live cells, and 10,000 counts per condition were collected. Data was 
analyzed using FlowJo. All flow cytometry was performed at the Brigham and Women’s Flow 
Cytometry Core facility.  
Immunoprecipitation 
Cells were treated as indicated and then lysed in a 1% Triton buffer supplemented with 
PhosSTOP tablets and sodium orthovanadate. Lysates were pre-cleared with protein G beads. 
IP was performed over night at 4˚C with an antibody against acetylated lysine, and then pulled 
down using agarose conjugated protein G beads.  
Electron Microscopy 
Mice were treated with rapamycin and vorinostat and then euthanized and tumor tissue was 
collected after the indicated amount of time. Tumor tissues were fixed in 2% glutaraldehyde 
and 4% paraformaldehyde in 0.1M sodium cacodylate buffer and processed for EM using 
standard methods. 
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Chapter 4: Conclusion and Future Directions 
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CONCLUSION 
 The goal of my thesis work was to identify novel combination therapies for NF1-mutant 
tumors, and MPNSTs in particular. We successfully discovered two new combination therapies 
for MPNSTs through two distinct approaches. First, by taking the approach of targeting 
signaling pathways that are hyper-activated when NF1 is lost, we developed an effective 
strategy by combining mTORC1 and MEK inhibitors. Second, by exploiting cellular stress 
pathways we found that the combination of HDAC and mTOR inhibitors is also effective in 
these tumors. Both combinations can be readily translated into patients.  
 When NF1 is lost, RAS and downstream effector pathways become aberrantly 
activated. There is a plethora of drugs targeting these effector pathways available, but the 
specific signaling nodes that represent the best therapeutic targets were unknown, making 
drug selection difficult. In Chapter 2, using genetic and biochemical techniques, I identified 
p110α as the key PI3K catalytic isoform downstream of NF1. When p110α was ablated, 
downstream mTORC1 activity was blocked, and proliferation of NF1-deficient cells was 
impaired. However, loss of either p110β or p110δ did not affect mTORC1 signaling or cellular 
proliferation. Together, this suggests that p110α represents a potential therapeutic target in 
NF1-deficient cancers. Conversely, inhibition of AKT did not affect mTORC1 signaling or 
MPNST cell proliferation, demonstrating that AKT was not necessary for NF1-deficient growth. 
Furthermore, we discovered that blocking mTORC1 activity slowed cell proliferation, but 
mTORC2 ablation had no effect. Together, these findings support an essential role for p110α 
and mTORC1, but suggest that mTORC2, AKT, and the other p110 catalytic isoforms are not 
likely to be effective therapeutic targets in NF1-deficient cancers.  
 Armed with the knowledge that mTORC1 was a key signaling node, I then wanted to 
use this information to develop an effective combination therapy. We had previously shown 
that inhibition of mTORC1 exerted a cytostatic effect on our mouse MPNST model. In Chapter 
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2, I demonstrated that when combined with a MEK inhibitor, mTORC1 inhibitors promote 
dramatic tumor regression in vivo. Importantly, we found that only sustained inhibition of both 
pathways was sufficient for this therapeutic effect. Because the major hurdle in developing 
combination therapies is identifying a dose that is both safe and effective, I wanted to identify a 
biomarker of combined mTORC1 and MEK inhibition, which could be used in clinical trials to 
determine whether these targets are inhibited at tolerable doses. I found that the glucose 
transporter GLUT1 was substantially downregulated by the combination treatment, and 
showed that protein levels of GLUT1 also decreased after combination treatment. Because 
GLUT1 is a key glucose transporter and can be the rate-limiting step in glucose uptake, this 
lead me to look at 18F-FDG PET imaging, a non-invasive measure of glucose uptake. I found 
that 18F-FDG uptake is significantly impaired in combination treated tumors, and that early 
change in 18F-FDG uptake was correlated with ultimate change in tumor size.  
 Together, these data support the conclusion that mTORC1 and p110α are key signaling 
nodes in NF1-mutant cancers. Furthermore, these findings support the clinical development of 
the combination of mTORC1 and MEK inhibitors in MPNSTs, and possibly other NF1- or RAS-
mutant cancers, with 18F-FDG PET imaging as a biomarker of successful target inhibition. Often 
when efficacy is not seen in clinical trials, it is not known if that is because the tolerable dose 
was not high enough to inhibit the intended target, or because inhibition of that target was 
achieved but was not as efficacious as anticipated. Our studies suggest that 18F-FDG uptake 
can be used to verify effective target inhibition non-invasively. This finding is now being 
incorporated into a clinical trial using mTOR and MEK inhibitors in combination.  
 In Chapter 3 we took an alternative approach to developing therapies, specifically by 
targeting cellular stress. We have previously shown that underlying proteotoxic and oxidative 
stress also represent a therapeutic opportunity for MPNSTs. I decided to look for an FDA-
approved drug that was also known to inhibit ER stress, so that any effective combination 
92 
could rapidly enter the clinic. In the work described in Chapter 3, I demonstrated that the pan-
HDAC inhibitor vorinostat induces ER stress in MPNSTs, and that the combination of 
vorinostat and an mTOR inhibitor had a potent cytotoxic effect in vitro and in vivo in a 
genetically engineered mouse model of MPNSTs. I found that combined treatment with HDAC 
and mTOR inhibitors leads to swollen ER and mitochondria. I further demonstrated that this 
effect is dependent on both the unfolded protein response and oxidative stress, as genetic 
ablation of the UPR effector PERK and treatment with the ROS scavenger NAC attenuated the 
therapeutic effect. Further supporting a role for ER stress and oxidative stress in the 
therapeutic response, we found that transcriptional signatures of both proteotoxic and 
oxidative stress were significantly altered by the combination therapy. Together, these data 
suggest that combined HDAC and mTOR inhibition exploits both proteotoxic and oxidative 
stress to promote cell death. 
 I next wanted to identify specific genes that were involved in mediating the response. 
Using transcriptional profiling, I discovered that expression of thioredoxin interacting protein 
TXNIP is significantly upregulated after combination treatment, and we verified that protein 
levels of TXNIP are also elevated. TXNIP expression is intimately connected with both the 
conversion to UPR-driven and oxidative-stress-induced cell death. I found that ablation of 
TXNIP protected cells from combined HDAC and mTOR inhibition, suggesting that TXNIP may 
be driving the cytotoxic effect of this therapy.  
 While the details of this model are being finalized, these studies have provided 
important mechanistic insight into how these agents cooperate. There are currently three 
different Phase I clinical trials underway in solid tumor settings to determine tolerable dosing of 
HDAC inhibitors and mTOR inhibitors (NCT01087554, NCT01174199, NCT01582009). 
 
93 
 As soon as a tolerable dose for this combination has been identified, trials in MPNSTs can 
move forward using this dosing strategy.  
 Together, these data support the clinical development of two different combination 
therapies for MPNSTs, and possibly other NF1-mutant tumors. Importantly, this work provides 
support for two distinct approaches to therapeutic development for cancer. We showed that 
hyperactivated signaling downstream of NF1-loss can be therapeutically targeted, and 
provided further support for the concept that cellular stress represents a vulnerability that can 
also be therapeutically exploited.  
 
FUTURE DIRECTIONS 
PI3K-Dependent, AKT-Independent Activation of mTORC1 
 It has been established PI3K typically activates mTORC1 through AKT. However, in 
Chapter 2 of this dissertation, I found that downstream of NF1-loss PI3K inhibition is sufficient 
to block mTORC1 activation but AKT inhibition is not. Similarly, mTORC2 inhibition, which 
reduces AKT activity, has no effect on mTORC1 activity. From a therapeutic perspective, this 
finding suggests that AKT inhibitors will not be very effective in this cancer type. However, 
mechanistically, this result raises several questions about how mTORC1 is regulated in NF1-
deficient MPNSTs (Figure 4–1). First, why is AKT inhibition not sufficient to inhibit mTORC1 in 
this setting? The lack of efficacy of AKT inhibitors suggests that there are other pathways that 
are feeding into mTORC1 activation, and can compensate for the loss of AKT signaling. One 
possibility is that the ERK pathway is promoting sustained mTORC1 activity in the context of 
AKT inhibition.  
TSC2 has several ERK phosphorylation sites and its activity can be regulated by ERK 
as well (Mendoza et al., 2011). As demonstrated in Chapter 2 of this dissertation, ERK inhibition 
is similarly not sufficient to block mTORC1 activity. In the context of activating RAS mutations 
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or NF1 loss, both the PI3K and ERK pathways are hyperactivated. Thus, we hypothesize that 
these there may be a shift in dependency when AKT is inhibited, allowing active ERK to drive 
mTORC1 signaling. It will be interesting to determine whether combined inhibition of AKT and 
the ERK pathway would be sufficient to inhibit mTORC1 signaling in this setting.  
 
AKT
TSC2
mTORC1
p110α
NF1
RAS
MEK
RAF
ERK
mTORC2
Figure 4–1. mTORC1 Regulation Downstream of NF1. When NF1 is lost, both the PI3K and 
ERK pathways are hyperactivated. In the present study we show that p110α and mTORC1 (red) 
are critical for MPNST proliferation, while AKT and mTORC2 (blue) are dispensable. Further, we 
find that AKT or mTORC2 inhibition does not affect mTORC1 signaling. The canonical signaling 
pathways are shown with solid lines. Our findings suggest that mTORC1 activity can be 
sustained even in the absence of AKT signaling, which could be explained by ERK inhibition of 
TSC2 (dotted inhibition arrow). However, these findings suggest that mTORC1 activity is p110α-
dependent, even though it is AKT-independent. Thus, p110α could regulate either TSC2 activity 
or mTORC1 activity directly, through unknown mechanisms (dotted lines). This represents an 
intriguing area for further study. 
???? 
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 A second, perhaps more interesting question arising from these findings is why PI3K 
and specifically p110α inhibition is sufficient to inhibit mTORC1 activation, if not through AKT? 
Our lab has previously shown that hyper-activation of PI3K occurs downstream of NF1 loss, 
and this seems to be the primary positive signal driving mTORC1 activation (Johannessen et 
al., 2005). This positive signal seems to be mediated by AKT. Moreover, we know that AKT 
inhibition is not sufficient to block mTORC1 activity. Therefore, PI3K inhibition must provide 
additional inhibitory signals to mTORC1, other than through loss of the positive signal from 
AKT. A better understanding of this signaling network will not only improve our mechanistic 
understanding of the pathway, but could also lead to alternative therapeutic approaches, as 
this may reveal additional ways to target mTORC1 activity.  
 Of primary interest is determining whether this effect is TSC2 dependent. TSC2 can be 
regulated by AKT, ERK, and RSK, so it is possible that PI3K inhibition is modulating TSC2 
through something other than AKT. It will be important to determine whether PI3K inhibition 
can ablate mTORC1 activity in NF1-deficient cells when TSC2 is ablated. If so, this would 
suggest that PI3K is having an effect downstream of TSC2, possibly affecting raptor or mTOR 
phosphorylation. Alternatively, PI3K inhibition could be affecting localization of the mTORC1 
complex to the lysosome, preventing its activation by RHEB. mTOR localization to the 
lysosome is thought to be primarily regulated by amino acid availability mediated by AMPK and 
the Ragulator Complex. PI3K inhibition could be causing a more generalized stress response 
that affects this signaling pathway, blocking mTORC1 activation. Regardless of the 
mechanism, this AKT-independent regulation of mTORC1 by PI3K is an unexpected and 
interesting finding, and warrants further study.  
Selecting PI3K/mTOR Inhibitors for Clinical Trials 
 As described in Chapter 2, I found that mTORC1 is the minimal, key signaling node in 
the PI3K pathway that must be inhibited for therapeutic benefit in NF1-mutant cancers. In our 
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mouse model, I found that rapamycin has superior pharmacodynamics relative to the PI3K 
inhibitor GDC-0941. However, these data suggest that a PI3K inhibitor with a better 
pharmacodynamics profile could be just as effective as a direct mTORC1 inhibitor. Thus, in 
selecting agents for human trials, it will be important to identify the inhibitors that display 
sustained target inhibition in humans, while still minimizing toxicity. Importantly, I found that 
AKT and mTORC2 inhibition are not important, and that AKT inhibition does not improve the 
response to rapamycin, alleviating any concerns about feedback activation on AKT in this 
context. Therefore, mTOR kinase inhibitors do not need to be favored over rapalogs unless 
they show superior pharmacodynamics. Another potential therapeutic approach to inhibiting 
mTOR is through the use of p110α-specific inhibitors or β-sparing inhibitors, which are 
expected to have less toxicity than pan-PI3K inhibitors (Liu et al., 2009). The specific 
pharmacodynamic and toxicity profiles of various mTOR and PI3K inhibitors can only be 
addressed in human clinical trials, but this work suggests that duration of mTORC1 inhibition 
should be a primary factor in selecting agents for clinical trials in this tumor type. 
Mechanistic Role of Reduced Glucose Uptake 
 In the present study, we explore the impaired glucose uptake in mTOR/MEK inhibitor 
treated tumors primarily as a biomarker for combined target inhibition. However, it is possible 
that suppression of GLUT1 expression has a mechanistic role as well. As Otto Warburg first 
described in the early 1900s, cancer cells typically preferentially use glycolysis instead of 
oxidative phosphorylation for ATP production, even in aerobic conditions. Cancer cells have an 
increased need for glucose relative to normal cells at least in part because this process is 
much less efficient. The observation that cancer cells take up more glucose than surrounding 
tissue lead to the development of 18F-FDG PET imaging as a prognostic and diagnostic tool, 
but more recently it has been appreciated that this might also represent a vulnerability in 
cancer cells.  
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 Glucose uptake and altered cancer metabolism are now being studies as potential 
therapeutic targets in cancer. Inhibition of GLUT1 has been shown to have an apoptotic effect 
in many cancer settings, so it would be interesting to determine whether the decreased GLUT1 
expression observed in the present study is contributing to the therapeutic effect (Adekola et 
al., 2012). If this is the case, then that would suggest that GLUT1 inhibitors, which have 
recently been discovered, might be effective in this model (Wang et al., 2012). The altered 
metabolism observed in cancer offers many intriguing therapeutic opportunities, so it will be 
important to better understand the potential mechanistic role of GLUT1 suppression and 
reduced glucose uptake in this therapy.  
18F-FDG PET Uptake as a Biomarker in other Tumor Types 
 The combination of mTOR or PI3K inhibitors with MEK inhibitors has been successful in 
a number of preclinical settings, most notably in RAS mutant cancers (Engelman et al., 2008; 
Posch et al., 2013). However, the challenge will be to identify a combined dosing strategy that 
is both tolerated and effective. I demonstrated in Chapter 2 of this dissertation that 18F-FDG 
uptake can serve as a non-invasive biomarker of combined target inhibition in NF1-deficient 
MPNSTs, and this will be a powerful tool for determining dosing in the clinic. It will be 
important to determine whether FDG-PET imaging can be similarly applied to other cancers 
where combined mTOR and MEK inhibition is effective. In VHL and LKB1 mutant cancers, 
mTOR inhibition alone is sufficient to reduce GLUT1 expression and 18F-FDG uptake 
(Shackelford et al., 2009; Thomas et al., 2006). In the present study we resolved a previous 
question in the field as to why mTOR inhibition was not sufficient to reduce GLUT1 in NF1-
deficient contexts, as we found that both the ERK and mTORC1 pathways must be inhibited to 
reduce GLUT1 expression. Thus we would hypothesize that this biomarker should be useful in 
other contexts where both pathways are hyper-activated, such as cancers with activating RAS 
mutations or other NF1-mutant cancers. Importantly, our lab has shown that the combination 
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of mTORC1 and MEK inhibition is also effective in a xenograft mouse model of NF1-mutant 
melanoma (Maertens and Cichowski, 2014). It will be interesting to determine whether these 
tumors also show a reduction in GLUT1 after combined treatment, and if FDG-PET imaging is 
an effective biomarker in this context. RAS mutant cancers are also sensitive to combined PI3K 
and ERK pathway inhibition in pre-clinical models (Engelman et al., 2008). As KRAS activating 
mutations, similar to NF1 loss, will lead to activation of both the PI3K and ERK pathway, we 
would expect that reduction in GLUT1 might similarly require inhibition of both pathways, in 
which case FDG-PET will also be an effective biomarker in this setting.  
Targeting Effectors Downstream of mTORC1 
 In Chapter 2 of this dissertation we provide proof of concept that combined inhibition of 
mTORC1 and MEK leads to tumor regression in NF1-mutant cancers. However, it remains to 
be determined whether an effective but tolerable dose can be identified in clinical trials. Given 
the differences in toxicity between humans and mice, this can only be addressed in human 
trials. The mTORC1 and ERK pathways are both master regulators of a number of cellular 
processes, and inhibition of all of these downstream targets may not be necessary for 
therapeutic efficacy. Identifying the minimal necessary components for therapeutic efficacy 
could allow for a better therapeutic window.  
mTORC1 directly regulates two distinct primary pathways, through phosphorylation of 
S6 kinase and 4E-BP1. S6 kinase directly phosphorylates a number of target proteins including 
ribosomal protein S6, eIF4B, eEF2K, CREM, Pdcd4, BAD1, and MDM2. Through the 
phosphorylation of these target proteins, S6 kinase regulates a number of downstream 
processes including protein synthesis, cytoskeletal rearrangement, proliferation, splicing, and 
cell survival (Fenton and Gout, 2011). On the other hand, when hypo-phosphorylated, 4E-BP1 
directly binds to eIF4E, the rate-limiting factor in cap-dependent translation. Phosphorylation of 
4E-BP1 by mTOR prevents the association with eIF4E, allowing cap-dependent translation to 
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occur (Morita et al., 2015). Given their divergent roles, it may be possible that directly targeting 
S6 kinase or cap-dependent translation would be sufficient to promote tumor regression in 
combination with ERK pathway inhibitors.  
Several pre-clinical S6 Kinase specific inhibitors have been developed, and could be 
easily tested in this model (Couty et al., 2013). Targeting 4E-BP1 is not as straightforward 
because it is not a kinase, but several approaches have been taken to inhibit cap-dependent 
translation by targeting eIF4E, including anti-sense RNAs and inhibitors of eIF4E assembly with 
eIF4G (Pettersson et al., 2014). eIF4E is also phosphorylated by the MNK kinases, and this 
phosphorylation event appears to be important for eIF4E activity in cancer, so MNK kinase 
inhibitors represent another potential therapeutic approach (Konicek et al., 2011). It will be 
important to determine if any of these therapeutic approaches, when combined with MEK 
inhibition can promote tumor regression. Recent studies in our lab suggest that eIF4E is indeed 
a critical component of therapeutic efficacy, and MNK inhibitors, which block eIF4E 
phosphorylation, can shrink MPNSTs when combined with MEK inhibitors.  
Mechanism of TXNIP Activation (Work in Progress)  
 In Chapter 3 of this dissertation, I identified TXNIP upregulation as a critical mediator of 
cell death in response to combined HDAC and mTOR inhibition. Interestingly, TXNIP 
upregulation appears to be a key factor in the switch from an adaptive UPR to a terminal UPR 
(Lerner et al., 2012; Oslowski et al., 2012). I also found that knockdown of the UPR-mediator 
PERK partially protects cells from combined treatment, suggesting that the UPR activation is 
contributing to the cell death phenotype. Given recent studies that have identified PERK 
activation as regulating TXNIP transcription through the transcription factors ATF5 and 
chREBP, I hypothesize that UPR activation may be contributing to the increased expression of 
TXNIP observed here. Therefore, it will be important to determine whether increased 
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expression of TXNIP induced by combined HDAC and mTOR inhibition is impaired in the 
context of PERK or ATF5 knockdown (Figure 3–8).  
 We hypothesize that TXNIP is being at least partially induced due to the activation of 
the UPR and irresolvable ER stress. However, it is also possible that TXNIP transcription is 
being more directly activated by HDAC inhibition through epigenetic regulation of the TXNIP 
gene. Therefore, it will also be important to determine whether acetylation marks on histones in 
the TXNIP gene are altered by vorinostat treatment in this context.  
Increased TXNIP expression after mTOR inhibition has been described to be regulated 
by the transcription factor complex MondoA-Mxl. mTOR appears to inhibit MondoA-Mxl 
transcription of TXNIP, so when mTOR is inhibited this releases MondoA-Mxl to drive TXNIP 
expression (Kaadige et al., 2015). Here, we find that mTOR inhibition can modestly increase 
TXNIP expression, but it remains to be determined if this is dependent on MondoA-Mxl. The 
combined effect of HDAC and mTOR inhibition on TXNIP expression seems to be critical for 
the efficacy of this therapy, so further study on their relative control of TXNIP transcription is 
warranted.  
TXNIP-Driven Cell Death 
 The experiments outlined above will answer how TXNIP is upregulated. However, 
another question is how TXNIP activation contributes to cell death. Interestingly, TXNIP is 
known to mediate cell death through two distinct mechanisms. TXNIP can mediate apoptosis 
through ASK1, and can induce cell death through activation of the NLRP3 inflammasome, a 
process referred to as pyroptosis (Lu and Holmgren, 2012; Zhou et al., 2010). Activation of 
ASK1 and the NLRP3 inflammasome have been demonstrated in the context of oxidative and 
proteotoxic stress (Sano and Reed, 2013; Zhou et al., 2010). Therefore, it will be important to 
determine whether the TXNIP-mediated cell death observed here is either ASK1 or NLRP3-
dependent.  
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 The NLRP3 inflammasome is thought to play a critical role in mediating stress 
responses and cellular death in a number of contexts as a result of oxidative or proteotoxic 
stress. This complex has been well studied in the context of atherosclerosis, gout, diabetes, 
and other sterile inflammatory diseases (Ozaki et al., 2015). However, it remains relatively 
under-studied in cancer. Interestingly, unlike other inflammasome complexes, which seem to 
have very specific pathogenic-triggers, the NLRP3 complex can be formed in response to a 
broad number of stimuli, so it is though that rather than direct binding of activators, NLRP3 is 
activated through a more proximal signal. Of note, ROS are currently thought to be one of the 
proximal signals that can lead to NLRP3 formation (Abderrazak et al., 2015). Given the high 
level of ROS observed in cancers, and the further induction of ROS observed here upon 
treatment with HDAC inhibitors, it will be very interesting to determine whether the NLRP3 
complex is indeed activated in this context. More recently, direct binding of TXNIP to NLRP3 
has been reported to activate NLRP3 in response to high cellular ROS and drive a terminal cell 
fate (Zhou et al., 2010). If TXNIP-driven cell death is independent of ASK1 in the context of 
combined HDAC/mTOR inhibition this would provide a very interesting avenue of study.  
 ASK1 drives canonical apoptosis and can also be directly regulated by the thioredoxin 
system. Reduced TRX is a negative regulator of ASK1, but in conditions of high cellular ROS 
TRX is oxidized and releases ASK1, allowing ASK1 to drive an apoptotic cell fate. Importantly, 
TXNIP is also a direct binding partner and inhibitor of reduced TRX, preventing the interaction 
with ASK1, so high levels of TXNIP can also result in activation of the ASK1 cascade (Saxena 
et al., 2010). Ultimately, understanding the mechanism of TXNIP-driven cell death in the 
context of combined HDAC and mTOR inhibition will be critical to our understanding of the 
therapy described in Chapter 3, and could possibly further our knowledge of the terminal 
stress response in cancer as well.  
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Identifying Specific HDACs Contributing to Therapeutic Efficacy 
 In Chapter 3 of this dissertation we report the therapeutic efficacy of vorinostat, a pan-
HDAC inhibitor, when combined with mTOR inhibition. Vorinostat has activity against all Zn2+-
dependent HDACs, which includes Class I (HDAC 1, 2, 3, and 8), Class IIa (HDAC 4,5, 7, and 
9), Class IIb (HDAC6 and 10) and Class IV (HDAC 11). Vorinostat inhibits HDACs 1-3 and 
HDAC6 at low nanomolar concentrations, but is less potent against the other Zn2+-dependent 
HDACs. Vorinostat is one of two currently FDA-approved HDAC inhibitors, but more selective 
inhibitors are being developed in the hope that this will reduce toxicity. Therefore it is important 
to identify which HDAC(s) must be effectively inhibited to promote a therapeutic response. In 
Chapter 3 we find that neither HDAC6 knockdown nor HDAC6-specific inhibitors have a 
cytotoxic effect when combined with mTOR inhibition, demonstrating that HDAC6 inhibition 
alone is not sufficient. However, it remains possible that inhibition of select HDACs is driving 
the therapeutic response, and if this is the case, identifying the responsible HDACs could 
inform therapeutic development in the future as more HDAC-specific inhibitors are available 
because it is anticipated that these inhibitors will have better toxicity profiles.  
HDAC and mTOR Inhibitors in other Therapeutic Contexts 
In addition to the combination of mTOR and MEK inhibitors described in Chapter 2, we 
found that mTOR inhibitors and HDAC inhibitors also combine to promote tumor regression, as 
detailed in Chapter 3. Our lab has previously found that the combination of HSP90 inhibitors 
and mTOR inhibitors, which was effective in this model, was also effective in an aggressive 
model of KRAS-mutant lung cancer. Because the HDAC/mTOR inhibitor combination seems to 
be targeting similar cellular vulnerabilities, it is likely that KRAS mutant lung cancer will also 
respond to this combination (De Raedt et al., 2011). Unlike the combination described in 
Chapter 2, which targets activation of specific signaling pathways, this combination targets a 
more generalized phenotype and thus might be effective in any number of cancer types. 
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Therefore it will be important to understand the specific biological characteristics that make 
cancers sensitive to this therapy. 
Predictive Biomarkers of Response to Combined HDAC and mTOR Inhibition 
 In Chapter 3 of this dissertation, we describe the effective combination of HDAC and 
mTOR inhibitors in MPNSTs, but as discussed above, a broad number of tumor types could be 
responsive to this therapy. Additionally, we saw a variable response in our mouse model, which 
recapitulates what is typically seen in patients and is expected because each of these tumors 
arises from an independent genetic event and the tumors are heterogeneous. In order to 
identify the cancer types most likely to be vulnerable to this combination, as well as identify 
specific patients who could benefit from this therapy, it will be important to understand the 
factors governing sensitivity and identify tractable biomarkers.  
 One possible factor that contributes to sensitivity is aneuploidy. Aneuploidy is known to 
contribute to proteotoxic stress due to imbalanced stoichiometry (Oromendia and Amon, 
2014). Alternatively, basal activation of the UPR could be a predictor of sensitivity, as these 
tumors already have a high level of ER stress (De Raedt et al., 2011). Given the critical role of 
ROS and ROS scavengers for therapeutic efficacy, high basal ROS may also be a predictor of 
sensitivity. Regardless, it will be important to determine if there are any biomarkers that are 
predictive of sensitivity as this will aid in the translation of this combination to other cancer 
types, as well as patient selection in the clinic.  
Other Therapeutic Approaches Targeting Oxidative and Proteotoxic Stress 
 We have now identified two combination therapies that exploit cancer cell stress—the 
combination of HDAC and mTOR inhibitors described in Chapter 3 of this thesis, as well as the 
combination of HSP90 and mTOR inhibitors that we have previously published (De Raedt et al,. 
2011, reprinted in Appendix B). Together, this provides compelling support for the concept that 
proteotoxic and oxidative stress represent serious vulnerabilities in cancer cells that can be 
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exploited successfully. While these data are compelling and we are optimistic that one or both 
of these combinations will yield clinical benefit, these data also suggest that a large number of 
agents that perturb these stress responses could be effective.  
 For example, ER associated degradation (ERAD) is a critical process that prevents 
accumulation of misfolded proteins and inhibiting this process induces ER stress (Kim et al., 
2008). One critical component of ERAD is p97, for which inhibitors are now available (Chapman 
et al., 2015). Thus p97 inhibitors may be able to synergize with mTOR inhibition to promote 
cancer cell death. Alternatively, they may be able to synergize with either HSP90 inhibitors or 
HDAC inhibitors as well, because while all three drugs converge on ER stress and the UPR, 
they appear to do so through distinct mechanisms. Conversely, instead of driving activation of 
the terminal UPR by inducing ER stress, we might be able to use agents that inhibit the UPR. 
Several inhibitors targeting IRE1 endonuclease activity and PERK kinase activity have been 
developed. These agents might be effective in combination with mTOR inhibitors, or in 
combination with a second inducer of ER stress.  
 In addition to the role of proteotoxic stress, these findings further underscore the 
importance of oxidative stress. The efficacy of the HDAC/mTOR combination and the 
HSP90/mTOR combination can be blocked by the addition of ROS scavengers, demonstrating 
that ROS induction is critical. Thus we might be able to directly induce reactive oxygen 
species, and promote a similar therapeutic effect. Several drugs are known to induce ROS 
including arsenic trioxide, elesclomol, and buthionine sulfoximine. To date we have not been 
able to identify a combination of ROS inducers with mTOR inhibitors that is both effective and 
tolerated in our mouse model (data not included in this dissertation), but this remains an 
interesting avenue for exploration.  
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Sequential or Alternate Dosing of Combination Therapies 
 We have now identified a number of different combination therapies that are effective in 
this mouse model of MPNSTs, in addition to the two described in this dissertation (De Raedt et 
al., 2011; 2014). We are optimistic that these combinations will show significant clinical benefit 
and that responses will be durable. However, for therapies currently in the clinic, the reality is 
that most responders will eventually relapse. Therefore, it will be interesting to determine 
whether animals that are no longer responding to one combination therapy remain sensitive to 
another. The two therapeutic approaches presented in this dissertation target different 
underlying vulnerabilities: the combination of mTOR and MEK inhibitors described in Chapter 2 
targets specific signaling pathways, while the combination described in Chapter 3 exploits 
underlying stress in the cancer cell. Thus, a tumor that has become resistant to one therapeutic 
approach could remain sensitive to the other. Therefore, it will be interesting to determine 
whether sequential dosing of the combination therapies results in an improved and more 
durable response. The population of tumor cells that is sensitive to one combination therapy 
versus another may also differ, in which case superior efficacy could be seen by alternating 
therapeutic strategies. For example, sustained treatment with an mTOR inhibitor and 
alternating treatment with a MEK inhibitor and an HDAC inhibitor might improve efficacy over 
either combination therapy alone if the population of sensitive tumor cells is not entirely 
overlapping. In any case, a better understanding of how these combination therapies can be 
sequentially or alternately dosed could provide insight into the factors governing sensitivity and 
resistance as well as inform future clinical strategies. These questions can be readily 
addressed in our mouse model.  
  
The findings presented here, as well as the future directions, aim to provide a better 
understanding of NF1-mutant cancers. Specifically, the studies presented in this dissertation 
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expand our understanding of signaling and stress vulnerabilities in NF1-mutant cancers, and 
provide promising pre-clinical data for two combination therapies. We sincerely hope that 
these findings, in conjunction with the future directions they inspire, will ultimately improve 
patient outcome for these devastating tumors.  
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INTRODUCTION 
Previous work has demonstrated efficacy of IPI-504, an HSP90 inhibitor, and mTOR 
inhibition in a genetically engineered mouse model of NF1-deficient MPNSTs as well as KRAS 
mutant lung cancer (De Raedt et. al 2011, reprinted in Appendix B). This work inspired a clinical 
trial of IPI-504 and everolimus in KRAS mutant non-small cell lung cancer (NCT01427946). This 
trial was recently completed, with results still pending. However, in any combination therapy 
there is a concern about combined toxicity in the clinic. Therefore a major goal of this thesis is 
to develop novel therapies using a variety of different agents that exploit this mechanism (as 
discussed in Chapter 3).  
IPI-504 is a first-generation HSP90 inhibitor derived from the natural compound 
geldanamycin (Hanson and Vesole, 2009). Rationally designed second-generation inhibitors, 
which are structurally distinct from first generation 17-AAG derivatives, are now entering 
clinical trials. Ganetespib (STA-9090) a second-generation inhibitor binds HSP90 in more of its 
confirmations, in more multi-protein complexes, and has a 50-fold increased affinity for HSP90 
relative to 17-AAG. Importantly, while other second-generation inhibitors have shown high 
ocular toxicity in the clinic, ganetespib does not appear to have this side effect. Here we report 
that STA-1474, a pro-drug of ganetespib, is effective in combination with rapamycin in vitro, 
and in vivo, supporting the clinical development of second-generation HSP90 inhibitors in 
combination with mTOR inhibitors.  
RESULTS 
Similar to other ER stress inducing agents, STA-1474 was cytotoxic as a monotherapy 
in MPNST cells in vitro (Figure A–1A). However, the addition of rapamycin leads to cell death at 
sub-lethal concentrations of STA-1474 (Figure A–1B).  
 To verify the potential clinical efficacy of this combination, a genetically engineered 
mouse model of MPNSTs was used. These mice are Nf1 and p53 heterozygous and develop 
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spontaneous MPNSTs. Tumor bearing mice were treated with STA-1474 or STA-1474 in 
combination with rapamycin. Similar to what was observed with IPI-504, STA-1474 had little 
effect on tumor growth as a monotherapy. However, when combined with rapamycin, this lead 
to potent tumor regression, suggesting that ganetespib is a promising agent to combine with 
mTOR inhibitors in clinical trials (Figure A–1C).  
DISCUSSION 
Here we show that the second-generation HSP90 inhibitor induces a cytotoxic effect on 
MPNSTs in vitro and in vivo when combined with the mTORC1 inhibitor rapamycin. We have 
Figure A–1. Second-generation HSP90 Inhibitor STA-1474 Synergizes with mTORC1 Inhibition in 
vitro and in vivo. (A) Experimentally determined LD50 for human MPNST cell line S462 for first-
generation inhibitor IPI-504 and second-generation inhibitor STA-1474. (B) S462 cells treated were 
treated with 50nM of STA-1474 +/- 100nM rapamycin for 72 hours. Shown is the log2 of fold change 
relative to day 0 counts,. (C) Tumor bearing NPCis mice were treated with 50mg/kg STA-1474 once a 
week (purple) or STA-1474 plus 5mg/kg Rapamycin daily (Combo—blue). Shown is the change in 
tumor size after 10 days. Left y-axis indicates the log2 of fold change after 10 days, right y-axis 
indicates percent change in tumor volume. Vehicle and rapamycin (grey) are historical data shown for 
comparison. Historical data previously published in De Raedt et al, 2011.  
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previously shown that the geldanamycin derivative IPI-504 is similarly effective, but this work 
further supports that this is on-target efficacy. IPI-504, like other geldanamycin-derivatives, 
contains a quinone group which is oxidized by NAD(P)H: quinone oxidoreductase 1 (NQO1). 
This quinone activity has been reported to induce reactive oxygen species independent of 
HSP90 inhibition (Dikalov et al., 2002). The efficacy observed with STA-1474, which does not 
contain a quinone group, demonstrates that HSP90 inhibition is sufficient to induce the 
therapeutic effect observed, and that the quinone group is not necessary although it may be 
contributing to IPI-504’s efficacy.  
Importantly, this quinone activity is also associated with hepatotoxicity. These findings 
suggest that inhibitors that do not contain the quinone group can be used with similar efficacy, 
so that hepatotoxicity can be avoided without sacrificing therapeutic benefit.  
Together, these findings further support the clinical development of HSP90 inhibitors in 
combination with mTORC1 inhibitors, and specifically demonstrate that STA-1474, the pro-
drug of ganetespib, is effective in the pre-clinical setting. These results lay the groundwork for 
a Phase I/II clinical trial (NCT02008877) of ganetespib and sirolimus, which is now enrolling.  
MATERIALS AND METHODS 
Cell Lines and Reagents 
S462s were purchased from ATCC. Cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum and L-glutamine. STA-1474 was 
generously provided by Synta Pharmaceuticals. Rapamycin was purchased from LC Labs. 
Cellular Death Assays  
Cells were seeded into 6-well plates at approximately 250,000 cells per-well. 24-hours after 
plating, cells were counted using a hemocytometer and drug was added as indicated. Final 
counts were taken after 72 hours.  
Drug Treatments and Dosing Schedule 
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Animal procedures were approved by the Center for Animal and Comparative 
Medicine in Harvard Medical School in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals and the Animal Welfare Act. C56/BL6 NPcis mice have been previously 
described (Cichowski et al., 1999). Mice were treated daily with rapamycin via IP injections at 5 
mg/kg prepared as previously described (Johannessen et al 2008). STA-1474 was prepared in 
PBS and administered via tail vein injection once per week, starting on day 1, at a dose of 
50mg/kg. Compounds given in combination were administered sequentially.  
Tumor Volume Measurements 
Mice were enrolled in the study when tumor size was measured at 300-800 mm3. Tumor size 
was monitored every 2-3 days via measurement with a Vernier caliper. Tumor volume was then 
calculated using the standard formula L x W2 X 0.52.  
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This Appendix contains a reprint of the following publication, in which I performed the 
experiments shown in Figure 3F, and 4E and F. This publication also provides the basis for the 
work presented in Chapter 3 of this thesis. 
 
Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven 
Tumors. Thomas De Raedt, Zandra Walton, Jessica Yecies, Dana Li, Yimei Chen, Clare F. 
Malone, Ophélia Maertens, Seung Min Jeong, Roderick T Bronson, Valerie Lebleu, Raghu 
Kalluri, Emmanuel Normant, Marcia C Haigis, Brendan D. Manning, Kwok-Kin Wong, and 
Karen Cichowski (2011). Cancer Cell 20, 400-413.  
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SUMMARY
Ras-driven tumors are often refractory to conventional therapies. Here we identify a promising targeted ther-
apeutic strategy for two Ras-driven cancers: Nf1-deficient malignancies and Kras/p53 mutant lung cancer.
We show that agents that enhance proteotoxic stress, including the HSP90 inhibitor IPI-504, induce tumor
regression in aggressive mouse models, but only when combined with rapamycin. These agents synergize
by promoting irresolvable ER stress, resulting in catastrophic ER and mitochondrial damage. This process
is fueled by oxidative stress, which is caused by IPI-504-dependent production of reactive oxygen species,
and the rapamycin-dependent suppression of glutathione, an important endogenous antioxidant. Notably,
the mechanism by which these agents cooperate reveals a therapeutic paradigm that can be expanded to
develop additional combinations.
INTRODUCTION
Although significant advances have been made in developing
targeted therapies, identifying treatments for tumors driven by
mutations that do not affect a targetable protein represents
a major challenge in cancer research. Ras-driven cancers are
a classic example of this challenge and despite the fact that
Ras signaling has been studied for over 25 years, there are still
no effective targeted therapies (Young et al., 2009). Small-mole-
cule inhibitors that target Ras effectors are being evaluated;
however, studies suggest that the therapeutic efficacy of single
targeted agents may be limited, underscoring the need to
identify additional targets and/or more effective drug combina-
tions (Engelman et al., 2008; Young et al., 2009).
To develop new therapies, we initially focused on a distinct
subset of Ras-driven tumors: those that possess mutations in
the NF1 tumor suppressor. NF1 encodes a Ras GTPase-acti-
vating protein (RasGAP), which negatively regulates Ras by
catalyzing the hydrolysis of Ras-GTP (Martin et al., 1990;
Cawthon et al., 1990). Accordingly, NF1-deficient tumors are
driven by aberrant Ras activation (DeClue et al., 1992; Johannes-
sen et al., 2005). NF1 mutations underlie neurofibromatosis
type 1 (NF1) (Martin et al., 1990; Cawthon et al., 1990) and NF1
is mutated or suppressed in sporadic glioblastoma (TCGA
Significance
Ras-driven tumors are often refractory to conventional therapies and a clinically effective targeted therapy has not yet been
developed. Moreover, in some cancers KRAS mutations are used to exclude patients from being treated with specific tar-
geted agents. As such, developing an effective targeted therapy for Ras-driven tumors is an important endeavor. We have
identified a promising therapy for two distinct Ras-driven cancers:Nf1-deficient nervous systemmalignancies andKras/p53
mutant non-small cell lung cancer (NSCLC). Importantly, these studies have defined a specific drug combination that can
now be assessed in patients with these largely untreatable cancers. Moreover, these studies establish a therapeutic para-
digm that can be expanded to develop additional drug combinations.
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Consortium, 2008; Parsons et al., 2008; McGillicuddy et al.,
2009), NSCLC (Ding et al., 2008), and neuroblastoma (Ho¨lzel
et al., 2010), demonstrating a broader role forNF1-loss in cancer.
Themost commonmalignancy associated with NF1 is malignant
peripheral nerve sheath tumors (MPNSTs), which are highly
aggressive and frequently metastasize. Despite radiation, and
in some cases chemotherapy, inoperable tumors rapidly prog-
ress and can become lethal within months. As such, identifying
an effective treatment for these tumors is critical.
We and others have reported that mTOR is hyperactivated
in NF1-deficient tumors as a consequence of aberrant Ras
signaling (Johannessen et al., 2005, Dasgupta et al., 2005).
Using an Nf1/p53-mutant MPNST model, we further demon-
strated that the mTOR inhibitor rapamycin suppressed tumor
growth (Johannessen et al., 2008). However, although the
response to rapamycin was potent, effects were cytostatic.
Therefore, we have been using this model to developmore effec-
tive mTOR-inhibitor-based combination therapies, with the
expectation that successful combinations might also be effec-
tive in other Ras and/or mTOR-driven tumors.
To identify additional therapeutic agents, we considered drugs
that might exploit specific cellular vulnerabilities of cancer cells.
In addition to the pro-tumorigenic hallmarks of cancer (Hanahan
and Weinberg, 2000), tumor cells often exhibit specific stress-
related phenotypes caused by insults such as excessive DNA
damage, as well as replicative, metabolic, and proteotoxic stress
(Luo et al., 2009). Accordingly, it has been suggested that agents
that further enhance or sensitize cancer cells to these stresses
could be developed as potential therapies (Luo et al., 2009;
Taipale et al., 2010.). In this study we investigated agents that
augment proteotoxic or ER (endoplasmic reticulum) stress. ER
stress is induced when unfolded proteins accumulate in the ER
(Ron and Walter, 2007). Cancer cells frequently exhibit high
levels of ER stress caused by factors such as high mutational
load, copy number variation, oxidative stress, hypoxia, and
nutrient deprivation (Luo et al., 2009; Taipale et al., 2010). Aneu-
ploidy in particular has recently been shown to induce proteo-
toxic stress in both normal and cancer cells (Tang et al., 2011).
Oncogenic RAS also causes ER stress (Denoyelle et al., 2006).
Once triggered, ER stress activates a signal transduction
pathway known as the unfolded protein response (UPR) (Ron
and Walter, 2007). The UPR is initially engaged as a protective
mechanism to reduce protein accumulation; however, when
ER stress levels become insurmountable, cell death ensues
(Ron and Walter, 2007). This observation has led to the specula-
tion that agents that further enhance ER stress in vulnerable
cancer cells could be developed as anti-cancer therapies
(Luo et al., 2009; Tang et al., 2011). In this study we evaluated
the therapeutic effects of compounds that augment proteotoxic
stress in cancer cells, alone and in combination with mTOR
inhibitors, in two Ras-driven mouse tumor models.
RESULTS
MPNSTsAre Sensitive to Agents that Enhance ERStress
To determine whether MPNSTs might be sensitive to agents that
induce ER stress, we first evaluated basal stress levels. MPNSTs
are highly aneuploid and are driven by constitutive activation of
Ras and therefore might be subject to substantial ER stress.
Indeed, ER stress levels were much higher in tumors compared
with normal peripheral nerve, as confirmed by three independent
markers of UPR activation: BiP upregulation, phosphorylation of
eukaryotic translational initiation factor 2a (eIF2a), and accumu-
lation of the spliced active form of XBP-1 (sXBP-1) (Figure 1A)
(Ron and Walter, 2007). Next, we assessed the sensitivity of
human and mouse MPNSTs to classic ER stress-inducing
agents: thapsigargin (an ER calcium ATPase inhibitor) and tuni-
camycin (a glycosylation inhibitor). Both agents enhanced ER
stress (Figure 1B) and triggered cell death at concentrations
that did not affect the viability of normal cells (Figure 1C,D), indi-
cating that MPNSTs are hypersensitive to these ER stress-
inducing agents.
ER Stress-Inducing Agents Promote Tumor Regression
In Vivo but Only When Combined with Rapamycin
Based on the hypersensitivity of MPNST cells to these agents
in vitro, we hypothesized that they might promote tumor regres-
sion. In the Nf1/p53 tumor model, animals develop MPNSTs in
!5 months (Cichowski et al., 1999) and survive an average of
10.7 days after tumor detection (Johannessen et al., 2008).
Tumor-bearing animals were treated with vehicle, thapsigargin,
or rapamycin (Figure 1E). Thapsigargin exhibited minimal effi-
cacy (red bars) and was less potent than rapamycin (yellow
bars). This finding was unexpected given the cytotoxic versus
cytostatic effects of thapsigargin and rapamycin observed
in vitro (Figure 1D) (Johannessen et al., 2008). However, com-
bined rapamycin/thapsigargin treatment triggered rapid tumor
regression (green bars; p = 0.013). On average tumors shrank
45%; however, some tumors regressed >75% (Figure 1F) and
remaining masses were largely comprised of hemorrhage and
cellular debris (Figure 1G). Maximal effects were observed within
10 days, although significant tumor regression was detected
in 3 days (Figure 1F,G). Extensive long-term survival studies
were not performed because mice often scratched or bit these
rapidly shrinking lesions, resulting in ulceration that necessitated
euthanasia. Nevertheless, when animals were successfully
treated for a longer duration, tumors did not re-grow (Figure 1F).
One animal survived 107 days after tumor development with no
evidence of relapse, surviving more than 10 times as long as
control animals (Figure 1F,G). Tunicamycin also induced tumor
regression when co-administered with rapamycin, consistent
with the conclusion that excessive ER stress was a critical driver
of this response (Figure S1).
The HSP90 Inhibitor IPI-504 Cooperates with
Rapamycin to Promote Tumor Regression
Although these observations were striking, thapsigargin and
tunicamycin do not represent clinically viable agents. HSP90
inhibitors are another class of drugs known to induce ER
stress and are currently being investigated in the clinic (www.
clinicaltrials.gov). HSP90 maintains protein homeostasis by
folding newly synthesized and misfolded proteins, assembling
and dissembling protein complexes, and resolving protein
aggregates (Whitesell and Lindquist, 2005). HSP90 also directly
stabilizes two key stress-sensing components of the UPR:
IRE1 and pPERK/PERK (Marcu et al., 2002). Therefore, HSP90
inhibitors would be expected to promote ER stress in can-
cer cells via two cooperating mechanisms: first, by directly
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Figure 1. Therapeutic effects of rapamycin and ER stress-inducing agents on MPNSTs
(A) Immunoblots of tumor tissue derived from Nf1/p53mutant murine MPNSTs and normal peripheral nerve (NN). BIP, phospho-EIF2a (pEIF2a), and the spliced
form of XBP-1 (sXBP-1) indicate UPR activation.
(B) Immunoblots of pEIF2a and sXBP-1 in MPNST cells after 4 hr of 100 nM thapsigargin (TG) or 0.5 mg/ml tunicamycin (TN). Actin is a loading control.
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impairing global protein folding in these already compromised
tumor cells, and second, by inactivating subsequent adaptive
responses provided by two arms of the UPR. Accordingly, we
assessed the therapeutic effects of IPI-504, a hydroquinone
hydrochloride salt of the geldanamycin-derivative 17-AAG
(Sydor et al., 2006).
As predicted, IPI-504 rapidly induced ER stress and activated
the UPR, demonstrated by the upregulation of BiP, pEIF2a,
sXBP-1, IRE1, and phosphorylated PERK within 2–4 hr (Fig-
ure 2A) (Healy et al., 2009). However, prolonged exposure to
IPI-504 resulted in a destabilization of IRE1 and pPERK/PERK
(Figure 2A). Consequently, downstream UPR signals including
sXBP-1 and pEIF2a were inactivated by 8 hr, as expected
(Marcu et al., 2002) (Figure 2A). Notably, BiP levels, which are
not dependent on IRE1 and PERK, were elevated further by
16 hr, demonstrating that ER stress was enhanced in two phases
in response to IPI-504 (Figure 2A) (Marcu et al., 2002). Similar to
thapsigargin and tunicamycin, MPNST cells were sensitive to
low doses of IPI-504 in vitro (Figure 2B,C).
Using a previously established dosing schedule of IPI-504
(Douglas et al., 2009), we assessed the effects of this agent alone
and in combination with rapamycin in vivo. Like thapsigargin, IPI-
504 was unable to promote tumor regression as a single agent
but did so when combined with rapamycin (Figure 2D) (p =
0.001). On average, tumors shrank 49% (Figure 2D, green
bars). Tumor regression was visually apparent (Figure 2E) and
histological analysis revealed massive cell death and accumu-
lating debris (Figure 2F).
The pharmacodynamic response to IPI-504 in clinical trials is
assessed by measuring HSP70 levels, which increase when
HSP90 is effectively inhibited (Ramanathan et al., 2007). Target
inhibition was confirmed in vivo using this readout (Figure 2G).
Rapamycin also effectively suppressed the mTOR pathway
(Figure 2G). Maximal tumor regression in response to rapamy-
cin/IPI-504 treatment occurred within 3–5 days and no toxicity
was observed in the course of this study as determined by
weight, grooming, or body score (Figure S2). TUNEL staining
was apparent within 16 hr, which was not observed in tumors
from animals exposed to rapamycin or IPI-504 alone (Figure 2H).
To mimic the dose of IPI-504 used in clinical trials, IPI-504 was
administered once rather than twice per week at 100 mg/kg.
This treatment schedule also promoted tumor shrinkage and
significantly prolonged survival (Figure 2I) (p = 8.9 3 10!5).
This Kaplan-Meier curve likely underestimates survival, because
most animals were euthanized because of self-inflicted damage
at the site of residual lesions (denoted by Xs) (Figure 2I). No long-
term toxicity was observed as determined after 50 days of
treatment.
IPI-504Mediates its Therapeutic Effects bySuppressing
HSP90 and Promoting ER Stress
HSP90 is encoded by more than one gene, is extremely abun-
dant, and interacts with more than 20 co-chaperones (Taipale
et al., 2010). Therefore, it is not possible to completely inactivate
HSP90 activity by genetically suppressing a single gene.
However, two additional structurally distinct HSP90 inhibitors,
BEP800 and AUY-922 (Massey et al., 2010), as well as 17-AAG
itself, killed MPNSTs, induced ER stress, and impacted the
UPR with the same kinetics as IPI-504 (Figure 3A, B, C and Fig-
ure S3A), confirming that these agents all function by suppress-
ing HSP90.
The observation that HSP90 inhibitors enhance ER stress, and
that three distinct ER stress-inducing agents (IPI-504, thapsigar-
gin, tunicamycin) induce the same therapeutic response,
supports the hypothesis that IPI-504 mediates its effects by trig-
gering excessive ER stress. To formally address this possibility,
we assessed whether ectopic expression of sXBP1, a down-
stream UPR component that can reduce ER stress (Ozcan
et al., 2008), might attenuate the therapeutic effects of IPI-504.
Notably, sXBP1 expression reduced and delayed cell death in
response to IPI-504 (Figure 3D). Conversely, siRNAs that recog-
nize PERK and IRE1 sensitized MPNSTs to sub-threshold doses
of IPI-504 (Figure 3E). Together these data indicate that exces-
sive ER stress plays a causal role in driving the therapeutic
response.
Rapamycin sensitized MPNSTs to IPI-504 in vitro as it does
in vivo (Figure 3F) and genetic ablation of raptor, a critical
component of TORC1, did so as well (Figure 3F). Rapamycin
also enhanced the suppressive effects of PERK and IRE1
siRNAs (Figure 3G). However, this combination was not as
potent as rapamycin and IPI-504, consistent with the notion
that PERK and IRE1 destabilization contribute to the therapeutic
response but do not entirely mediate the effects of HSP90
suppression, which has a more global effect on protein homeo-
stasis in these impaired cancer cells. Thus, both genetic and
chemical studies demonstrate that IPI-504 and rapamycin func-
tion through their intended targets (HSP90 and TORC1) and that
ER stress is an important mediator of the therapeutic response.
Interestingly, although the proteasome inhibitor bortezomib can
induce proteotoxic stress in professional secretory cells (e.g.,
multiple myeloma cells), bortezomib did not substantially induce
ER stress in MPNSTs and did not promote tumor regression
when combined with rapamycin (Figure S3B), further underscor-
ing the importance of the ER stress response in mediating the
observed therapeutic effects.
The limited clinical efficacy of mTOR inhibitors has been
proposed to result from AKT activation that can occur via the
(C) LD50 values in response to TG or TN (48 hr) in normal cells (IMR90), human MPNST cell lines (S462, SNF96.2), and mouse MPNST cell lines (185-3, 1A50).
(D) Growth curves comparing the effects of different doses of thapsigargin and tunicamycin in S462 human MPNSTs and IMR90s.
(E) Waterfall plot depicting tumor growth after 10 days of treatment with vehicle (blue), thapsigargin (red), rapamycin (yellow) and rapamycin/thapsigargin (green).
The left y axis indicates the log2 of tumor fold growth versus day 0 and the right y axis shows the change in fold volume. The table shown reports mean and
standard deviation for each treatment arm (n = 8) and mean tumor shrinkage.
(F) Graph depicting the change in tumor size over time. Three animals on the rapamycin/thapsigargin combination are shown (green). For simplicity, the yellow line
is an average volume of rapamycin-treated tumors (n = 8). Blue and red lines represent vehicle- and thapsigargin-treated animals, respectively.
(G) H&E-stained tumor remnants from animals treated with rapamycin/thapsigargin. Sections from tumors after (a) 107 days of treatment, (b) 35 days (c), 21 days,
and (d) 4 days, showing pyknotic nuclei throughout the tumor. All images were taken using 10x objective, except (d), which has been magnified to 40x. (See also
Figure S1.)
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Figure 2. Rapamycin and IPI-504 promote MPNST regression
(A) Immunoblots of BIP, pEIF2a, sXBP-1, IRE1a, and PERK in human MPNSTs treated with IPI-504 over time (hours). Note that the activation of pEIF2a, sXBP1,
IRE1, and PERK (*denotes activated phosphorylated PERK) and initial upregulation of BIP occurs within 2–4 hr. A second wave of BIP upregulation occurs
between 8 and 16 hr, as pEIF2a, sXBP-1, IRE1a, and PERK become suppressed. Actin serves as a loading control.
(B) LD50 values in response to IPI-504 (72 hr) for normal cells (IMR90), human MPNST cell lines (S462, SNF96.2), and mouse MPNST cell lines (185-3, 1A50).
(C) Growth curves of the S462 cell line treated with different concentrations of IPI-504.
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suppression of negative feedback pathways (Dancey et al.,
2009). However, as we have previously reported, rapamycin
did not induce AKT activation in MPNSTs in vivo (Figure 3H)
(Johannessen et al., 2008). Moreover, combined rapamycin/
IPI-504 treatment did not suppress AKT phosphorylation or
expression levels, indicating that this combination is not more
effective because it inhibits AKT (Figure 3H). However, it is
still possible that an mTOR kinase inhibitor or dual PI3K/mTOR
inhibitor may synergize even more potently with HSP90 inhibi-
tors, by concomitantly suppressing this well-established survival
pathway.
Rapamycin and IPI-504 Trigger a Catastrophic
Destruction of the ER and Mitochondria in MPNSTs
In Vivo
To elucidate the biological consequences of combined rapa-
mycin/IPI-504 treatment, we performed transmission electron
microscopy on MPNSTs in vivo. Within 7 hr, rapamycin/IPI-504
induced amassive accumulation of double-membraned vesicles
(Figure 4A) (n = 5). These structures exhibited cellular hallmarks
of autophagosomes and contained visible cargo (Figure 4B)
(Klionsky et al., 2008). The ER and mitochondria can both act
as a source of membranes for autophagosomes (Hayashi-
Nishino et al., 2009; Yla¨-Anttila et al., 2009; Hailey et al. 2010).
We detected autophagosomes emerging from both organelles
in response to rapamycin/IPI-504, the significance of which is
discussed below (Figure 4C). The appearance of autophagic
vesicles can be caused by autophagy induction or can occur
when productive autophagy is blocked (Klionsky et al., 2008).
However rapamycin/IPI-504 induced the degradation of p62/
SQSTM1 in these tumors, which is degraded as a consequence
of productive autophagy (Figure 4D) (Klionsky et al., 2008). In
addition, rapamycin/IPI-504 triggered a rapid increase in LC3-
expressing punctae in MPNSTs, which fused with lysozomes
shortly thereafter, indicating that autophagy was induced
rather than blocked (Figure 4E, F) (N’Diaye et al., 2009; Pankiv
et al., 2007). Notably, excessive ER stress actively triggers
autophagy, which is engaged as a protective mechanism to
degrade unfolded protein aggregates (Hotamisligil, 2010). How-
ever, although IPI-504 and rapamycin can both induce signals
that promote autophagy, individually each agent was unable to
elicit a potent autophagic response in vivo (Figure 4A), suggest-
ing that these agents were somehow synergizing.
To investigate this synergy we examined ER andmitochondria
in MPNSTs. Notably, there is a complex interdependent relation-
ship between the ER and mitochondria in response to ER
stress (Malhotra and Kaufman, 2007) (Figure 4G). ER stress
triggers intraluminal calcium release, which promotes mitochon-
drial membrane depolarization and ROS production (Malhotra
and Kaufman, 2007;Kim et al., 2008). ROS further promotes
protein misfolding, thereby enhancing ER stress. In response
to low levels of ER stress, adaptive responses are engaged;
however, when ER stress levels become insurmountable, a
vicious cycle ensues, resulting in catastrophic damage to the
ER and mitochondria, and in cell death (Malhotra and Kaufman,
2007). Consistent with the notion that rapamycin and IPI-504
synergize to induce irresolvable ER stress, we observed severe
ER swelling within 7 hr (Figure 4H). In addition, we detected a
dramatic accumulation of polyubiquitinated protein aggregates,
which occur when unfolded proteins accumulate (Figure S4).
Interestingly, after 16 hr ER membranes were nearly undetect-
able in rapamycin/IPI-504-treated tumors (Figure 4I), suggesting
that ER membranes may have been depleted by excessive
and continuous autophagy emanating from these membranes.
Finally, because excessive ER stress ultimately triggers severe
mitochondrial damage, after 16 hr mitochondria became
swollen and highly vesicularized, and were engulfed by auto-
phagosomes (mitophagy) (Figure 4J). The dramatic effects of
combined rapamycin/IPI-504 treatment on autophagy, ER
swelling and destruction, and mitochondrial damage were
observed in all tumors examined (R5/5 for each condition)
and were not detected in tumors from animals exposed to single
agents.
Oxidative Stress Plays a Critical Role in Mediating the
Therapeutic Response to Rapamycin and IPI-504
These observations suggest that rapamycin and IPI-504
promote tumor regression by inducing irresolvable ER stress,
continuous autophagy, and progressive damage to ER andmito-
chondria (Figure 4G). Because ROS are thought to play a critical
role in fueling this vicious cycle, we assessed the requirement
for ROS in the therapeutic response in vitro and in vivo. Impor-
tantly, IPI-504 triggered ROS production (Figure 5A) and the
antioxidant vitamin C suppressed MPNST cell death by 73%
(Figure 5B). More strikingly, when mice were pre-treated with
vitamin C, rapamycin/IPI-504 was no longer capable of inducing
tumor regression (Figure 5C). Because geldanamycin derivatives
may induceROS viamechanisms in addition to effects onHSP90
(Sreedhar et al., 2003), we evaluated a structurally unrelated
HSP90 inhibitor. Notably, BEP800 also induced an increase in
ROS production (Figure S5A). Vitamin C also suppressed the
therapeutic effects of this agent by 78% (Figure 5D), providing
additional evidence that ROS is a general mediator of cell death
in response to this class of drugs.
Given the demonstrated importance of ROS, we investigated
whether IPI-504 and rapamycin might be synergizing in these
tumors by enhancing oxidative stress. PML has been proposed
to be an in vivo sensor of oxidative stress, because it becomes
(D) Waterfall plot depicting tumor growth after 10 days of treatment with vehicle (blue), IPI-504 (red), rapamycin (yellow), and rapamycin/IPI-504(green). The left
y axis indicates the log2 of tumor fold growth versus day 0, and the right y axis shows the change in fold volume. The table reports mean and standard deviation
for each treatment arm (n = 8) and mean tumor shrinkage. The Shapiro-Wilk test shows that all datasets have a normal distribution.
(E) A photograph of an MPNST is shown at day 0 and after 10 days of treatment with rapamycin/IPI-504.
(F) H&E-stained tumors from animals treated with rapamycin/IPI-504.
(G) Pharmacodynamic analysis of lung tissue after 16 hr of treatment as shown by an Hsp70 and phosphoS6 immunoblots. p120 serves as a loading control.
(H) TUNEL staining of tumors treated for 16 hr.
(I) Kaplan-Meier curve of tumor-bearing Nf1/p53 mutant mice treated with vehicle (black) or rapamycin (blue) as described. Xs indicate an animal that was
euthanized because of skin ulceration. All error bars show ± SD. (See also Figure S2.)
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associated with nuclear bodies in a ROS-dependent manner
(Jeanne et al., 2010). Interestingly, only rapamycin/IPI-504 treat-
ment induced the formation of PML-containing nuclear bodies in
MPNSTs (Figure 5E), suggesting that rapamycin and IPI-504
together were required to achieve maximal levels of oxidative
stress. These results were confirmed by measuring ROS levels
in tumor tissue using dihydroethidium (DHE), where ROS was
elevated within 7 hr of treatment (Figure 5E). Moreover, vitamin
C suppressed the accumulation of polyubiquitin aggregates
(Figure S5B), the formation of nuclear PML bodies (Figure S5C),
the robust and sustained autophagic response (Figure S5D), ER
swelling and destruction, and mitochondrial damage (Fig-
ure S5E). Collectively, these results demonstrate that oxidative
stress is required for the therapeutic response in vivo. The finding
that ER swelling, protein aggregation, and ROS production all
occur within 7 hr of treatment (see Figures 4H, 5E, and 5F; Fig-
ure S4) and precede ATP depletion and mitochondrial destruc-
tion (Figures 5G and 4J), demonstrates that these effects are
Figure 3. Cell death induced by IPI-504 is caused by inhibition of HSP90 and subsequent effects on the UPR and ER stress
(A) Growth curves of the MPNST cell line S462 treated with two different HSP90 inhibitors (500nM IPI-504 and 500nM BEP800).
(B) S462 cells were treated with the HSP90 inhibitor AUY-922 (100 nM) for 72 hr. The left y axis indicates the log2 of tumor fold change versus day 0 and the right
y axis shows the relative change in cell number compared with day 0.
(C) Immunoblots showing the effects of AUY-922 on BIP, pEIF2a, sXBP-1, IRE1a, and PERK in human MPNST cells over time (hr). Actin serves as a loading
control.
(D) Relative level of cell death in the presence of 1 mM IPI-504with and without overexpression of sXBP1 (the activated spliced form of XBP1). The right hand panel
confirms expression of sXBP1.
(E) Growth curves in response to low doses of IPI-504 in cells where IRE1a and/or PERK are knocked down by siRNA. The immunoblot confirms knock down.
(F) S462 cells were treated with 100nM IPI-504 for 72 hr, with and without rapamycin pretreatment (100 nM) (left) or Raptor shRNA (right). The left y axis indicates
the log2 of tumor fold change versus day 0 and the right y axis shows the relative change in cell number compared with day 0.
(G) Relative number of S462 cells after combined knock down of IRE1a and PERK with or without rapamycin (100 nM) compared with rapamycin plus IPI-504
(300nM).
(H) pAKT/AKT immunoblots of tumor tissue from animals treated for 16 hr in mice exposed to vehicle (Veh), IPI-504 (IP), rapamycin (R), and rapamycin/IPI-504
(RIP). All error bars show ± SD. (See also Figure S3.)
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triggered by ER stress and are not a secondary consequence of
a mitochondrial metabolic collapse. This conclusion is further
supported by the observation that sXBP1 expression sup-
presses cell death (Figure 3D).
Rapamycin and IPI-504 Promote Excessive Oxidative
Stress by Inducing ROS and Simultaneously
Suppressing the G6PD/Glutathione Antioxidant
Pathway
Oxidative stress is caused by an imbalance between ROS
production and ROS clearance pathways. Given that IPI-504
stimulates ROS production, we investigated whether rapamycin
might be enhancing the effects of IPI-504 by suppressing endog-
enous antioxidants. Because of its high concentration and
central role inmaintaining redox state, the reduced form of gluta-
thione (GSH) is one of the most important endogenous cellular
antioxidants (Meister and Anderson, 1983). Glutathione reduc-
tion is dependent on NADPH, which is primarily produced by
the pentose phosphate pathway (PPP). The first and rate-limiting
enzyme of the PPP is Glucose 6-phosphate dehydrogenase
(G6PD). Accordingly, G6PD plays a well-established role in pro-
tecting cells from oxidative stress via its effects on GSH produc-
tion (Pandolfi et al., 1995; Xu et al., 2010; Efferth et al., 2006). The
importance of G6PD in this pathway is highlighted by the obser-
vation that hypomorphic mutations in G6PD underlie favism,
which causes acute hemolytic anemia in affected individuals
exposed to fava beans and other oxidative stressors (Belsey,
1973). Interestingly, a direct connection between G6PD and
the mTOR pathway has recently been established. Specifically,
G6PD expression can be suppressed by mTOR inhibitors
in vitro, through inhibitory effects on the transcription factor
SREBP1 (Du¨vel et al., 2010). Therefore, we examined the
components of this pathway (SREBP1, G6PD, GSH) in MPNSTs.
Consistent with cellular studies showing that SREBP1 is regu-
lated by mTOR (Du¨vel et al., 2010; Porstmann et al., 2008), rapa-
mycin significantly decreased the expression of known SREBP
targets including SREBP1 itself, ACC, and FASN in vivo within
7 hr (Figure 5H,I). IPI-504 exerted a slightly suppressive effect
on SREBP1, but together both agents reduced SREBP1 expres-
sion by 92% and effectively suppressed ACC and FASN (Fig-
ure 5H,I). Rapamycin also potently suppressed G6PD mRNA
levels in MPNST tumor tissue (Figure 5J). However, rapamycin
alone had inconsistent effects on G6PD protein levels (Figure 5I),
perhaps reflecting a slower turnover of G6PD protein within this
short time frame. Nevertheless, rapamycin and IPI-504 together
dramatically suppressed both G6PDmRNA and protein expres-
sion inMPNSTs in vivo (Figure 5I, J). Accordingly, rapamycin/IPI-
504 caused a 34% decrease in reduced glutathione levels in
these tumors (Figure 5K, p = 0.003). The magnitude of this
decrease in GSH is particularly significant given that individuals
affected by favism similarly exhibit a 34% mean reduction of
GSH in red blood cells, which sensitizes these cells to oxidative
stressors, resulting in severe protein misfolding and protein
aggregate formation (Szeinberg et al., 1958). Finally, to geneti-
cally confirm that G6PD can play a functional role in protecting
tumor cells from IPI-504-induced oxidative stress, we ectopi-
cally expressed G6PD in MPNSTs. Importantly, G6PD sup-
pressed IPI-504-induced MPNST cell death by 50% (Figure 5L).
Taken together, these data suggest that rapamycin and IPI-504
synergize by promoting excessive oxidative stress, which is
a consequence of both IPI-504-induced ROS production and
rapamycin-dependent suppression of G6PD and GSH.
Rapamycin/IPI-504 Promotes Tumor Regression
in a Model of Kras/p53 Mutant NSCLC
To determine whether the efficacy of this combination might
extend to KRAS mutant tumors, we performed a similar study
in a mouse model of NSCLC (Jackson et al., 2005). Notably,
NSCLCs are also highly aneuploid, illustrating an additional
similarity between these two tumor types. In this model, lung
adenocarcinomas are induced by intranasal administration of
adenoviral Cre, which causes the concomitant expression of
a single KrasG12D allele and loss of p53 (termed LSL-KrasG12D/+;
p53fl/fl). 8.5–9 weeks after infection, tumor burden was assessed
by MRI. Animals were re-imaged 1 week later to assess the rate
of tumor growth, and treatment commenced thereafter. In this
mixed genetic background, 50%–80% of the tumors were
confirmed to be adenocarcinomas within 10 weeks after Cre
exposure (DuPage et al., 2009)(Figure S6). Neither rapamycin
nor IPI-504 induced tumor regression alone; however, combined
rapamycin/IPI-504 treatment resulted in dramatic tumor shrink-
age (Figure 6A). 6/8 mice exhibited this potent response and
individual responding masses shrunk up to 82% as determined
by MRI analysis (Figure 6B). The overall reduction in total
tumor volume, which is the sum of numerous independent
tumors per mouse, is shown for each animal (Figure 6C). Histo-
logical analysis of tumors two weeks after treatment confirmed
substantial tumor regression (Figure 6D). However, although
tumor regression in response to rapamycin/IPI-504 was robust,
three types of tumor remnants were detected. Minimal tumor
remnants comprised of a few cells surrounding alveolar space
were observed (Figure 6E, a,b). Slightly larger remnants sur-
rounding alveoli were also detected (Figure 6E, c,d). Finally
some lesions, albeit vastly smaller than vehicle, rapamycin, or
IPI-504-treated tumors, were found (Figure 6E, e,f). However,
even in these cases, significant gaps between tumor cells were
observed, resulting in increased alveolar space (Figure 6E, f) in
contrast to the dense, high-grade lesions observed in control
animals. Moreover, there was a rapid and qualitatively obvious
improvement in breathing in rapamycin/IPI-504-treated animals.
The observation that not all tumors exhibit the identical thera-
peutic response is consistent with the fact that each individual
lung tumor in this model represents an independent genetic
event. Notably, although combined MEK and PI3K inhibitors
have been shown to promote tumor regression in murine
NSCLCs harboring the KrasG12D mutation alone (Engelman
et al., 2008), no targeted therapy has been shown to promote
the regression of the more aggressive KrasG12D, p53-deficient
tumors, underscoring the significance of this finding and its
potential impact on therapeutic development in KRAS mutant
NSCLC.
DISCUSSION
Currently, there are no effective targeted therapies for Ras-
driven cancers. Moreover, in some cancers KRAS mutations
are used to exclude patients from being treated with specific
targeted agents (Karapetis et al., 2008). As such, identifying
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a targeted therapy for Ras-driven tumors is an important
endeavor. In this study we took an orthogonal therapeutic
approach: combining an agent that targets an important down-
stream oncogenic pathway (mTOR) with agents that capitalize
on a cancer-associated cellular vulnerability, specifically the
enhanced sensitivity to proteotoxic stress (Luo et al., 2009).
Importantly, we found that several agents that induce ER stress,
including the HSP90 inhibitor IPI-504, cooperated with rapa-
mycin to promote dramatic tumor regression in two distinct
Ras driven-cancers. To date, no targeted agents have been
shown to be capable of causing tumor regression in either of
these highly aggressive genetically engineered models or,
more importantly, in cognate human tumors. Given that these
human cancers are generally refractory to standard therapies
there is an urgent need to develop improved treatments. Thus,
these studies have identified a promising therapeutic strategy
for these two aggressive malignancies.
However, although we found that this combination was effec-
tive in two specific Ras-driven cancers, it will be important to
determine whether its efficacy will extend to other Ras-driven
tumors, other mTOR-driven tumors, and/or other tumors that
exhibit high levels of ER stress. Our data suggest that a combina-
tion of these factors will be involved and that responsive tumors
will require some dependence on mTOR and will also exhibit
high levels of ER stress. On a molecular level, mutations in
RAS, NF1, and possibly other genes that affect the mTOR
pathway, may promote sensitivity to these combined agents.
However, other variables, such as the extent of aneuploidy or
copy number variation will likely impact the therapeutic response
due to direct effects on basal ER stress levels. The recent obser-
vation that aneuploidy confers sensitivity to proteotoxic agents
in normal cells, and cancer cells in some settings, supports
this hypothesis (Tang et al., 2011).
Finally, although these studies provide compelling data to
support the clinical investigation of rapamycin and IPI-504,
they also serve as a foundation for developing combinations
using other related agents. For example, mTOR kinase or dual
mTOR/PI3K inhibitorsmay enhance the efficacy of this combina-
tion. Similarly, there are several structurally unrelated HSP90
inhibitors in clinical development, which should provide an array
of compounds that may differ in efficacy and/or toxicity. More-
over, the mechanism by which IPI-504 and rapamycin cooperate
reveals an even broader range of drug options. For example,
other agents that enhance proteotoxic stress and/or alter the
heat shock response could be combined with agents that either
suppress antioxidant pathways or further stimulate ROS produc-
tion. In this respect it is noteworthy that ROS production is
thought to play a functional role in mediating the cytoxic effects
of many conventional chemotherapies. However, targeted
agents may prove to bemore effective if they are better tolerated
and consequently confer a greater therapeutic index. Regard-
less, the potential utility of these agents may be overlooked if
they are assessed exclusively as monotherapies in genetically
heterogeneous tumors, where individually they may exhibit
minimal activity. Indeed, none of the single agents investigated
in this study exerted a cytotoxic response when administered
individually. Moreover, our studies suggest that potential drug
combinations need to be tested empirically in rigorous models
in vivo. For example, although the proteasome inhibitor bortezo-
mib can induce proteotoxic stress in professional secretory cells
(e.g., multiple myeloma cells), bortezomib did not substantially
induce ER stress in MPNSTs and therefore did not promote
tumor regression when combined with rapamycin. These obser-
vations highlight the challenge of developing effective combina-
tion therapies and underscore the utility of using robust animal to
rapidly identify the most effective drug combinations among
numerous possibilities.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
S462, SNF96.2, and IMR90s (ATCC). 1A50 and 237-1 aremouseNf1/p53-defi-
cient MPNST cell lines (Johannessen et al., 2008). Antibodies were obtained
from the following sources: Cell Signaling Technologies: pAKT (4060), AKT
(9272), pEIF2a (3557), pS6 (2211), total S6 (2317), BIP (3183), FASN (3180),
ACC (3676) and IREa (3294), PERK (3192); Anti-p120 (G12920) (Trans. Labs);
Hsp70 (Sc24) and p62 (sc-10117) (Santa Cruz Biotechnology); actin (A2066)
(Sigma); XBP-1 (619502) (Biolegend); poly-Ub (FK1)(Biolegend Int); PML
(05-718)(Millipore); G6PD (A300-404A)(Bethyl Labs). IPI-504 and IPI-504
vehicle were supplied by Infinity Pharmaceuticals; Thapsigargin, tunicamycin
17-AAG and ascorbic acid (Vitamin C) (Sigma); BEP800 (Selleck Chemicals);
AUY922 (Chemietek); Rapamycin (LC Labs).
Real-Time PCR
Tissues were crushed using an in-liquid-nitrogen-cooled Bessman Tissue
Pulverizer and dissolved in Trizol reagent (Invitrogen). RNA was treated with
DNaseI (Roche) and reverse-transcribed using the qScript Reverse transcrip-
tase kit (Quanta). Real-time PCR analysis was performed using the PerfeCTa
SYBR Green kit (Quanta) for the following genes: mouse G6PDx (50-cctacc
atctggtggctgtt-30 50-tggctttaaagaagggctca-30); humanG6PD (50-aagaacgtgaa
gctccctga-30 50-aatataggggatgggcttgg-30); mouse SREBP1 (50-gatcaaagagga
gccagtgc-30 50-tagatggtggctgctgagtg-30); human SREBP1 (50-tgcattttctgacac
gcttc-30 50- ccaagctgtacaggctctcc-30).
RNAi
Non-targeting siRNAs and siRNAs against PERK were purchased from
Dharmacon (D-001810-10-05 and L-004883-00 respectively); siRNA targeting
IREa (QIAGEN, S100605248). siRNAs were transfected using lipofectamine
RNAiMAX from Invitrogen. A lentiviral pLKO vector containing the following
shRNA (50-CGACTACTACATCTCCGTGTA-30 ) was used to target Raptor.
(E) S462 cells were infected withmCherry-EGFP-LC3B and treated for 2 and 8 hr with 100nM rapamycin and 4 mM IPI-504. Yellow/green spots punctae represent
autophagosomes. Red spots represent autophagolysosomes.
(F) Bar graph representing the average number of autophagosomes (yellow bar) and autophagolysosomes (red bar) after 0, 2, and 8 hr of treatment of rapamycin
and IPI-504.
(G) Model illustrating cross-talk between ER stress, mitochondria, and ROS production.
(H) TEM depicting the relative size of the ER in tumors exposed to vehicle, IPI-504, rapamycin, or rapamycin/IPI-504.
(I) TEM showing numerous ERmembranes in rapamycin-treated tumors (blue dots) in contrast to tumors exposed to rapamycin/IPI-504 for 16 hr, where they are
not visible. Black arrows show a few autophagosomes in rapamycin-treated tumors and many in rapamycin/IPI-504-treated tumors.
(J) TEM showing normal mitochondria in vehicle-treated tumors (blue arrows, left) versus swollen vesicularized mitochondria in tumors treated with rapamycin/
IPI-504 for 16 hr (blue arrows, right). The mitochondria on the left in this panel are being engulfed by an autophagosome. (See also Figure S4.)
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Figure 5. Oxidative stress plays a critical role in mediating the therapeutic response to IPI-504 and rapamycin
(A) Levels of ROS induced by IPI-504 in MPNST cell lines in vitro. The red line depicts the shift in fluorescence intensity, reflecting ROS production.
(B) Relative levels of cell death in the presence of 500nM IPI-504 ± 100 uM vitamin C.
(C) Waterfall plot depicting tumor growth after 10 days of treatment with rapamycin/IPI-504 as shown in Figure 2 (green) versus rapamycin/IPI-504 and vitamin C
(black). The left y axis indicates the log2 of tumor fold growth versus day 0.
(D) Relative levels of cell death in response to 500nM BEP800 ± 100 uM vitamin C.
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Immunofluorescence
Tissues were fixed in formalin and embedded in paraffin. A standard immuno-
fluorescence protocol was followed. Antigen unmasking was performed by
boiling the slides in 10mM citrate (pH 6) for 10 min followed by 30 min cooling.
Blocking and hybridization were performed in 1x PBS with 5% serum and
0.3% Triton X-100. Antibodies were diluted 1:250.
TUNEL Staining, ROS detection, GSH assay, and ADP/ATP Ratio
TUNEL staining was performed with the ApopTag Fluorescein In Situ
Apoptosis Detection Kit (Millipore). Reactive oxygen species were evaluated
by MitoSOX Red (M36008) in vitro and by dihydroethidium staining in snap-
frozen tumor sections (D11347) (both Invitrogen). GSH was measured using
the GSH-glo Glutathione Assay Kit (Promega, V6911. The ADP/ATP ratio
was determined using the ApoSENSOR ADP/ATP Ratio Assay Kit (K255-
200) (Biovision).
Constructs
HumanG6PD (Open Biosystems) andmouse sXBP-1were cloned into a pLenti
CMV/TO Puro vector. The pBabe-puro mCherry-EGFP-LC3B construct was
obtained from Addgene. Lentiviral and retroviral infections were performed
as previously described (Johannessen et al., 2005).
Drug Treatment and Dosing Schedule
Animal procedures were approved by the Center for Animal and Comparative
Medicine in Harvard Medical School in accordance with the NIH Guild for the
Care and Use of Laboratory Animals and the Animal Welfare Act. IPI-504
(E) (Top 4 panels) Immunocytochemistry using a PML antibody (green) on tumors treated for 7 hr as indicated. (Bottom 2 panels) Dihydroethidium staining (red)
of frozen MPNST tumor tissue depicting an increase in ROS levels in response to Rap/IPI-504 after 7 hr of treatment.
(F) Kinetics of ROS induction in S462 cells in response to IPI-504/Rap.
(G) Kinetics of the ratio of ADP/ATP in S462 cells in response to IPI-504/Rap. Note that ROS production precedes the increase in ADP/ATP levels (decrease
in ATP).
(H) SREBP1 mRNA levels in tumors from animals that were treated for 7 hr as indicated.
(I) Immunoblots showing expression of FASN, ACC, and G6PD in tumors from animals treated for 7 hr as indicated. Actin serves as a loading control.
(J) G6PD mRNA levels in individual tumors treated as described in (I).
(K) Relative levels of reduced glutathione (GSH) in tumors treated with vehicle or rapamycin/IPI-504 (n-6).
(L) Relative levels of cell death caused by IPI-504 in cells ectopically expressing G6PD or a GFP control plasmid. Immunoblot demonstrating G6PD protein levels
in MPNSTs used in the left panel. (See also Figure S5.)
Figure 6. Rapamycin/IPI-504 promotes regression of KrasG12D, p53-deficient NSCLC
(A) MRI images of animals pre- and post-treatment as specified. The red circles highlight tumor masses.
(B) Table listing the volumetric change of individual tumor masses as determined by MRI.
(C) Waterfall plot depicting the reduction of total tumor volume in individual animals treated with rapamycin and IPI-504.
(D) H&E stain of histological sections of the lung after 14 days of treatment (2x).
(E) H&E stain of lesions from animals treated with vehicle, rapamycin, IPI-504, or rapamycin/IPI-504 for 2 weeks. Images b, d, and f are enlargements of images
a, c, and e, respectively. (See also Figure S6.)
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(100 mg/kg) was administered once or twice weekly. Thapsigargin (0.2 mg/kg)
and tunicamycin (0.2 mg/kg) were administered twice a week. Rapamycin
was administered daily at 5 mg/kg (Johannessen et al., 2008). Compounds
given in combination were administered sequentially. Mice were treated daily
with 40 mg/kg vitamin C by oral gavage before IP injections of rapamycin and
IPI-504.
Tumor Volume Measurements
MPNST Model:
Mice were enrolled in the study when tumor size reached 300–700mm3. Tumor
size was measured every 2–3 days by Vernier calipers. Tumor volume was
calculated using the standard formula L 3 W2 3 52. Tumor volume and log2
of fold growth versus day 0 were calculated and graphed.
Lung Cancer Model:
Mice were infected with Adenoviral Cre (University of Iowa) by nasal instillation
(Jackson et al., 2005). Tumor burden was determined by MRI 8 weeks after
inhalation and again 1 week later (Engelman et al., 2008). Nine weeks after
inhalation, tumor-bearing mice were divided into cohorts and were treated
with single or double agents for 2 weeks. Lung tissues were harvested for
histopathology after the last MRI. Fixed lung tissues were stained by H&E;
tumor burden was subsequently analyzed using the ImageJ software (NIH).
EM
Tumor tissues were fixed for EM after 7 and 16 hr of a single dose and further
processed for standard EM techniques (Barth et al., 2010).
Statistics
All statistical analysis was performed using SYSTAT 12 software. For each da-
taset, basic statistical values (mean and standard deviation) were calculated
and normality determined (Shapiro-Wilk normality test); all datasets were
normally distributed. Thapsigargin and IPI-504 were compared with vehicle-
treated tumors; rapamycin/thapsigargin and rapamycin/IPI-504 were com-
pared with rapamycin-only-treated tumors all by Student’s t test. Survival
analysis was analyzed using the Mandel method. For the comparison of lung
tumor burden in the lung cancer model we performed an ANOVA test, followed
by Student’s t test.
SUPPLEMENTAL INFORMATION
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Figure C–1. AKT inhibitors do not slow proliferation of MPNST cells 90-8TL cells were treated 
with the rapamycin (Rap) at 100nM, Torin1 at 250nM or MK- 2206 (concentration indicated). Bar 
graph represents the relative change in cell number from day 0 to 96 hours as compared to 
vehicle treated control cells. Data points show triplicate averages ± SD. Immunoblots show pAKT 
T308, pAKT S473, pTSC2 T1462, pS6, and 4E-BP1 levels in the presence of the specified 
inhibitors. AKT, TSC2, S6, and actin serve as controls. * indicates p<0.00001 
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Table C–1. Reported in vitro Isoform Specificities of PI3K Inhibitors. Reported in vitro 
isoform specificities of PI3K inhibitors. The IC50 (nM) reported in the literature for each PI3K 
inhibitor against Class IA catalytic isoforms in in vitro binding assays is shown. The source 
for each data set is listed. A66-(S) is termed a p110α-specific inhibitor, AZD-6482 is 
classified as a p110β-specific inhibitor, and CAL-101 shows selectivity for p110δ. GDC-
0941 does not show significant isoform selectivity.  
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Table C–2. Two Class Comparison Between Combination Treated Samples and 
Controls for other GLUT Proteins and Hexokinase Family.  Two class comparison 
between combination treated samples and controls for the other GLUT proteins and 
hexokinases.  The log2 of fold (combination/control) expression for each gene in the GLUT 
and hexokinase family are shown, such that negative values indicate a decrease in the 
combination relative to control, and positive values represent an increase. The p-value for 
the difference in expression between classes is shown.  
